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Human immunodeficiency virus (HIV) infected patients with a history of injection
o
neurological dysfunction. The use of combined anti-retroviral therapy has significantly 
reduced the prevalence of mortality and progression to AIDS. Due to extended life 
expectancy, these patients are still at a great risk for HIV-associated neurological disorders 
and impairment in their later life. Neural progenitor cells (NPCs) play critical roles in brain 
growth and repair after injury and insult. Pediatric HIV patients whose glial populations are 
still developing are especially at risk for central nervous system (CNS) damage. Our 
previous reports suggest that HIV-1 transactivator of transcription (Tat) can directly cause 
pathology in neural progenitors and oligodendroglia (OLs) (Hauser et al. 2009). Thus, we 
have hypothesized that NPCs and/or glial progenitors may be targets of HIV proteins ± 
opiates drugs of abuse.  
 To determine whether progenitors are targets of HIV-1, a multi-plex assay was 
performed to assess chem
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increased amount of the beta-chemokines CCL5/regulated upon activation, normal T cell 
expressed and secreted (RANTES), CCL3/macrophage inflammatory protein-1α (MIP-1α), 
and CCL4/macrophage inflammatory protein-1β (MIP-1β) after 12 h exposure to HIV-1 
Tat, but no to gp120. Secreted factors from Tat-treated progenitors were chemoattractive 
towards microglia, an effect blocked by 2D7 anti- C-C chemokine receptor type 5 (CCR5) 
antibody pre-treatment. Tat and opiates have interactive effects on astroglial chemokine 
secretion, but this interaction did not occur in progenitors.  
 We also examined effects of Tat and morphine on proliferation and lineage 
progression of NPCs in vitro and in vivo. In vitro, Tat and morphine independently reduced 
the proliferation and population of Sox2+ and Olig2+ cells in the absence of cell death. The 
gth, light-dark box) 
an fe
interactive effects of morphine and either Tat or supernatant from HIV-1SF162 infected 
monocytes varied depending on outcome measure and time of exposure, but interactive 
effects occurred primarily on proliferation. In rare instances, viable human progenitors 
were associated with p24 immunolabeling suggesting that progenitors may be infected, a 
concept that is still controversial. To investigate effects of Tat and morphine on NPCs in 
vivo, we used a mouse model in which HIV-1 Tat1-86 is conditionally expressed in astroglia. 
In vivo results in neonatal striata were similar to those in cell cultures. 
 We extended the experiments into adult mice with inducing Tat expression for 3 
month and the effect of sexes was examined in these animals. Intriguingly, males showed 
more Tat-induced impairment in behavioral tests (rotarod, grip stren
th males. Tat+ males also showed a greater reduction in the proportion of NeuN+ cells 
and NeuN immunoreactivity in the striatum, accompanied by greater microglial activation 
(3-nitrotyrosine+/Iba-1+). Unbiased stereological estimation in Nissl staining revealed that 
xi 
 
xii 
 
n progenitor dynamics may alter the balance of cell populations 
the depletion of NeuN immunoreactivity in these mice was not due to neuron cell death or 
loss, because the total neuron number in striatum and total striatal volume were not 
affected by long-term Tat induction. Tat exposure appears to selectively reduce levels of 
NeuN in living neurons, although the reason is not known. Therefore, both the enhanced 
microglial reactivity and depletion of NeuN levels in males may help to explain sex-
specific behavioral outcomes. Sox2+ and Olig2+ cells showed equivalent reduction in their 
population in both sexes.  
 Overall, our findings show that CNS progenitors, including both undifferentiated 
NPCs and glial progenitors, are vulnerable to individual or combined effects of HIV-1 or 
Tat and opiates. Changes i
in both the developing and adult CNS. We speculate that such changes may contribute to 
the behavioral abnormalities that we observed in Tat+ mice and which appear to model 
aspects of motor, cognitive and anxiety deficits in HIV-infected patients. 
 
Chapter 1  
Introduction to the Neuroscience of HIV 
 
Epidemiology of HIV 
 Over 1 million individuals in the United States (US) and nearly 33 million people 
worldwide are estimated to be infected and living with HIV (UNAIDS 2010). An estimated 
number of people newly infected with HIV in 2009 are 43,000 in the US and 2.6 million 
worldwide. Injection drug abusers are a major part in this population; 3 million people 
having the history of injection drugs are living with HIV. The rate of HIV infection along 
with drug injection are raising fast in developing countries and over 80% of all HIV 
infections in some countries are estimated to be related to drug use (UNAIDS 2009). 
Twenty to thirty percent of new HIV infections in the US occur among injection drug 
abusers annually (CDC 2009). Furthermore, they a have high a risk for faster progression 
to be acquired immune deficiency syndrome (AIDS), and higher incidence of HIV-related  
neurocognitive deficit/impairments compared to non-drug abusers (Bell et al. 2002). The 
population of women living with HIV in US are less than 25% of HIV positive people 
(CDC 2009), while 51% of people HIV positive population in worldwide are women 
(UNAIDS 2009), and HIV infections in women appear to be increased with globalization. 
HIV infection does not exclude children as its victims; about 370,000 children under 15 
years old are also living with HIV globally (UNAIDS 2009), around 10,000 children in US 
were diagnosed as AIDS in US 2009 (CDC 2009). Children are known to be more 
vulnerable to HIV complication and neuropathogenesis than adults (Civitello 1991; Drotar 
et al. 1997; Drotar et al. 1999; Lobato et al. 1995; Sharer and Cho 1989; UNAIDS 2009; 
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Van Rie et al. 2007). Since the introduction of combination antiretroviral therapies (cART) 
since 1996, survival rates related to HIV infection have dramatically improved in the US 
and other developed countries. Despite these outstanding improvements in mortality and 
co-morbidity of HIV, the prevalence of HAND continuously raises and remains as a 
significant public health concern. 
 
Virology of HIV-1 
HIV-1 has a single RNA genome consisting of seven structural elements (LTR, 
TAR, RRE, PE, SLIP, CRS, and INS), and nine genes (gag, pol, env, tat, rev, nef, vif, vpr, 
and vpu). Six genes transcript into accessory proteins and nine other genes produce 
envelope, core, and polymerase of HIV-1 (Kuiken et al. 2008). The viral proteins from 
these genes are essential for infection and new viral replication, and some of them are 
known to have significant toxicity to neural cells. In this thesis, we will focus two viral 
proteins, Tat and gp120, which are well studied in HIV neuropathogenesis.  
Firstly, gp120 is a viral envelop protein and plays a critical role in HIV infection. 
The gene env encodes gp160, the precursor of both gp120 and gp41. During HIV 
replication, furin, one of the host cell's protease, cleaves gp160 into the external gp120 and 
the transmembrane gp41 prior to viral assembly (Kuiken et al. 2008). For the initiation of 
HIV infection, gp120 binds the CD4 protein of target cells then the envelope complex 
undergoes a structural change, exposing the chemokine binding domains of gp120 and 
allowing them to interact with the target chemokine receptors, C-X-C chemokine receptor 
type 4 (CXCR4) and/or C-C chemokine receptor type 5 (CCR5), co-receptors for HIV-1. 
This allows the N-terminal fusion peptide gp41 to penetrate the cell membrane as a last 
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step of infection (Chan et al. 1997; Chan and Kim 1998; Wyatt and Sodroski 1998). gp120 
is also known to give the viral tropism to HIV by the preference of gp120 to bind either 
CXCR4 or CCR5 to infect specific cells (Chan et al. 1997). For examples, T-tropic strains 
of HIV-1 use the α-chemokine receptor, CXCR4, for entry to CD4+ T cells (Coakley et al. 
2005; Deng et al. 1996; Feng et al. 1996). M-tropic strains use the β-chemokine receptor, 
CCR5, to infect macrophage/microglia (Coakley et al. 2005). Dual-tropic HIV-1 strains are 
known to be able to use both CCR5 and CXCR4 as co-receptors for viral entry. As well as, 
other chemokine receptors, such as CCR2, CCR3 and C-X3-C chemokine receptor 1 
(CX3CR1)/fractalkine receptor, have been shown to serve as co-receptor for viral entry 
(Choe et al. 1996; Garin et al. 2003; Parczewski et al. 2009; Puissant et al. 2003).  
Another HIV-1 protein, Tat, refers to trans-activator of transcription. This protein is 
one of regulatory proteins, which is synthesized at the early and late stage of viral 
replication. Tat can be released by HIV-infected cells into the extracellular environment, 
and can be taken up by the surrounding cells (Westendorp et al. 1995). This protein is 
known to have multiple forms; 86 or 110 amino acid forms are formed from two exons. 
The first exon contributes to the 1-72 amino acid variant, and the second exon forms the 
remaining 14 to 32 amino acids (Jeang et al. 1999; Kuiken et al. 2008; Li et al. 2010; Nath 
et al. 1996). HIV-1 Tat is one of the transactivating proteins regulating in HIV expressions. 
It is essential for retroviral replication by binding to long terminal repeat (LTR) of HIV to 
lead massive transcription level of the HIV dsRNA. HIV-1 Tat also is required for efficient 
HIV genomic transcription. The presence of Tat can induce more than hundred-fold levels 
of HIV transcription compared to activation of the absence of Tat (Cann et al. 1985). There 
are five functional domains in Tat protein including N-terminal, cysteine-rich, core, basic, 
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and C-terminal domains. Before identifying the function of Tat in HIV replication, HIV-1 
Tat was firstly recognized as having a unique protein transduction domain (Frankel and 
Pabo 1988; Green and Loewenstein 1988). This domain in HIV-1 Tat contains specific 
amino acid sequence, GRKKR, which act as a nuclear localization signal. Tat could enter 
cells by crossing the cell membrane due to its rich lysine and arginine content of this 
domain (Morris et al. 2001; Schwarze et al. 2000). In summary, viral envelop protein 
gp120 and regulatory protein HIV-1 Tat can contribute to AIDS pathogenesis in multiple 
ways. These include facilitating infection, activating HIV transcription, increasing 
replication of HIV and dysregulating the host’s cytokine expression and immune responses. 
These proteins can affect the cells that are not infected in secondary manner, by their 
directly binding to target cells which can induce abnormal multiple signal transductions 
and morphological changing. Understanding the mechanism of these viral proteins in 
neurobiology may allow us to have opportunities to control or manage HIV associated 
neurological defects HIV.  
 
Invasion of HIV into CNS  
The central nerve system (CNS) is susceptible to infection by HIV. It has been 
elusive and controversial when and how HIV invades into brain. Although it is unclear 
wheather HIV infection remains in the CNS, or is cleared and re-enters in later stage of 
infection, HIV appears to infiltrate into the CNS with different amount of infection and in 
different regions of the brain (An et al. 1999; Davis et al. 1992; Gonzalez-Scarano and 
Martin-Garcia 2005; Shapshak et al. 1999; Smit et al. 2004). The HIV infiltrations in 
multiple brain regions supports researchers in HIV-neuropathogenesis studies to establish 
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the various mechanisms that how the virus can infiltrate into CNS. Even there are a lot of 
mechanisms for HIV infiltration in CNS; we will briefly discuss some of mechanisms 
which are widely accepted. One of mechanisms, once HIV infect monocyte, macrophage or 
CD4+ lymphocytes in peripheral system, these infected cells brought the virus into brain by 
accrossing the blood brain barrier (BBB), because the HIV infected cells can express 
adhesion molecules on their surface to help the infected cells to attach to brain endothelial 
cells and lead transendothelial migration into the CNS (Dhawan et al. 1997; Hickey et al. 
1991; Hult et al. 2008). Second, HIV infected cells released cytokine/chemokines (de Jong 
et al. 1996; Nottet et al. 1996; Persidsky et al. 1997), Tat (Hofman et al. 1994; Lafrenie et 
al. 1996a; Lafrenie et al. 1996b) and gp120 (Annunziata et al. 1998), which can up-regulate 
adhesion molecules on brain endothelial cells and also alter the permeability of BBB, 
which allow HIV infiltrate easily into the CNS.  Third, as HIV can do transcytosis itself 
(Hocini and Bomsel 1999), HIV in circulating blood stream firstly infect brain endothelial 
cells lining besides BBB and then HIV can be released by viral budding from the 
endothelial cells to infect astrocytes in BBB. Therefore, the process of transcytosis allows 
HIV passage into the CNS (Banks et al. 2001; Bomsel 1997; Owens et al. 1991). Once the 
virus enter the CNS by utilizing all these mechanisms, HIV can affect all cell types in CNS 
to induce neuropathogenesis both in direct and indirect manner. Many of the cell types in 
CNS, including astrocytes, microglia, neurons, oligodendrocytes, endothelial cells and 
NPCs, are considered to be either direct or indirect targets of HIV. The former two are 
considered to be target of HIV infection in CNS (Gonzalez-Scarano and Martin-Garcia 
2005). These cells will be discussed in sections that follow. 
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Interaction of HIV-1 and opiate in neuropathogenesis   
Injection drug abuse and HIV-1 are tightly interacted in epidemics mentioned 
above. HIV-1 is widely spread through injection drug use, because of their risk drug-
seeking behaviors, needle sharing and sex-trading for drug purchase. Indeed, injection drug 
users are at higher risk both for HIV-1 infection and for developing neuropathological 
complications (Hauser et al. 2006; Hauser et al. 2007; Nath et al. 2000; Nath et al. 2002). 
Opiates, including heroin, oxycodone, morphine and fentanyl, are known to intrinsically 
exacerbate the pathogenesis and neurological complications of HIV-1 through direct 
actions in the CNS (Hauser et al. 2006; Hauser et al. 2007).  Opiates majorly act through μ-
opioid receptors (MORs), and κ-/δ- opioid receptors play roles in their signaling cascades. 
All these receptors are G-protein coupled receptors and are known to activate inhibitory G 
proteins (Al-Hasani and Bruchas 2011). The neurotoxicity of opiates has been well 
documented in opiate addition studies, and furthermore recent studies suggested that opiate 
abuse might lead Alzheimer-like changes in brains. These studies have shown that opiate 
alone can increase the depositions of hyper-phosphorylated tau and beta amyloid in brains 
of drug abusers; even these patients do not have history of HIV infection (Anthony et al. 
2010; Ramage et al. 2005). The interaction of opiate and HIV-1 in the CNS mediated by 
either indirectly or directly manners in astrocytes (1.), microglia (2.), neurons (3.), 
oligodendrocytes (4.) and neural progenitor cells (5.) will be demonstrated in followed 
sections.  
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1. Astrocytes 
Firstly, astrocytes can be infected by HIV-1 with low productive manner, and the 
infected astrocytes can shed HIV-1 protein Tat and gp120 into extracellular spaces. 
Additionally these HIV proteins can direct affect neighboring astrocytes and other cells. In 
a way of bystander effects on neurons, infected or affected astrocytes may fail to provide 
metabolic support to neurons, show reduced ability to buffer toxic substances from 
surrounding environment, release neurotoxic molecules, increase inflammation response 
and spread cell death signals through their gap junction to affect other cells (Eugenin and 
Berman 2007; Eugenin et al. 2011). As subsets of astrocytes express several types of opioid 
receptors, including mu-opioid receptor, these cells can be affected by and respond directly 
to opiate drugs (Hauser et al. 1996; Stiene-Martin et al. 2001). In in vitro studies, the 
combination of HIV-1 Tat and morphine causes an exacerbated loss in intracellular Ca2+ 
homeostasis in astrocytes and increased  various cytokines released by affected astrocytes 
(El-Hage et al. 2008b; El-Hage et al. 2005; El-Hage et al. 2006b) and increased in astrocyte 
death (Khurdayan et al. 2004). Activated astrogliosis by Tat induction was also detected in 
transgenic mice and this activation might contribute stress to neurons with co-exposure to 
opiates (Bruce-Keller et al. 2008; Fitting et al. 2010b; Fitting et al. 2010c). Astroglia can be 
also influenced by glycoprotein 120 (gp120), this HIV viral protein can increase the levels 
of intracellular calcium (Codazzi et al. 1995; Codazzi et al. 1996; Holden et al. 1999) and 
modify gene expression (Galey et al. 2003; Wang et al. 2004) to enhance 
chemokine/cytokine secretion (Buriani et al. 1999; Fitting et al. 2010b; Kong et al. 1996; 
Ronaldson and Bendayan 2006; Yeung et al. 1995). However, gp120 relatively induces less 
chemokine/cytokine secretion than Tat with regional heterogeneity and diversity in 
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chemokine/cytokine production (Fitting et al. 2010b). In the interaction of opiates and 
gp120, morphine-induced CCL5/RANTES secretion from astrocytes might be 
neuroprotective against the HIV protein gp120 (Avdoshina et al. 2010), it still 
controversial. Interaction of opiates and other viral proteins in responses of astrocytes have 
been less well investigated, thus opioid-induced changes in astrocytes function associated 
with HIV viral proteins may have critical implications for the neuropathogenesis of HIV. 
 
2. Microglia 
Microglia are the brain-resident immune cells to be productively infected by HIV-1. 
These cells are considered as a major reservoir of viral replication in brain, and can 
massively produce toxic viral proteins, such as Tat, gp120, and Vpr during viral 
replication. Moreover, various toxic cellular products are released by infected microglia 
include cytokines such as tumor necrosis factor alpha (TNF-α), interleukins, platelet 
activating factor, as well as mediators of inflammation arachidonic acid, L-cysteine, 
glutamate, quinolinic acid, and nitric oxide (Bruce-Keller et al. 2008; Gupta et al. 2010; 
Persidsky and Gendelman 2003). As these cellular toxins can activate adjacent uninfected 
microglia and astrocytes, their activation may initiate cascades through the whole brain 
which may occur chronically in HIV infected patients (Hult et al. 2008). Abnormal 
microglia activation is prominently detected in various neuropathological diseases 
including brains from the end stage of HANDs (Kaul et al. 2001; Persidsky and Gendelman 
2003; Tyor et al. 1995). Microglia also express most opioid receptors and each receptor can 
be a target of opiates and may have different responses corresponding to HIV-1. For 
example, opiate drugs increase HIV-1 replication in microglia through the activation of µ-
8 
 
opioid receptors (MOR), and can also induce apoptosis in microglia (Singhal et al. 2002). 
Furthermore, co-exposure to morphine synergistically increased Tat-induced 
chemokine/cytokine production and microglial activation through CCL5/RANTES- driven 
amplification of CCL2/MCP-1 (El-Hage et al. 2008b; El-Hage et al. 2006a; El-Hage et al. 
2006b), and that may partly explain relatively high incidences of microglial activation, 
neuropathology and cognitive disturbance among HIV patients who abuse opiates 
(Anthony and Bell 2008; Arango et al. 2004; Bell et al. 2006; Bouwman et al. 1998; 
Dougherty et al. 2002) et al. 2008). Otherwise, the activation of κ-opioid receptor (KOPr) 
activation is known to reduce viral replication in microglia (Chao et al. 1996). These facts 
implicate that the interaction of HIV-1 and opiates underlay complicate mechanism in HIV 
neuropathogenesis.  
 
3. Neurons 
It is generally accepted that neurons are defiantly direct and major target of viral 
proteins, such as such as gp120 (Dreyer et al. 1990), Tat (Haughey et al. 1999; Sabatier et 
al. 1991), and Vpr (Piller et al. 1998). These viral proteins are considered as major 
contributing factors to developing neuropathogenesis. Even neurons that are not infected 
with HIV are also considered as targets of indirect or bystander inflammations and 
toxicants released by infected microglia and astrocytes, mentioned above. Infected 
astrocytes and microglia may produce inconsistent amounts of individual viral proteins 
(Brack-Werner 1999), each HIV-1 protein released from infected cells is directly toxic to 
neurons (Mattson et al. 2005). Various studies in the neurotoxicity of HIV-1 viral proteins 
suggests that opiate exposure exacerbates the toxic effects of HIV-1 Tat and gp120 in 
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neurons, and this interaction of HIV-1 and opiates can induce cell death in neurons, as well 
as in glial cells (Gurwell et al. 2001; Hu et al. 2005; Khurdayan et al. 2004). Interestingly, 
opiate exposure seems to reduce the threshold for neurotoxicity (Zou et al. 2011), but 
opiates make neurons be more susceptible to toxic insults (Hauser et al. 2005; Nath et al. 
2002). Moreover, the interactions also results in the destabilization of Ca2+ in astrocytes 
and induce them to release proinflammatory cytokine/chemokines like monocyte 
chemoattractant protein-1 (MCP-1), monocyte chemoattractant protein-5 (MCP-5), and 
regulated upon activation, normal T-cell expressed, and secreted (RANTES) (El-Hage et al. 
2005), which can significantly affect the functional integrity of neuronal synapse and 
morphology of neurons (Fitting et al. 2010c). How interactions between opiate drug abuse 
and HIV-1 toxicity affect the relationships between microglia, astrocytes and neurons is 
necessary to understand the mechanisms of HIV-1 pathogenesis in the CNS.  
 
4. Oligodendrocytes 
The oligodendrocytes are the myelin producing cell in CNS, responsible for proper 
conduction of axonal signals. Even they have significant contributions for proper function 
of CNS and the specific vulnerability to many neuropathologic disease, these cells have 
been underestimated and have a short history in HIV neuropathogenesis compare to 
neurons. Generally autopsy studies in HIV infected brains detected demyelination, 
oligodendrocyte cell death and white matter abnormality although the exact mechanism is 
unknown (Petratos and Gonzales 2000; Richardson-Burns et al. 2002). At least, HIV-1 
protein Tat seems to have more direct toxicity to oligodendrocytes than gp120 has by 
changes of cell morphology (Fitting et al. 2008; Hauser et al. 2009). Oligodendrocytes 
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express most of opioid receptors including MOR, κ-opioid receptor (KOR), and δ-opioid 
receptor (DOR), which play important roles in proliferation, differentiation and maturation 
of oligodendrocytes (Hahn et al. 2010a; Hayashi et al. 2004; Persson et al. 2003). However, 
the condition of opiate drugs act by mimicking the endogenous opioid system can enhance 
toxicity of HIV-1 to oligodendrocytes. Previous in vitro and in vivo data from our 
laboratory strongly indicated that Tat and morphine significantly induce stress in 
oligodendrocytes without cell death in vitro, but the combined exposure of Tat and 
morphine synergistically increase oligodendrocyte stress and cell death in vivo (Hauser et 
al. 2009) with their morphological changes. Oligodendrocytes might be more sensitive to 
co-exposure of HIV-1 than neurons are. For examples, Tat induction through 7 to 10 days 
significantly increase the proportion of caspase-3 activity, as an indication of stress rather 
than cell death, in NeuN+ cells. While the Tat induction in the same period increase 
TUNEL staining in O4+ and APC+ cells, which indicates cell death (reviewed by Bruce-
Keller et al. 2008; Hauser et al. 2009). Therefore, opiate drugs in HIV neuropathogenesis is 
also likely to be complicatedly involved in the development and survivals of 
oligodendrocytes. 
 
5. Neural Progenitor cells (NPCs) 
The definition of neural progenitor cells (NPCs) in this thesis is the early 
(primitive) stage of cells having the capacity of proliferation and the multi-potential ability 
to generate various neural lineages of mature brain cells including neurons, astrocytes, and 
oligodendrocytes. The NPCs are abundant in different distinct regions of the brain during 
embryonic and postnatal development, while the adult brain contains these NPCs in limited 
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neurogenic regions including the subgranular zone (SGZ) in the dentate gyrus, the 
subventricular zone (SVZ) in the lateral walls of the lateral ventricles, and the olfactory 
bulb (Ming and Song 2005). In the normal adult brain, NPCs is known to be involved in 
learning and memory and neural turnover in the hippocampal dentate gyrus and olfactory 
bulb. However, accumulating evidence suggest that NPCs exist in numerous regions of the 
brain including the neocortex, spinal cord, tegmentum, substantia nigra, amygdala, and 
brain stem, as well as in the hippocampal dentate gyrus and olfactory bulb (Ming and Song 
2005). The functional significance of the NPCs in these regions is incompletely 
understood; however, they may play critical roles in damage repair following any injury or 
insult as well as in learning and memory formation (Brazel et al. 2003; Gage 2000; Gage et 
al. 1998; Gould 2007; Kempermann and Gage 2000; Ming and Song 2011; Nait-Oumesmar 
et al. 2008; Romanko et al. 2004). 
The procedure of NPCs turning into matured neural cells mainly requires the 
multiple steps including proliferation, migration, differentiation, survival, and integration 
of the newly formed matured neural cells into the pre-existed environmental cells in the 
brain (reviewed Trapp et al. 1997). These multiple steps of NPCs are known to be affected 
by various endogenous factors (Yoneyama et al. 2011). Although neurological deficits due 
to brain injury/insults or neuropathogenesis are mainly caused by loss of synaptic integrity, 
malfunction or loss/death of neurons, the disruption of endogenous neuro/gliogenesis from 
NPCs might contribute to neurological deficits by hindering the recovery from brain 
injury/insults. Notably, cumulative reports indicate that the properties of NPCs in HIV 
neuropathogenesis can be affected by cytokine/chemokines, neurotransmitters, and reactive 
oxygen/nitrogen species (ROS), which are released by HIV-1 affected neurons as well as 
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by activated macrophages, microglia, and astrocytes (Whitney et al. 2009; Yoneyama et al. 
2011), mentioned above. 
Although the critical roles of these cells is in maintaining and repairing of 
mammalian CNS system, the underlying mechanism of NPCs in HIV neuropathogensis is 
still elusive. The RNA/DNA of HIV-1 was detected in regions of neurogenesis in human 
adult and pediatric brain, and in vitro studies suggested the prolonged HIV-1 infection of 
NPCs, it is still controversial whether NPCs can be infected by HIV or not (reviewed Das 
and Basu 2011; Mishra et al. 2010; Rothenaigner et al. 2007; Schwartz et al. 2007). 
Moreover, the limited availability and purity in human primary NPCs make numerous 
difficulties in studies of HIV neurobiology.  Since NPCs express opioid receptors, MOR, 
KOR and DOR (Buch et al. 2007; Hahn et al. 2010b; Hauser et al. 2009; Knapp et al. 
2009), these receptors play important roles in proliferation, differentiation and survival of 
NPCs through endogenous opioids and also make these cells become targets of opiates and 
their antagonists. Besides, various cytokine/chemokine receptors, including CXCR4 and 
CCR5, are also expressed on surface of NPCs (Kao and Price 2004; Li et al. 2011; Li and 
Ransohoff 2008; Tran and Miller 2005), which allow NPCs can be direct and indirect 
targets of HIV-1. As the indirect way HIV-1 affects NPCs, there have been some reports 
that cytokine/chemokines released by HIV-1 infected macrophage/microglia affect 
proliferation and differentiation of NPCs (Peng et al. 2011; Peng et al. 2008) and 
reductions of NPCs in hippocampus paralleled increased HIV-1-infected microglial 
activation in mice model of HIV encephalopathy (HIVE) (Poluektova et al. 2005). A few 
studies indicated that the direct effect of HIV-1 Tat and gp120 can attenuate the 
proliferation and differentiation of NPCs and exposure to these proteins might lead cell 
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death in NPCs (Mishra et al. 2010; Okamoto et al. 2007; Tran et al. 2005). Moreover, 
NPCs may be preferentially vulnerable to HIV-1 infection or chronic opiate exposure 
because Tat or morphine alone or in combination caused significant increases in NPC cell 
death in vitro and in vivo (Buch et al. 2007; Khurdayan et al. 2004). However, most of 
studies in NPCs with HIV-1 or their viral proteins were only concentrated on reduction in 
proliferation of NPCs or decreased differentiation into neurons rather than any other cells 
in brain. Questions still remain, such as what specific stage of NPCs are affected by HIV-1, 
how HIV-1 affects the properties of NPCs and what population can be generated after the 
HIV-1 affect NPCs etc. The detail of studies in NPCs under the condition of HIV and 
opiates are required in HIV neuropathogenesis.  
NPCs are relatively less investigated in HIV neuropathogenesis compared to other 
major neural cells in brain, even these cells might have a significant potential to contribute 
the recovery or marinating of normal CNS functions during HIV-1 invasion in CNS. 
Furthermore, NPCs are likely to have different responses from HIV-1 or its viral effects on 
mature glia as well as neurons. This may critically contribute the facts that pediatric 
patients frequently present with early and with more pathological forms of neuroAIDS 
(Drotar et al. 1997; Lobato et al. 1995; Van Rie et al. 2007), since these patients have 
abundant NPCs which are still developing in their CNS. Thus, opiate-induced changes in 
functions of NPCs may have critical implications for the pathogenesis of HIV.  
Taken altogether, the studies in this article will show that NPCs in striatum can be 
major target of HIV-1 Tat proteins with opiates exposures by altering their 
chemokines/cytokines secretions, proliferation and population in specific stage of 
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progenitors and these potential consequences may result in changing behavior of animal 
model with sex-specific manner. 
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Chapter 2  
β-Chemokine Production by Neural and Glial Progenitor Cells is Enhanced 
by HIV-1 Tat: Effects on Microglial Migration. 
 
(This chapter was published as a paper in the Journal of Neurochemistry in April of 2010, 
114(1):97-109) 
 
Introduction   
 
 Human immunodeficiency virus (HIV) infection within the central nervous system 
(CNS) causes a variety of neuropathological changes.  Neurons are not generally thought to 
be infected by HIV, although latent neuron infection has been reported (Torres-Munoz et 
al. 2001; Trillo-Pazos et al. 2003).  Neuropathology is instead mediated by direct 
neurotoxic actions of released viral proteins, or secondarily, through toxic effects 
orchestrated by glial cells (Brack-Werner 1999; Gendelman et al. 1994; Hauser et al. 2007; 
Kaul et al. 2001; Kramer-Hammerle et al. 2005b; Persidsky and Gendelman 2003).  HIV-
infected macrophages/microglia reaching the brain create a reservoir of viral infection, and 
lay the groundwork for inflammation leading to neuropathology and cognitive changes.  
Although there is little evidence that macroglial cells in vivo are productively infected by 
HIV (Brack-Werner 1999; Gorry et al. 2003; Kramer-Hammerle et al. 2005b), activation of 
astroglia by viral proteins, or by substances released from reactive microglia, can amplify 
brain inflammation and neurotoxic sequelae, and also promote infiltration of infected 
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monocytes from the periphery.  Thus, HIV neuropathology results from collective effects 
of viral proteins and inflammatory mediators on several cell types. 
 Astroglia from humans and rodents secrete chemokine/cytokines in response to 
HIV-1 transactivator of transcription (Tat) protein (Conant et al. 1998; El-Hage et al. 2005; 
Kutsch et al. 2000; McManus et al. 2000; Nath et al. 1999; Rappaport et al. 1999).  We 
have shown that Tat-induced [Ca2+]i responses mediate (CC motif chemokine ligand) 
2/monocyte chemoattractant protein-1 (MCP-1), CCL5/regulated upon activation, normal T 
cell expressed and secreted (RANTES) and interleukin-6 (IL-6) release, resulting in 
downstream signaling through necrosis factor kappa B-dependent pathways (El-Hage et al. 
2008b; El-Hage et al. 2005).  Concurrent exposure to morphine exacerbates Tat-induced 
chemokine/cytokine production and microglial activation through CCL5/RANTES-driven 
amplification of CCL2/MCP-1 (Bruce-Keller et al. 2008; El-Hage et al. 2008a; El-Hage et 
al. 2006a; El-Hage et al. 2006b), an observation that may partly explain relatively high 
incidences of microglial activation, neuropathology and cognitive disturbance among HIV 
patients who abuse opiates (Anthony and Bell 2008; Arango et al. 2004; Bell et al. 2006; 
Bouwman et al. 1998; Dougherty et al. 2002).  Astroglia are also sensitive to glycoprotein 
120 (gp120), which can elevate [Ca2+]i (Codazzi et al. 1996; Holden et al. 1999), and alter 
gene expression (Galey et al. 2003; Wang et al. 2004) leading to chemokine/cytokine 
secretion (Buriani et al. 1999; Kong et al. 1996; Ronaldson and Bendayan 2006; Yeung et 
al. 1995), with some evidence for exacerbation by opiates (Mahajan et al. 2005).  In our 
hands, Tat generally elicits a much higher chemokine and cytokine response than gp120, 
and we observe regional heterogeneity in secretion by astroglia (Fitting et al. 2010c). 
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Responses of astroglia to other HIV-1 proteins have been less well studied (Kramer-
Hammerle et al. 2005a; Lehmann et al. 2006). 
 We were intrigued by the possibility that less differentiated CNS cells, in addition 
to microglia and astroglia, might contribute to inflammation.  This would parallel situations 
in other tissues.  Unstimulated bone marrow or cord-derived mesenchymal stem cells 
secrete a spectrum of chemokine/cytokines and growth factors, including multiple 
fibroblast growth factors (FGFs), interleukins, insulin like growth factor 1 (IGF-1), 
leukemia inhibitory factor (LIF), CCL2/MCP-1, CCL3/macrophage inflammatory protein-
1α (MIP-1α), and CCL4/macrophage inflammatory protein-1β (MIP-1β), stromal cell 
derived factor-1 (SDF-1), and vascular endothelial growth factor (VEGF) (Chen et al. 
2008; Croitoru-Lamoury et al. 2007; Liu and Hwang 2005; Rafei et al. 2008; Schinkothe et 
al. 2008; Wagner et al. 2007).  As mesenchymal stem cells differentiate, the balance of 
factors released varies with cell fate (Kilroy et al. 2007; Molloy et al. 2009).  Neural 
progenitor cells (NPCs), which derive from undifferentiated neuroepithelial cells, are a 
self-renewing and multipotential source of neurons and macroglial cells.  Common markers 
for NPCs include the intermediate filament nestin and the transcription factor Sox2 (sex 
determining region of Y (SRY)-related HMG-box gene 2).  As NPCs continue to 
differentiate, they become largely restricted to either neuronal or glial fates. Differentiating 
glial-restricted progenitors (GPCs) express markers typical of oligodendrocytes (e.g. Olig1, 
Olig2, Sox10, myelin proteins) or astroglia (e.g. GFAP, EAAT2). Nestin+ and Sox2+ cells 
continue to be found in the mature CNS, although in more restricted germinal zones 
(Komitova & Eriksson 2004, Ellis et al. 2004).  There is evidence that neurally-restricted 
progenitors may have a secretory role.  For example, human NPCs expressing nestin and 
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A2B5 release IP-10/CXCL10 and MCP-1/CCL2 after exposure to TNF-α (Sheng et al. 
2005).  NPCs also secrete neurotrophins and other growth regulators (Benoit et al. 2001; 
Llado et al. 2004; Shingo et al. 2001; Taupin et al. 2000), and transplantation of stem cells 
and/or NPCs increases their own survival (autocrine effects), as well as promoting neuron 
survival after injury (paracrine effects) (Chang et al. 2003; Llado et al. 2004). 
 Effects of HIV proteins on NPCs or GPCs are relatively unexplored, and are likely 
different from effects on mature glia.  They may be critically important to pediatric 
patients, who frequently present with early and with more pathological forms of 
neuroAIDS (Drotar et al. 1997; Lobato et al. 1995; Van Rie et al. 2007). The majority of 
these patients are infected at birth, when glial populations are still developing.  The present 
study was designed to determine whether NPC/GPCs from striatum have the capacity to 
produce chemokines/cytokines, and if so, whether exposure to HIV proteins can modify 
production, with potential functional consequences.  
 
Materials and Methods 
 
 All experimental protocols conformed to local Institutional Animal Care and Use 
Committee (IACUC) and national (PHS) guidelines on the care and ethical use of animals.  
Experiments were designed to minimize the total number of animals used and their 
discomfort. 
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Progenitor Cell Cultures 
 The striatum is a region that is particularly vulnerable to both HIV-induced and 
opiate-induced degenerative changes, and is a region of great interest for the synergistic 
effects of these two insults.  Progenitor cell cultures were prepared from the striatum of 
embryonic day 15 (E15) mice using modifications of a previously published technique 
(Khurdayan et al. 2004).  In brief, embryos were aseptically removed from the uterus of 
timed pregnant ICR dams (Charles River, Boston, MA) following cervical dislocation.  The 
striata from 10-12 embryos were dissected from the rest of the cortex, finely minced, and 
incubated with DNase (0.015 mg/ml, Sigma-Aldrich Co., St. Louis, MO) in Dulbecco's 
Modified Eagle's Medium without additives (15 min, 37˚C).  Tissue was triturated through 
a 5 ml pipette, centrifuged, and resuspended in 5 ml of defined, progenitor maintenance 
medium containing 1:1 DMEM/F12 (Invitrogen Corp., Carlsbad, CA) and 10% 
Knockout™ SR (Invitrogen), a commercial serum replacement product that does not 
contain serum or growth factors.  Additional additives included insulin (25 µg/ml), 
transferrin (100 µg/ml), progesterone (20 nM), putresceine (60 µM), Na-HCO3 (6 mM), 
and sodium selenite (30 nM) (all from Sigma-Aldrich Co.).  Resuspended cells were 
filtered through a 70 µm nylon Cell strainer (BD Falcon, Bedford, MA), counted, 
centrifuged as above, and resuspended in the appropriate volume of the same medium to 
obtain desired plating densities.  Cells were plated on either poly-L-lysine coated 24 well 
plates for Multi-plex assay (105 total cells per well) or poly-L-lysine coated 15mm glass 
coverslips for immunostaining (5x104 cells in 150 µl), and medium was changed after 2 
days.  Cells were growth at 37˚C, in a humidified atmosphere with 5% CO2 throughout.  At 
5 days the medium was refreshed again and cells were treated with Tat1-86 (100 nM; 
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ImmunoDiagnostics, Woburn, MA), and/or gp120 (MN strain; 500 pM; 
ImmunoDiagnostics), and/or morphine sulphate (500 nM; NIDA Drug Supply System, 
Rockville, MD), and/or naloxone (1.5 μM; Sigma-Aldrich, St. Louis, MO).  Morphine, the 
major bioactive product of heroin in the brain, is a potent µ-opioid receptor agonist, and 
naloxone is a broad spectrum opioid receptor antagonist.  These are concentrations of HIV 
proteins and opiates that have elicited functional effects, including increases in 
chemokine/cytokine secretion, in astroglia, oligodendrocytes, and neural progenitors in our 
earlier studies (Buch et al. 2007; El-Hage et al. 2005; Hauser et al. 2009; Khurdayan et al. 
2004).  In studies with naloxone, the inhibitor was applied 30 min prior to other treatments, 
which were applied simultaneously in pre-warmed medium.  
 
Primary microglial cultures 
Primary cultures enriched in microglia were prepared from mixed murine glial cultures 
using modifications of rat culture protocols (Kong et al. 1997; Levesque et al. 2010). 
Briefly, meninges and blood vessels were removed from whole brains of 1 day postnatal 
pups. Tissues were gently triturated in microglia-enrichment media and seeded (four brains 
or > 5 × 107 cells) in poly-L-lysine-coated 150 cm3 flasks. Microglia-enrichment medium 
consists of 1 : 1 DMEM/F12 containing 10% heat-inactivated fetal bovine serum, 2 mM L-
glutamine, 1 mM sodium pyruvate, 100 µM non-essential amino acids, 50 U/mL penicillin, 
and 50 µg/mL streptomycin (Invitrogen). Cell suspensions were filtered through nylon 
mesh with 70 µm pores before plating onto 150 cm3 flasks. Cultures were maintained at 
37˚C in a humidified, 5% CO2 atmosphere. Medium was replenished every third day after 
the initial seeding. 10~12 days after seeding, when the glia had formed a confluent 
21 
 
monolayer, microglia were mechanically dislodged and the detached cells were panned on 
uncoated tissue culture dishes for 1–2 h to remove more adherent cells such as astrocytes 
and progenitors. Microglia were pelleted at 100 g for 5 min, then resuspended in fresh 
medium. We confirmed that the primary microglia were > 95% pure by immunostaining 
with the specific marker, Iba-1 (not shown). 
 
Immunohistochemistry and Quantification 
 Progenitor cell cultures were immunostained at 5 days post-plating, using cell-
specific and lineage-specific markers including the O4 antibody which detects sulfatide 
(Sommer and Schachner 1982), and antibodies to glial fibrillary acidic protein (GFAP; 
1:2,000, Chemicon/Millipore, Billerica, MA), CD11b (1:100, Millipore, Billerica MA), 
Olig2 (1:100, Immuno-Biological Laboratories, Minneapolis, MN), Sox2 (1:100, R&D 
Systems; Millipore) and nestin (1:5,000, Aves Labs, Inc., Tigard, OR).  In some 
experiments, and based upon the Bio-plex data, cells were double-immunostained with 
CCL5/RANTES (1:100, Santa Cruz Biotechnology Inc., Santa Cruz, CA), CXCR4 (clone 
12G5, 1:50, Abcam Inc., Cambridge, MA), and CCR5 (clone 45523, 25 g/ml, R&D 　
Systems; clone 2D7, 1:100, BD Pharmingen TM, San Jose, CA) to examine whether 
precursors and other cells within the cultures could express particular chemokines and their 
receptors. In all cases, cells were fixed with 4% paraformaldehyde, and for intracellular 
markers, cells were permeabilized with 0.1% Triton X-100 in PBS containing 5% normal 
goat serum for 30 min. Double-staining was performed sequentially, with staining for 
chemokines and receptors followed by immunostaining for precursor markers. Antibodies 
were applied overnight at 4˚C, followed by visualization with appropriate fluorescent-
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conjugated second antibodies (Molecular Probes/Invitrogen, Carlsbad, CA).  
Immunostained coverslips were finally incubated with Hoechst 33342 dye (8 min) to 
identify nuclei (Molecular Probes/Invitrogen), then mounted in ProLong Gold antifade 
reagent (Molecular Probes/Invitrogen) and dried for 8h in the dark.  To assess the 
proportion of different cell types in the cultures, 350-500 Hoechst+ cells were selected 
randomly per coverslip and assessed for nestin, Olig2, Sox2, O4, GFAP, or CD11b 
immunostaining (N=3-5 different experiments) under oil immersion at 63× using a Zeiss 
AxioObserver system with an integrated MRM camera system (Carl Zeiss, Inc., 
Thornwood, NY).  At least 100 random Olig2+ cells were assessed for RANTES in similar 
cultures.  Similar staining methods were applied to 10 µm tissue sections from adult mouse 
striatum.  
 
Immunoblotting  
 CXCR4 and CCR5 expression was examined in 5-day cultures. Cells were 
harvested by scraping into ice-cold RIPA buffer (50 mM Tris, pH 7.4; 150 mM NaCl; 1% 
Nonidet; 0.5% deoxycholic acid; 0.1% SDS; protease inhibitor cocktail, Roche, 
Indianapolis, IN, USA).  Cell lysates were pelleted and stored at −80°C until use.  Protein 
was assayed using the BCA protein assay (Pierce, Rockford, IL, USA).  Duplicate samples 
of 20μg total protein were loaded per well onto 4-20% Tris–HCl Ready Gels (Bio-Rad 
Laboratories, Hercules, CA) using Precision Plus Protein Dual Color Standards (Bio-Rad; 
MW range: 10–250 kDa) to monitor protein transfer and molecular weight. Proteins were 
transferred to Hybond-P PVDF membranes (Amersham Biosciences, Piscataway NJ), 
probed with a monoclonal antibodies to either CXCR4 (ab2074, 1:1,000, Abcam) or CCR5 
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(clone 45523, 1:1,000, R&D Systems), and visualized using a chemiluminescent substrate 
(Super Signal West Femto substrate, Pierce).  Protein bands were detected on a Kodak 
Image Station 440CF and analyzed using 1D software.  
 
Multi-plex Assay 
 After 12 hrs of treatment, 450 µl of media were harvested from each well and 
stored at -80˚C. 50 µl of media from each treatment group was analyzed for 
chemokine/cytokine content using the Bio-Plex 200 System (Bio-Rad) and standard mouse 
23-plex assay kits or custom 12-plex assay kits, according to the manufacturer’s 
instruction. Concentrations were determined using Bio-Plex Manager Software (Version 
5.0), based upon individual standard curves calculated for each chemokine/cytokine. 
 
Microglial Chemotaxis Assay and CCR5 Antibody Neutralization 
 An 8.0-µm transwell system (Costar, Corning, NY, USA) was used to measure 
changes in the motility of BV-2 microglia-derived cells or primary microglia in response to 
Tat- or gp120-treated glial precursor cells in 24-well plates. BV-2 cells were cultured in T-
75 flasks in medium consisting of DMEM (Invitrogen, Carlsbad, CA, USA) supplemented 
with glucose (27 mM), Na2HCO3 (6 mM), 10% defined fetal bovine serum (Hyclone 
Laboratories, Inc., Logan,UT, USA) and antibiotics. Cells were harvested at 90% 
confluency using a non-enzymatic cell dissociation solution (Sigma-Aldrich Co.), washed 
and resuspended in DMEM supplemented with glucose (27 mM), Na2HCO3 (6 mM), and 
1% fetal bovine serum, and then plated onto transwell inserts (105 BV-2 cells per insert). 
Primary microglia were grown in microglia-enrichment medium and mechanically 
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harvested as described earlier. They were washed, resuspended and plated onto inserts 
similarly to BV-2 cells. Prior to the addition of transwell inserts containing microglia or 
BV-2 cells, 106 progenitors were cultured in each well of a poly-L lysine coated 24 well 
plate for 5 days, then treated with Tat or gp120 ± opiates for 12 h. A transwell insert 
containing BV-2 cells or microglia was then placed into each well. The transwell inserts 
were incubated for an additional 3 h and then removed for analysis. Cells remaining on the 
upper surface of the insert were carefully aspirated, leaving those which had migrated to 
the surface underneath in place. The insert was then transferred to a clean well containing 
225 µL of non-enzymatic cell dissociation solution (Sigma-Aldrich Co.) and incubated for 
30 min, at 37˚C, during which time each insert was gently tilted several times to 
completely detach cells. The inserts were discarded and 75 µL of 4 × Lysis 
Buffer/CyQuant® GR dye solution (Millipore) wereapplied to each well and incubated per 
manufacturer’s instructions. 200 µL of dye/buffer/lysate solution were transferred to a 96-
well plate, and the fluorescence intensity of each sample was measured using a PHERAstar 
FS plate reader (BMG LABTECH Inc. Cary, NC, USA) with a 485 nM excitation filter and 
520 nM emission filter. In experiments to assess the role of CCR5 in migration, the BV-2 
cells or microglia were incubated with anti-CCR5 (clone 2D7, without sodium azide; BD 
PharmingenTM) or control IgG (mouse, IgG2a, BD Pharmingen) at a dose of 2 µg per 106 
cells for 1 h at 4˚C, prior to the placement of the inserts.  
 
Viability Assay  
 Neural/glial precursor cells were cultured on poly-L-lysine precoated 48 well plates 
and treated at 5 days after plating with morphine, Tat, gp120, and naloxone either alone or 
in combination as in experiments described above. After 12 h, medium containing 
treatments was replaced with sterile, tissue culture–grade D-phosphate- buffered saline 
containing the LIVE/DEAD® reagents (Invitrogen; calcein AM, 2 µM and EthD-1, 4 µM) 
and 5 µg/mL Hoechst 33342. The working solution was added directly to cells and 
incubated for 15 min, at 37˚C. The fluorescence intensity of each color was measured using 
a PHERAstar FS plate reader (BMG LABTECH) in n = 8 different cultures using 
appropriate excitation and emission filters (calcein AM: 495/515 nm; EthD-1: 495/635 nM; 
Hoechst: 350/510 nM). 
 
Statistical Analysis 
 Statistical analyses were done by analysis of variance (ANOVA) followed by 
Bonferroni’s post-hoc testing using StatSoft software (Statistica, Tulsa, OK).  
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Results 
 
Progenitor cells from E15 striatum secrete chemokines: Effects of viral proteins and 
opiates  
 After 5 days growth in chemically defined medium, the progenitor cell cultures 
consisted overwhelmingly of a mixture of immature cell types (Fig. 2.1 A), containing both 
NPCs and GPCs at various states of differentiation.  The majority of the cells were 
immunostained for nestin (82%) and/or Sox2 (44%), markers of relatively undifferentiated 
CNS progenitors (Ellis et al. 2004; Komitova and Eriksson 2004; Lendahl et al. 1990; 
Tanaka et al. 2004).  Of the nestin-positive cells, 47% also showed Sox2 immunreactivity.  
Approximately 20% of the cells had entered the oligodendrocyte lineage, as indicated by 
expression of Olig2 (Ligon et al. 2006; Woodruff et al. 2001).  Another ~40% expressed 
DCX, a microtubule-associated protein found almost exclusively in neuronal precursors. 
Somewhat surprisingly, very few of the cells expressed the astrocyte marker GFAP (< 3%). 
Many DCX+, Olig2+ and GFAP+ cells also were nestin+ or Sox2+, suggesting relatively 
recent entry into a specific lineage. Less than 0.8% of cells stained with the CD11b 
microglial marker. As reported previously, over 70% of the Olig2+ cells in these cultures 
expressed the µ-opioid receptor (MOR) (Hauser et al. 2009). Most cells that were Olig2- or 
DCX- were also MOR+, indicating that MOR was also expressed in uncommitted 
precursors (Fig. 2.1 B and C). Thus, multiple types of progenitors are potential targets of 
MOR agonists and antagonists such as morphine and naloxone. 
 Progenitors were treated for 12 hr with HIV-1 proteins and/or opiates, after which 
their conditioned medium was harvested and screened for expression of an array of 
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chemokines and cytokines significant in the pathobiology of inflammatory disease and/or 
displaying cross-sensitization to opiates. The 12 hr time-point was chosen because it gave a 
consistently detectable accumulation of secreted products.  Based on our earlier studies 
with other types of glia (El-Hage et al. 2005), longer time-points can result in higher 
accumulation, but they also increase the likelihood that autocrine and paracrine effects of 
the chemokines/cytokines will influence cell secretions. Of the 23 factors initially tested, 
only 10 were expressed and/or secreted at detectable levels by untreated striatal progenitor.  
The concentrations of the individual chemokines/cytokines detected after 12 hrs (pg/ml) 
are given in Table 1. Exposure of progenitors to viral proteins and/or opiates did not 
change the factors that were secreted, but did affect the accumulated amounts of several. 
The secretion of β-chemokines CCL3/MIP-1α, CCL4/MIP-1β and CCL5/RANTES were 
all significantly increased by Tat exposure, but not by gp120 exposure (Fig. 2.2). Unlike 
prior observations in astrocytes, concurrent exposure to Tat and morphine did not have an 
interactive effect on chemokine/cytokine release, even though the majority of cells in the 
cultures expressed MOR. Neither was there an interactive effect of Tat and gp120. 
CCL2/MCP-1 showed a trend towards a Tat response, but the effect was not significant 
using ANOVA analysis. It is likely that cells at multiple stages of differentiation 
contributed to both baseline and Tat induced secretion, as CCL5/RANTES was detected by 
immunostaining in a subset of both Sox2+ and Olig2+ cells in vitro (Fig. 2.3 A–C). 
CCL5/RANTES staining was also evident in Sox2+ cells in vivo (Fig. 2.3 D), but it was 
quite difficult to detect in Olig2+ cells in vivo (not shown), suggesting down-regulation in 
oligodendroglial precursors in the brain. We also examined expression of the β-chemokine 
receptors CXCR4 and CCR5, known to be co-receptors for gp120 binding and HIV entry 
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into cells. Immunohistochemistry showed that both CCR5 and CXCR4 were present on 
Olig2+ and Sox2+ progenitors, as well as on neighboring Olig2- and Sox2- cells. Both 
receptors were also readily detected on western blots from progenitor cultures (Fig. 2.4 E; 
20-µg load), as well as astroglia and striatal homogenates.  Major bands were found at ~40 
kD, which is the reported molecular weight of both CCR5 and CXCR4. 
 
Progenitor cells induce a chemotactic response in microglial cells 
 A transwell apparatus was used to test whether secreted factors from progenitors 
could influence the movement of BV-2 and primary microglial cells. All tests were 
conducted over a 3-h period. Some cells moved randomly across the membrane during the 
test period (Fig. 2.5 A–C, medium only). Addition of Tat or gp120 to the medium in the 
absence of NPC/GPCs did not change the migration of either BV-2 cells or primary 
microglia (Fig. 2.5 A–C, medium + Tat, medium + gp120). When NPC/GPCs were plated 
in a 24 well plate and transwell inserts were added after 5 days, secretions from NPC/GPCs 
did not alter BV-2 or primary microglial migration (Fig. 2.5 A–C, NPC/GPC). However, 
when the progenitors were pre-treated for 12 h with HIV-1 Tat the result was quite 
different (Fig. 2.5 A–C, NPC/GPC + Tat). In that case, there was a significant increase in 
migration of both BV-2 cells and primary microglia across the transwell membrane 
towards the Tat-treated progenitors. NPC/GPCs treated with gp120 did not elicit a similar 
enhancement of migration in either type of microglial cell.   
 As microglia can be attracted by signals from dying cells, we examined cell death 
using a fluorescent LIVE/DEAD assay kit (Invitrogen). Approximately 10% of the total 
Hoechst-labeled nuclei belonged to dead cells, but there were no significant differences 
29 
 
among treatments that might account for the additional BV-2 cell migration induced by 
HIV-1 Tat (n = 8; Fig. 2.6). This suggests that the microglial chemotaxis observed in our 
experiments is most likely to result from enhanced chemotactic signals released from 
progenitors stimulated by viral proteins. CCR5 is the common receptor for the b-
chemokines that were up-regulated by Tat in progenitor cultures. To further confirm that 
chemokines up-regulated by Tat were contributing to the enhanced migration of microglial 
cells, we conducted experiments to neutralize CCR5. Both BV-2 cells and primary 
microglia were incubated for 1 h with the 2D7 antibody (sodium azide-free), which has 
been shown by others to be suitable for receptor blockade studies (De Clercq 2009; 
Jayasuriya et al. 2004; Lee et al. 1999). Figure 2.5 (B) and (C) shows, respectively, that 
treatment of both BV-2 and primary microglia with the 2D7 monoclonal CCR5 antibody 
prior to their addition to the transwell insert completely abolished the enhanced migration 
elicited by NPC/GPCs.  
 
Discussion 
 
 HIV-associated neuropathology in the CNS is generally thought to result from the 
combined effects of direct viral protein toxicity, and inflammatory/toxic conditions 
propagated by surrounding glial cells.  Because of our interests in the effects of co-
morbidity between opiate drugs of abuse and HIV exposure in the CNS, we chose to 
examine the striatum, an area which is both rich in opiate receptors and extremely 
vulnerable to HIV-induced neuropathology.  Our data show that progenitors from 
embryonic striatum secrete a variety of chemokines/cytokines in culture, and that exposure 
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to HIV-1 Tat1-86 selectively increases secretion of a subset of these. The concept that 
NPC/GPCs in the normal brain may secrete factors to regulate either their own function or 
fate, or that of surrounding cells, has been previously established (Benoit et al. 2001; 
Chang et al. 2003; Shingo et al. 2001; Taupin et al. 2000). Further, it is known that 
progenitors or stem cells from other regions have this ability. Mesenchymal stem cells, for 
instance, secrete multiple chemokine/cytokines and growth factors, including multiple 
FGFs, IGF-1, IL-1β, IL-6, CCL2/MCP-1, CCL3/MIP-1α, CCL4/MIP-1β, SDF-1, VEGF, 
and others (Chen et al. 2008; Croitoru-Lamoury et al. 2007; Liu and Hwang 2005; Rafei et 
al. 2008; Schinkothe et al. 2008; Wagner et al. 2007).  Importantly, this is the first study to 
show that secretions from a neural progenitor population have a chemotactic effect on 
microglial cells, and that these secretions and their effects can be enhanced by exposure to 
HIV-1 Tat.   
 A previous study on E15 striatal progenitors grown as proliferating neurospheres 
(Benoit et al. 2001) examined some of the cytokines that we initially screened.  In 
agreement, we both found a complete lack of IL-3, IL-4 and IL-1α secretion. However, our 
cells also secreted detectable levels of granulocyte macrophage colony-stimulating factor, 
IL-6, IL-9 and TNF-α, as well as five other chemokines/cytokines that were not assayed in 
the previous study.  Our cells were grown in monolayers, and assayed at an earlier in vitro 
age using a different methodology, so these differences are perhaps not surprising. There 
are likely to be additional chemokine/cytokines secreted by striatal progenitors, as our 
initial screening process used the manufacturer’s standard kit which assays for a group of 
23 selected analytes.   
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 The progenitor cultures from E15 striatum contain a mixture of cells at different 
stages of differentiation (Fig. 2.1). Immunocytochemistry showed that most expressed 
either nestin, Sox2, or both. While 20% expressed Olig2, a transcription factor that 
indicates commitment to an oligodendroglial fate, there was a complete absence of O4 
staining, suggesting that the Olig2+ cells were still quite immature.  Likewise, the 3% of 
cells that were GFAP+ seemed quite immature based on morphology and variable co-
expression of nestin or Olig2. As expected in a striatal progenitor culture, many of the cells 
were young neural precursors expressing DCX (~40%), but the absence of NeuN reactivity 
suggested their relative immaturity. Individual chemokines/cytokines appear to be secreted 
by cells across several stages of development, and there is also variability of expression 
within specific populations. For example, although most CCL5/RANTES+ cells do not 
immunostain for Olig2, a subset are Olig2+ (Fig. 2.3); and among Olig2+ cells, only about 
50% are CCL5/RANTES+ (data not shown).  
 Regardless of the stage at which progenitors release these factors, our results show 
that the production of CCL5/RANTES, CCL3/MIP-1α and CCL4/MIP-1β, is significantly 
increased following exposure to HIV-1 Tat for 12 hr (Fig. 2.2).  In contrast, exposure to 
gp120 did not affect levels of any of the chemokines/cytokines. It is unlikely that the very 
small populations of microglia (< 0.8%) or immature astroglia (3%) are responsible for 
either baseline or Tat-induced chemokine/cytokine secretion, especially as MIP-1α and 
MIP-1β were not been detected in our other studies. The earlier studies also showed that 
co-exposure to morphine enhanced Tat-induced CCL5/RANTES production by astroglia 
(El-Hage et al. 2008b; El-Hage et al. 2005). The lack of morphineinduced synergy in the 
present results also suggests that astroglia are not the primary source.  
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 In striatal astroglia there is a synergistic effect of morphine on Tat-induced 
secretion of CCL2/MCP-1, CCL5/RANTES and IL-6. The lack of morphine-induced 
synergy in progenitor cultures is not because of a lack of appropriate receptors as most 
progenitors express MOR (Fig. 2.1) (Buch et al. 2007; Hauser et al. 2009). However, the 
signaling pathways leading to synergistic secretory responses may not be functional in 
immature cells. gp120 did not increase NPC/GPC secretion of the panel of analytes that we 
examined. This is similar to our observations in mature astroglia fromseveral brain regions 
(Fitting et al. 2010c), although gp120 from different HIV strains is variably reported to 
induce TNF-α, IL-1α, IL-1β, and IL-6 in other astroglial preparations (Buriani et al. 1999; 
Kong et al. 1996; Ronaldson and Bendayan 2006; Yeung et al. 1995). CD4 is the major 
receptor for gp120 binding and virus entry, and binding is facilitated by expression of CD4 
co-receptors such as CCR5 and CXCR4. The strain of gp120 that we used (MN) 
preferentially uses the CCR5 co-receptor. Progenitors expressed abundant CCR5 (Fig. 2.6), 
but do not express CD4 and therefore may have limited ability to respond to gp120. 
Binding of chemokine ligand versus gp120 to a chemokine receptor may have 
fundamentally different consequences. For example, in a previous study, gp120 IIIb 
required ‘priming’ by exposure to soluble CD4 in order to elicit a simple CXCR4-mediated 
Ca2+ response from similar murine progenitors (Tran et al. 2005).   
 As Tat exposure can clearly enhance chemokine secretion from progenitors, might 
this have functional consequences?  A transwell assay showed that progenitors exposed to 
HIV-1 Tat for 12 h were able to enhance the directed movement of both BV-2 cells and 
primary microglia (Fig. 2.5). gp120 did not enhance chemokine production, so it was not 
surprising that progenitors treated with gp120 did not elicit the same migratory response 
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(Fig. 2.5). Importantly, blockade of the CCR5 receptor on microglial cells eliminated the 
enhanced migration (Fig. 2.5 B and C), showing that secretions of the CCR5 ligands 
RANTES, MIP-1α and MIP-1β, from progenitors have the potential to direct microglial 
movement. We believe that our data suggest chemotaxis, not just enhanced, random 
motility, as there is only a modest exchange of medium over the short assay period through 
the small membrane plating area. The BV-2 cells are plated into a well containing their 
original culture medium and are moving towards the continually renewed source of 
chemokines. 
 What are the potential consequences of chemokine/cytokine secretion by 
NPCs/GPCs, and the upregulation of β-chemokine production by HIV-1 Tat? These are 
best discussed considering the two very different contexts of interest – the normal brain and 
the HIV-infected brain. Ten of the chemokines/cytokines we examined were secreted at 
detectable levels by untreated progenitors, and several of these are chemoattractants for 
inflammatory cells.  Under normal conditions, attracting monocytes/microglia may not be 
harmful.  They serve diverse roles essential for normal brain function, independent of the 
innate immune response, which include providing trophic support, regulating neurogenesis 
and neuron development, and clearing toxic debris (Aarum et al. 2003; Block et al. 2007; 
Polazzi and Contestabile 2002; Simard et al. 2006; Walton et al. 2006; Whitney et al. 2009; 
Ziv et al. 2006). During HIV-infection there are different considerations. CCL5/RANTES, 
CCL3/MIP-1α and CCL4/MIP-1β are all known to act as endogenous suppressors of HIV 
infection and cell damage due to their ability to block gp120 binding with its CCR5 co-
receptor (Catani et al. 2000; Cocchi et al. 1995), and both CCR5 and its ligands are the 
subject of ongoing investigation as therapeutic targets to reduce viral entry (reviewed in 
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DeVico and Gallo 2004; Vangelista et al. 2008).  Thus, enhanced β-chemokine secretion 
might afford a degree of protection. However, all three β-chemokines are also implicated in 
HIV-neuropathology.  Depending upon the severity of inflammation they may contribute to 
an environment that is detrimental to neurons.  RANTES is a well known chemoattractant 
for T-cells, granulocytes, and monocytes, and is thought to recruit HIV-infected monocytes 
to the brain, either alone or through triggering MCP-1 production (Conant et al. 1998; El-
Hage et al. 2005; Kelder et al. 1998; Luo et al. 2003; Schall et al. 1990).  CCL3/MIP-1α 
and CCL4/MIP-1β are routinely produced by activated macrophages and attract monocytes 
as well as lymphocyte subpopulations including granulocytes and neutrophils (Menten et 
al. 2002).  β-chemokines also stimulate synthesis and release of pro-inflammatory 
cytokines, are upregulated and expressed by astroglia and microglia in the HIV infected 
brain (Kelder et al. 1998; Letendre et al. 1999; Schmidtmayerova et al. 1996), and correlate 
positively with HIV dementia (Letendre et al. 1999). Thus, dysregulated β-chemokine 
expression by progenitors and glia might potentiate local inflammation, and might enhance 
local trafficking of HIV-infected cells into the brain.  Supporting this concept, multiple 
indicators of inflammation were reduced after intrastriatal injection of HIV-1 Tat into 
RANTES/CCL5 deficient mice compared to control (El-Hage et al. 2008a).  
 The concept that chemokine/cytokine effects may differ in normal versus 
inflammatory situations is well-illustrated by considering CCL2/MCP-1. While 
CCL2/MCP-1 can be protective towards isolated neurons (Eugenin et al. 2003; Madrigal et 
al. 2009; Yao et al. 2009), in the context of HIV-1 infection, the negative effects of 
attracting infected monocytes and driving inflammation are likely to outweigh direct, 
neuroprotective effects observed in isolation. The complexity of these issues is clearly 
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highlighted by disparate results in two studies using mice deficient in CCR2, showing 
either protection (Eugenin et al. 2003; Madrigal et al. 2009; Yao et al. 2009) in the context 
of HIV-1 infection, the negative effects of attracting infected monocytes and driving 
inflammation are likely to outweigh direct, neuroprotective effects observed in isolation. 
The complexity of these issues is clearly highlighted by disparate results in two studies 
using mice deficient in CCR2, showing either protection (El-Hage et al. 2006a) or 
exacerbation (Yao et al. 2009) after intrastriatal Tat injection, depending on timing, region 
examined, and outcome measure.  
 Importantly, we found robust expression of CCL5/RANTES associated with some 
Sox2+ cells in the striatum (Fig. 2.3 D), suggesting that secretion of chemokines by NPCs 
does occur in vivo, and in the adult CNS.  Progenitors are a relatively small population in 
the mature brain and will have less influence on overall inflammatory tone than microglia 
and astroglia.  However, we speculate that they may have an important influence on the 
local milieu, and particularly in situations where progenitor populations are increased, such 
as regions of active CNS repair, or during development. In the context of HIV, progenitors 
may particularly contribute to the neuropathology that occurs in young pediatric patients, 
where glial populations are still developing.  HIV-1 associated progressive encephalopathy 
occurs in a relatively high percentage of pediatric HIV patients, where it develops 
aggressively and is frequently the earliest clinical manifestation of disease (Drotar et al. 
1997; Ensoli et al. 1997; Schwartz and Major 2006; Van Rie et al. 2007).  Chemokine 
production by progenitors might normally be an adaptive process, to encourage the 
immune surveillance and approval of cells before they make additional contributions to 
neural or glial populations.  Enhanced secretion of chemokines in the context of HIV might 
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circumvent this adaptive strategy, by attracting HIV-infected microglia/monocytes to 
NPC/GPCs, which can be infected by HIV (Lawrence et al. 2004; Rothenaigner et al. 
2007), and which appear to pass the virus to their neuronal and glial progeny (Lawrence et 
al. 2004). 
 
 In summary, we have shown that HIV-1 Tat increases production b-chemokines by 
striatal progenitors, resulting in the CCR5-mediated movement of microglial cells. As Tat 
mRNA and/or protein have been detected in CNS tissue samples from both patients with 
HIV-1 encephalitis and rhesus macaques infected with a chimeric HIV-SIV (SHIV) virus 
(Hudson et al. 2000), these findings have significant disease relevance. The effects of 
enhanced chemokine release will be contextual, because of complex interplay between 
multiple secretory and responder cell types in vivo, as well as temporal issues during 
normal and disease processes. Emerging evidence suggests that human neural progenitors 
may be cellular reservoirs of HIV infection (Lawrence et al. 2004; Rothenaigner et al. 
2007; Schwartz and Major 2006), although the extent of NPC/GPC infection in the brain 
remains unclear.  The potential contribution of this infected population to the chemokine 
milieu must also be considered.   
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Table 2. 1: Chemokines/cytokines secreted by progenitor cells from E15 striatum 
(pg/ml) 
  IL-1β GM-CSF TNF-α IL-6 IL-9 
C <0.85 
# <1.17 # <0.3 # 1.78±1.06 <20.4 # 
M 1.10±0.25 <1.17 
# <0.3 # <0.72 # 23.21±2.57 
T 5.54±1.52 2.43±0.83 0.68±0.28 5.10±2.88 28.85±3.15 
G 1.35±0.32 1.64±0.47 0.44±0.09 <0.72 
# 27.54±6.53 
N <0.85 
# <1.17 # 1.27±0.21 <0.72 # <20.4 # 
MT 5.76±2.31 1.64±0.47 1.14±0.36 4.81±3.00 26.03±3.15 
MG <0.85 
# 1.96±0.79 0.34±0.04 <0.72 # <20.4 # 
MTN 7.46±4.47 2.46±1.29 0.76±0.23 6.72±4.74 23.21±2.57 
MTG 6.99±2.77 3.22±0.96 1.20±0.81 3.09±1.06 26.03±3.15 
MTGN 9.87±4.02 1.81±0.64 0.51±0.14 1.78±1.61 <20.4 
# 
MN <0.85 
# <1.17 # <0.3 # <0.72 # <20.4 # 
   KC RANTES MIP-1α MIP-1β MCP-1 
C 6.70±2.42 5.74±0.56 57.86±15.59 135.5±36.09 68.77±26.9 
M 6.21±2.52 5.09±0.35 26.94±0.02 98.07±22.08 57.03±24.12 
T 25.40±10.81 336±26.8 312.5±25.11 957±102.5 183.6±78.2 
G 7.63±2.29 6.34±1.03 119.5±62.8 273±185.1 94.26±38.65 
N 6.11±2.39 3.59±0.81 26.95±0.0 75.17±16.64 58.83±23.72 
MT 20.61±9.52 292±59.7 307.1±62.06 714.5±127.8 170.15±76.58 
MG 5.74±2.03 5.06±1.09 48.63±21.69 94.12±17.35 47.85±16.08 
MTN 32.62±15.89 397±105 376.8±104.6 1009.1±194 237.2±131.6 
MTG 24.12±9.13 271.7±32.33 321.9±61.6 945±165.9 167.9±75.83 
MTGN 24.81±9.51 336.3±28.31 376.0±46.9 1063±116.3 124.8±75.26 
MN 5.85±2.58 4.08±0.58 26.94±0.0 66.93±18.06 55.79±21.8 
 
aSample concentration was determined to be below the accuracy limit of the assay 
software, based on the standard curve generated for the individual chemokine/cytokine. In 
those cases, we have indicated the lower limit value in pg/mL. For all samples, n = 6. 
The following proteins were not routinely detected in control or treated cells:  
IL-1α, IL-2, IL-3, IL-4, IL-5, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-17, G-CSF, 
Eotaxin, IFNγ. 
C, control; M, morphine; Tat, transactivator of transcription; G, gp120; N, naloxone. 
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Figure 2.1 
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Figure 2.1 Characterization of progenitor cultures from E15 striatum. Cultures were 
immunostained after 5 days for typical markers of neural and glial precursors, and for 
MOR. (a) Most cells stained for nestin (> 80%) and/or Sox2 (> 40%), indicating that they 
were relatively immature precursors. Approximately 40% were DCX+ and 20%  were 
Olig2+, indicating entry into the path leading towards a neuronal or oligodendrocyte fate, 
respectively, while less than 3% of cells were GFAP+. Many cells that expressed DCX, 
Olig2 or GFAP also expressed nestin or Sox2, suggesting very recent entry into a specific 
lineage. CD11b+ microglia were < 0.8% of the population. None of the cells stained for O4, 
a marker of more mature OLs. (B–E) Triple labeling shows that most precursors in these 
cultures, regardless of differentiation state, express MOR (red, B and D). The Hoechst+ 
nucleus of a cell that is MOR) is indicated by (*) in panel (d). Two Olig2+ cells the express 
MOR are indicated by arrowheads in each panel. Scale bar = 10 µM. 
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Figure 2.2 
 
 
 
 
Figure 2.2 Exposure to HIV-1 Tat1-86 increases progenitor secretion of a select group of 
chemokines. Cells were treated at 5 days after plating with morphine (M), Tat (T), gp120 
(G), and naloxone (N) either alone or in combinations as indicated. Of 23 factors tested, 10 
were secreted by unstimulated cells (see Table 1). Only RANTES, MIP-1α, and MIP-1β 
showed a significant change in concentration after 12-h treatment. Cells responded to Tat, 
but not to gp120. There was no synergistic response of concurrent exposure to either 
morphine or gp120. MCP-1 showed a similar trend towards a Tat response, but the effect 
was not significant. *p < 0.05; **p < 0.01; ***p < 0.001 vs. untreated control cells (C), 
ANOVA and post-hoc Bonferroni’s test. n = 6 independent cultures. 
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Figure 2.3 
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 Figure 2.3 Localization of CCL5/RANTES in NPC/GPCs in vitro and in vivo. Cultured 
cells were immunostained (A–C) at 5 days in vitro. In vivo staining (D and E) was done in 
adult striatum. (A and B) NPC/GPCs were immunostained with an antibody to Olig2 (A) to 
identify oligodendroglial precursors, and an antibody to CCL5/RANTES (B) to determine 
which cells are producing this chemokine. Of the five Olig2+ cells in this field, two show 
CCL5/RANTES expression in their cytoplasm (arrows indicate double-labeled cells). 
Three other cells that are Olig2+ (asterisks) do not express detectable levels of 
CCL5/RANTES. For (C–E), Z stacked images (AxioVision software, version 4, Carl Zeiss, 
Inc.) were taken through the entire depth of the cell layer (C) or section (D and E), then 
optimized for deconvolution microscopy (AutoQuant X Version 2, Media Cybernetics, 
Bethesda, MD, USA) in order to better demonstrate sub-cellular details of Sox2 and 
CCL5/RANTES co-localization. (C) Cells in the same NPC/GPC cultured stained for Sox2 
(green) and CCL5/RANTES (red). The Sox2+ cells are a mixture of CCL5+ (asterisks) and 
CCL5) (arrows). Note also that many CCL5+ cells are Sox2) (arrowheads). Hoechst 
staining (blue) identifies the nuclei of all cells in the field. (D and E) Co-localization of 
Sox2 (green) and CCL5/RANTES (red) in the adult mouse striatum in situ. Hoechst 
staining (blue) identifies nuclei of all cells in the field. As CCL5 is a secreted, soluble 
chemokine, it is difficult to associate specific cell boundaries with CCL5 immunostaining. 
However, it can be appreciated from panel (D) that Sox2+ cells (asterisks) in the striatum 
are frequently associated with significant CCL5 immunostaining. The region shown in (E) 
has a high density of Sox2- cells, as indicated by the Hoechst staining, and little CCL5 
signal. 
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Figure 2.4 
 
Figure 2.4 NPC/GPCs express both CCR5 and CXCR4 in vitro. Olig2+ (green) 
oligodendroglial precursors show both CCR5 (A) and CXCR4 (C) immunoreactivity. The 
signal for CXCR4 was generally light in these cells, and is indicated by arrows in (C). 
Undifferentiated Sox2+ NPC/GPCs (green) also are immuno-positive for CCR5 (B) and 
CXCR4 (D). Asterisks in (A–D) indicate double-labeled cells. Hoechst33342 nuclear 
staining (blue) shows that some cells positive for CCR5 or CXCR4 do not express Olig2 or 
Sox2. (E) A major band at approximately 40 kDa was noted on immunoblots of NPC/GPCs 
harvested at 5 DIV using antibodies to both CCR5 and CXCR4. Actin detection is included 
as a loading control. These bands are also detected in homogenates of cultured astroglia 
(AS) and whole striatum, preparations that are known to express both receptors. 
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Figure 2.5 
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Figure 2.5 Chemotaxis of BV-2 cells and primary microglia in response to NPC/GPCs in 
transwell cultures. (A) NPC/GPCs grown on a 24-well plate were treated with Tat or gp120 
for 12 h prior to the addition of transwell inserts containing BV-2 cells. Transwell inserts 
were removed after 3 h, and cells crossing the insert membrane were labeled with 
CyQuant® GR dye and quantified on a PHERAstar FS plate reader with appropriate filters. 
Migration of BV-2 cells was not affected when either Tat or gp120 alone was added to the 
medium. Untreated NPC/GPCs also had no effect on BV-2 migration. However, the 
number of BV-2 cells moving across the transwell membrane was significantly enhanced 
when NPC/GPCs were pre-treated with Tat for 12 h (***p < 0.001 vs. all other groups; n = 
6 independent cultures). Pre-treatment of NPC/GPCs with gp120 did not affect BV-2 
migration. The inset image shows Hoechst staining of BV-2 cells, and illustrates the effect 
of NPC/GPC treated with Tat to enhance migration. (B) Antibody neutralization of CCR5 
on BV-2 cells significantly attenuated Tat-enhanced migration. BV-2 cells on transwell 
inserts were preincubated with either 2D7 anti-CCR5 monoclonal antibody or control 
IgG2a for 1 h at 4˚C, then placed into wells containing treated or untreated NPC/GPCs. 
Incubation with 2D7 antibody, but not control IgG2a, reduced BV-2 cell migration in the 
NPC/GPC + Tat treatment group back to basal levels. This suggests that the enhanced 
microglial migration caused by secretions from Tat-treated NPC/GPC is entirely mediated 
by CCR5-signaling. Antibody neutralization did not reduce migration in other treatment 
groups to below basal levels. (**p < 0.01 vs. all other groups; n = 6 independent cultures). 
(C) Studies in (A) and (B) were repeated on primary murine microglia with similar results. 
Migration of primary microglia was significantly enhanced by the presence of NPC/GPCs 
pre-treated with Tat, although there was no effect of gp120 pre-treatment. Incubation with 
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2D7 antibody reduced migration in the NPC/GPC + Tat treatment group back to basal 
levels, but did not affect migration in other treatment groups. (***p < 0.001 vs. all other 
group; n = 4 independent cultures). 
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Figure 2.6 
 
 
 
 
 
 
 
 
Figure 2.6 A fluorescent viability assay reveals that 12-h exposure to HIV-1 Tat1-86 or 
gp120 alone or in combination with opiates did not increase the rate of NPC/GPC cell 
death in vitro. Cells were treated at 5 days after plating with morphine (M), Tat (T), gp120 
(G), naloxone (N) either alone or in the combinations indicated. There was no significant 
increase in cell death in any treatment group. n = 8 independent cultures 
48 
 
Chapter 3 
HIV-1 Alters Neural and Glial Progenitor Cell Dynamics in the CNS: 
Coordinated Response to Opiates During Maturation 
 
(This chapter was submitted as a paper to Glia and is accepted pending revision. 
 
Introduction  
 
Morbidity and mortality due to human immunodeficiency virus (HIV-1) infection has 
significantly decreased since the introduction of combined anti-retroviral therapy (cART). 
cART treatment has also changed the landscape of central nervous system (CNS) disorders. 
Fewer patients exhibit HIV associated dementia (HAD), but there is increased prevalence 
of asymptomatic and mild-to-moderate HIV-associated neurocognitive disorders (HAND) 
among patients with absence of peripheral viremia (Cysique et al. 2004; Gonzalez-Scarano 
and Martin-Garcia 2005; Gonzalez et al. 2002; Sacktor 2002; Simioni et al. 2010). Factors 
contributing to CNS pathology and dysfunction include an increased life expectancy of 
HIV-1 patients receiving cART, and potential toxic effects of long-term anti-retroviral 
exposure (Apostolova et al. 2011; Clifford 2002). In addition, many HIV therapeutics do 
not readily penetrate the blood brain barrier, leaving a reservoir of HIV in the CNS.  
Microglia are the principal source of active HIV infection in the brain; astroglia can also 
be infected but tend not to produce new virus (Gonzalez-Scarano and Martin-Garcia 2005; 
Jordan et al. 1991; Kaul 2008). Several studies suggest that CNS neural progenitor cells 
(NPCs), the undifferentiated precursors of both neurons and glia, are also susceptible to 
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HIV-1 infection (Lawrence et al. 2004; Rothenaigner et al. 2007; Schwartz et al. 2007), but 
the extent that this contributes to the spectrum of CNS disorders remains unclear. Even if 
NPCs are not readily infected, they may be affected either by HIV-1 proteins directly 
(Buch et al. 2007; Hahn et al. 2010b; Krathwohl and Kaiser 2004b; Lee et al. 2011; Mishra 
et al. 2010; Okamoto et al. 2007; Peng et al. 2008), or secondarily by changes in the 
extracellular milieu. NPCs are widely distributed in germinative zones within the 
developing CNS. Neurons in most brain regions are formed prenatally, but production of 
astroglia and oligodendroglia continues into the postnatal period in both rodents and 
humans (Chan et al. 2002; Geha et al. 2010; Lee et al. 2000; Skoff 1990; Skoff and Knapp 
1991; Suh et al. 2007). NPCs also are present in the adult CNS. While neurogenesis occurs 
in specific regions, including the subgranular zone in the dentate gyrus of the hippocampus 
and the subventricular zone of the lateral ventricles (Doetsch et al. 1997; Eriksson et al. 
1998; Kaplan and Hinds 1977; Kornack and Rakic 1999), glial progenitors are found 
throughout the adult CNS. There is a slow turnover of glial cells throughout life (Goldman 
and Sim 2005; Imamoto and Leblond 1978; Kornack and Rakic 1999; Kornack and Rakic 
2001; Liu et al. 2004; Messier et al. 1958; Sturrock 1979), and more active gliogenesis 
occurs during situations of injury/disease (Burns et al. 2009; Rola et al. 2006; Romanko et 
al. 2004). Glial progenitors constitute 1-to-4% of the cells in normal adult brains (Picard-
Riera et al. 2004; Reyners et al. 1986).   
To test the hypothesis that HIV-1 infection can affect the dynamics of cell production 
during development, we used stage-specific markers to follow changes in the proliferation 
rate and populations of NPCs (nestin+ and Sox2+ [SRY (sex determining region Y)-related 
HMG (high mobility group)-box gene2]) and their glial progeny both in culture and in the 
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intact brain during the perinatal period. Opioid receptors are present and functional on 
NPCs and glial progenitors in adult and neonatal rodent and human CNS (Buch et al. 2007; 
Hauser et al. 2009; Persson et al. 2003; Reznikov et al. 1999; Rius et al. 1991; Tripathi et 
al. 2008). Since co-exposure to opiate drugs of abuse enhances HIV-related deficits in the 
CNS in patients and experimental models (Anthony and Bell 2008; Bell et al. 2006; Burdo 
et al. 2006; Byrd et al. 2011; Hauser et al. 2007; Kopnisky et al. 2007), we also examined 
interactive opiate effects. HIV-1 Tat was used to model HIV exposure both in vitro and in 
vivo. We also assessed progenitor responses in a more clinically relevant model by 
exposing human NPCs (hNPCs) to supernatant from HIV-infected monocytes ± opiates. 
Results showed that HIV-1 Tat or morphine alone reduced NPC and glial progenitor 
proliferation and/or altered the population dynamics of murine progenitors both in vitro and 
in vivo. In certain subsets of progenitors, co-exposure to morphine accelerated the timing 
and extent of Tat effects. Similarly, the proliferation of hNPCs was reduced by exposure to 
Tat or R5 HIV-1SF162, and there was an interactive opiate-virus effect. Findings support the 
concept that HIV ± opiates can affect the expansion of specific CNS progenitor 
populations. We speculate that this might alter the balance of glia and neurons in the CNS 
of pediatric HIV patients. Since NPCs and glial progenitors in adult share certain 
characteristics with those found in neonatal brains, our findings might also relate to adult 
HIV patients. At either age, an altered progenitor pool is predicted to adversely affect CNS 
function.  
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Materials and Methods  
 
 Experimental protocols conformed to Virginia Commonwealth University 
Institutional Animal Care and Use Committee and national (PHS) guidelines on the care 
and ethical use of animals. Experiments were designed to minimize the total number of 
animals used and their discomfort.  
 
Murine neural progenitor cell cultures 
Murine NPCs were cultured from striata of embryonic day 15 (E15) mice (ICR 
strain; Charles River, Boston, MA) using modifications of a published technique 
(Khurdayan et al. 2004). In brief, embryos were harvested aseptically, and striata from 10 
to 12 embryos were dissected from the cortex. Striata were dissected out, finely minced and 
incubated with DNase (0.015 mg/mL, Sigma-Aldrich Co., St. Louis, MO) in Dulbecco’s 
Modified Eagle’s Medium (DMEM) (15 min, 37ºC). Tissue was triturated, centrifuged (5 
min at 1000 rpm), and resuspended in 5 mL of defined, NPC maintenance medium 
consisting of 1:1 DMEM/F12 (Invitrogen Corp., Carlsbad, CA), 10% Knockout® SR 
(Invitrogen; a serum replacement product), insulin (25 µg/mL), transferrin (100 µg/mL), 
progesterone (20 nM), putresceine (60 µM), Na-HCO3 (6 mM), and sodium selenite (30 
nM) (all from Sigma-Aldrich). Cells were filtered through a 70-µm nylon cell strainer (BD 
Falcon, Bedford, MA), counted, centrifuged as above, and resuspended in an appropriate 
volume of the same medium to obtain desired plating densities. A total of 5 ×104 cells were 
plated on poly-L-lysine coated coverslips, and medium was refreshed every 2-3 d until 
treatment started. Cells were grown at 37ºC in a humidified atmosphere of 5% CO2. After 5 
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d, the medium was replaced and cells were treated with Tat1-86 (100 nM; 
ImmunoDiagnostics, Woburn, MA), ± morphine sulphate (500 nM; NIDA Drug Supply 
System, Rockville, MD), ± naloxone (1.5 µM; Sigma-Aldrich) for 12 h, 24 h, or 48 h. 
Morphine, the major bioactive product of heroin in the brain, is a potent µ-opioid receptor 
(MOR) agonist; naloxone is a broad spectrum opioid receptor antagonist. These 
concentrations of Tat1-86 and morphine have been established to elicit functional effects in 
astroglia, oligodendrocytes (OLs), and neural progenitors in our earlier studies (Buch et al. 
2007; El-Hage et al. 2005; Hauser et al. 2009; Khurdayan et al. 2004). Naloxone was 
applied 30 min prior to other treatments, which were added simultaneously in pre-warmed 
medium. Lastly, 5-bromo-2′-deoxyuridine (BrdU, Sigma-Aldrich) was added to the 
medium at 12 h prior to harvest (10 µM) to detect proliferating cells in S phase.  
 
Opiate delivery to prenatal and postnatal Tat transgenic mice in vivo 
For in vivo studies in perinatal mice, we utilized Tat transgenic mice engineered to 
express the HIV-1 Tat1-86 protein under control of a glial fibrillary acidic protein (GFAP) 
promoter in a doxycycline-inducible manner. As previously described (Bruce-Keller et al. 
2008; Fitting et al. 2010b; Hauser et al. 2009), mice expressing the tat gene under control 
of a tet responsive element (TRE) in the pTREX vector (Clonetech, Mountain View, CA) 
were crossed with mice expressing the reverse tetracycline transactivator (RTTA) driven 
by a human GFAP promoter. Inducible Tat+ transgenic mice express both GFAP-RTTA 
and TRE-Tat genes; Tat- mice express only the GFAP-RTTA gene. To induce Tat 
production during the pre- and early postnatal period, pregnant dams were given chow 
containing doxycycline (Harlan, Indianapolis, IN; 6 mg/g) from gestational day 15-16 until 
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postnatal day 7. Doxycycline, a water-soluble tetracycline derivative that crosses the 
placenta and is secreted in breast milk, is reported to reliably induce transgene expression 
in embryos and postnatally via the tet-on system during perinatal development (Fedorov et 
al. 2001; Perl et al. 2002a; Perl et al. 2002b; Shin et al. 1999). All dams received the same 
chow, to control for effects of doxycycline unrelated to activation of the transgene in Tat- 
pups. Standard PCR procedures were performed on genomic DNA isolated from ear clip 
samples to confirm the genotype of individual mice. Morphine was delivered by 
subcutaneous (s.c.) injection (NIDA Drug Supply System) at a dose of 2 mg/kg in a 20 µl 
volume of saline, based on the average daily litter weight. Male, P4 to P7 Tat+ mice 
received a morphine injection twice daily at 10:00 am and 6:00 pm. For sham pups, 20 µl 
of saline was injected s.c. twice daily. According to a previous report, 2 mg/kg of morphine 
s.c., based on the average daily litter weight, gave circulating morphine levels that 
approximate the range measured in human preterm infants who are given an intermittent or 
continuous intravenous morphine infusion (Vien et al. 2009). For BrdU labeling in vivo, 50 
µl of 10 mg/ml BrdU (32.5 mM) was injected s.c. in sterile saline twice at 2 h intervals 
immediately prior to perfusion. Fewer than 5% of the neonatal mice in our studies died, 
and there was no relationship between morphine-induced toxicity and either genotype or 
doxycycline administration. For immunohistochemistry studies, pups were deeply 
anaesthetized with isoflurane (Baxter, Deerfield, IL) prior to perfusion with 4% 
paraformaldehyde (pH 7.4). After perfusion, brains were removed and post-fixed in fresh 
fixative overnight. Brains were hemisected, rinsed several times and overnight in 15 ml 
changes of phosphate-buffered saline, cryopreserved through graded sucrose solutions (10 
and 25 %), embedded in Tissue Tek OCT compound (Sacura Finetek, Torrance, CA), and 
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stored at –80˚C. 10 µm frozen sections containing the striatum were thaw-mounted on 
SuperFrost Plus slides (VWR Scientific, West Chester, PA) and processed for 
immunostaining. 
 
Immunohistochemistry and quantification 
 For in vitro studies, NPCs on coverslips were immunolabeled after 12, 24, and 48 h 
treatment, using antibodies to cell-specific and lineage-specific markers including nestin 
(1:5000, Aves Labs, Inc., Tigard, OR), Olig2 (oligodendrocyte transcription factor 2; 
1:100, Immuno-Biological Laboratories, Minneapolis, MN), and Sox2 (1:200, Millipore, 
Temecula, CA). Cells were fixed with 4% paraformaldehyde; for intracellular markers, 
cells were permeabilized with 0.1% Triton X-100 in phosphate-buffered saline containing 
1% bovine serum albumin (Sigma-Aldrich) for 30 min. Antibodies were applied overnight 
at 4ºC, followed by visualization with appropriate fluorescent-conjugated second 
antibodies (Invitrogen). Double-staining was performed with anti-BrdU (1:200, Abcam, 
Cambridge, MA) and anti-Sox2 or anti-Olig2 to detect proliferating progenitors. Coverslips 
were treated with 1 N HCL in PBS to expose incorporated BrdU followed by 
immunostaining for precursor markers. BrdU antibody was applied overnight at 4ºC, 
followed by appropriate fluorescent-conjugated second antibodies. Immunolabeled 
coverslips were finally incubated with Hoechst 33342 dye (0.5 µg/ml, 8 min) to identify 
nuclei (Molecular Probes/Invitrogen), then mounted in ProLong Gold anti-fade reagent 
(Molecular Probes/Invitrogen) and dried in the dark. To assess the proportion of different 
progenitors in the cultures, 300–350 Hoechst+ cells were selected randomly per coverslip 
and assessed for nestin, Sox2, and Olig2 (n = 6) under oil immersion at 63× using a Zeiss 
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AxioObserver system with integrated MRm camera system (Carl Zeiss, Inc., Thornwood, 
NY). Proliferation was assessed in the overall NPC population by scoring 300-350 
Hoechst+ cells for expression of BrdU. Proliferation was also assessed in each progenitor 
population by scoring BrdU expression in 200 nestin+, Sox2+, and Olig2+ cells on each 
coverslip. Similar immunodetection methods were applied to 10 μm tissue sections from 
neonatal brains. The proportion of different cell types in vivo was estimated by averaging 
the percentage of Sox2+ or Olig2+ cells among 250–350 randomly selected Hoechst+ cells 
per striatum (left side) in two sections, in a total of n = 6 mice. Proliferation was assessed 
in the same mice by scoring BrdU expression in 200 cells positive for each progenitor 
marker in two striatal sections per mouse. Double-immunolabeling was performed to assess 
whether hNPCs expressed the mu opioid receptor (MOR) and C-C chemokine receptor 
type 5 (CCR5) in vitro. MOR (1:250, Antibodies Incorporated, Davis, CA) and CCR5 
(1:200, BD Pharmingen, Mountain View, CA) antibodies were applied to fixed hNPCs and 
incubated overnight at 4°C, then visualized as described above, prior to labeling with NPC 
markers and Hoechst 33342. p24 was detected on hNPCs after exposure to HIV-1SF162, 
with an antibody commonly used to study infective processes (1:50, Dako, Carpinteria, 
CA) (Eugenin et al. 2011; Hahn et al. 2008; Lawrence et al. 2004). Images were taken 
under oil immersion at 63× using a Zeiss AxioObserver and integrated MRm camera 
system.  
 
Viability assay 
 Mouse NPCs were cultured on poly-L-lysine coated 48 well plates and treated at 5 
d after plating with Tat, morphine and naloxone either alone or in combination as in 
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experiments described above. After 12, 24, and 48 h, medium containing treatments was 
replaced with sterile, tissue culture–grade D-phosphate-buffered saline containing the final 
concentration of 4 µM ethidium homodimer-1 (EthD-1) and 5 µg/mL Hoechst 33342. The 
working solution was added directly to cells and incubated for 15 min, at 37˚C. The 
intensity of EthD-1 and Hoechst signals was measured using a PHERAstar FS plate reader 
(BMG LABTECH, Ortenberg, Germany) in n = 8-10 different cultures using appropriate 
excitation and emission filters (EthD-1: 495/635 nM; Hoechst: 350/510 nM). 
 
RNA Extraction and Reverse transcription PCR 
 Non-quantitative RT-PCR was performed to confirm expression of Tat mRNA in 
the striatum of 7 day postnatal pups treated with doxycycline administered through 
placenta and lactation as described. Pups were deeply anaesthetized with isoflurane prior to 
perfusion. The striata were rapidly dissected from brains, and stored at -80°C. Total RNA 
was isolated using TRIzol reagent (Invitrogen). Each RNA sample was cleaned using 
GenEluteTM Mammalian Total RNA kit (Sigma-Aldrich), after RNase-free DNase I 
treatment to eliminate genomic DNA. cDNA was synthesized from 2 μg of total RNA 
using the High-Capacity cDNA Archive Kit (Applied Biosystems, Warrington, UK) per 
manufacturer’s instructions. PCR procedures were performed to detect Tat mRNA 
expression using primers previously described with 18S mRNA as a control (Bruce-Keller 
et al. 2008; Hauser et al. 2009) Tat1 5′-ATGGAGCCAGTAGATCCTAG-3′, Tat2, 5′-
TCATTGCTTTGATAGAGAAACTTG-3′, rTta1 5′-AATCGAAGGTTTAACCCG-3′, 
rTta2, 5′-TTGATCTTCCAATACGCAACC-3′, 18S1 5’-
CACTTGTCCCTCTAAGAAGTTG-3’, 18S2 5’-GACAGGATTGACAGATTGATAG-3’) 
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(Chauhan et al. 2003). Final PCR products were separated by electrophoresis using a 1.5% 
agarose gel, stained with ethidium bromide, and visualized using a Kodak 440CF Image 
Station (Rochester, NY). 
 
Viral stock preparation  
 HIV-1SF162 viral stock was obtained from Dr. Jay Levy through the AIDS Research 
and Reference Reagent Program, Division of AIDS, NIAID, HIV (Cheng-Mayer and Levy 
1988). The R5 strain was propagated in a U937 monocyte cell line (ATCC, Chicago, IL). 
U937 cells were activated with IL-2 (10 U/ml) and phytohaemagglutinin (1 mg/ml) for 2 d 
in RPMI with 10% fetal calf serum. The peak of infection was monitored by p24 ELISA, 
and the culture supernatant was collected and passed through a 0.2 µm filter and stored at -
80˚C. For FACS analysis, 250 μl of media containing 500 pg virus measured by p24 
ELISA was added to hNPCs grown to 75-80% confluence in each well of 6-well plates, 
with a final volume of 1.5 ml per well. The viral exposure time was 12 h. 
 
Human neural progenitor cell line culture and CCR5 blocking assay 
These studies used the human neural progenitor ReNcell VM cell line, derived from 14-
wk gestation human ventral mesencephalon (Millipore). This cell line contains over 95% 
Sox2+ and nestin+ cells, and has the potential to produce dopaminergic neurons (Donato et 
al. 2007). For all experiments, cells frozen at passage 3 were thawed and expanded on 
laminin-coated T75 cm2 tissue culture flasks (Corning) in ReNcell NSC Maintenance 
Medium (Millipore) supplemented with epidermal growth factor (EGF) (20 ng/ml; 
Millipore) and basic fibroblast growth factor-2 (FGF-2) (20 ng/ml; Millipore). Three to 
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four days after plating (i.e., prior to reaching 80% confluence), cells were passaged by 
detachment with accutase (Millipore), centrifuged at 300 × g for 5 min and the cell pellet 
resuspended in fresh maintenance media containing EGF and FGF-2. For FACS analysis 
experiments, cells were replated in laminin-coated 6-well plates at a density of 30,000 cells 
per well. Three to four days after plating, cells were treated for 12 h with Tat or HIVSF162 ± 
morphine ± naloxone. For the CCR5 blocking experiment, a non-signaling   monoclonal 
antibody (2D7 antibody) to CCR5 (2 µg/ml; BD Pharmingen) (Lee et al. 1999) or mouse 
IgG (2 µg/ml; BD Pharmingen) were applied 1 h prior to treatment. The hNPCs were 
treated with BrdU solution (10 µM) 2 h prior to harvesting. For p24 immunolabeling, 5,000 
cells per well were replated on laminin-coated coverslips in 24-well plates and treated with 
HIV-1SF162 prior to reaching 80% confluence as described above. All experiments utilized 
cells from passage 4 to minimize changes in cell characteristics over multiple passages that 
might influence the results. 
 
FACS analysis of hNPC proliferation and p24 expression 
The APC BrdU Flow Kit (BD Pharmingen) was used to determine the proportion of 
hNPCs in S-phase of the cell cycle. Cells were incubated with BrdU (10 μM) for the final 2 
h of a 12 h exposure to Tat or to supernatant from HIV-1SF162 infected monocytes ± 
morphine. The cells were detached using enzyme-free cell dissociation buffer (Sigma-
Aldrich) and fixed with BD Cytofix/Cytoperm buffer (containing 4% paraformaldehyde). 
After permeabilization, cells were treated with DNase to expose BrdU incorporated in 
DNA. An APC-conjugated anti-BrdU antibody and 7-amino-actinomycin D (7-AAD) were 
used to determine cell cycle phases (Go/G1, S, G2+M) in all hNPC groups. Fluorescent 
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signals for APC (Ex: 650 nm; Em: 615 nm) and 7-AAD/DNA complexes (Ex: 546; Em: 
647) were detected on a FACSCanto (BD Biosciences, San Jose, CA) and analyzed using 
the DIVA FACS data program (BD Biosciences). Single and intact hNPCs were first gated 
by cell area and width. APC-BrdU fluorescence intensity was assessed after gating on 
approximately 3 x 105, 7-AAD+ cells. Go/G1 phase cells (APC-BrdU- and 7-AAD+) were 
defined using appropriate negative (non-specific IgG followed by APC-conjugated 
secondary antibody only); and positive (7-AAD only; APC-anti-BrdU antibody only) 
controls. S-phase cells were defined as being APC-BrdU+ and 7-AAD+.  
 After 12 h exposure to supernatant from HIV-1SF162 infected monocytes, p24 
expression on hNPCs was determined by FACS analysis. Cells were fixed and 
immunolabeled with p24 antibody and Alexa Fluor 488-conjugated second antibody, 
followed by incubation in 7-AAD. Single and intact hNPCs were gated as above. The 
intensity of p24 immunolabeling was assessed on approximately 3 x 104 intact, 7-AAD+ 
cells. A single laser (488 nm) and two color fluorescence emission (585/42 band pass; 
530/30 band pass) approach was used to account for autofluorescence. Controls included 
p24 labeling in untreated cells and non-specific IgG followed by second antibody in HIV-
treated cells. 
 
Statistical analysis 
 Significance was assessed by analysis of variance (ANOVA) followed by Duncan’s 
post-hoc testing if indicated, using StatSoft software (Statistica, Tulsa, OK). 
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Results 
 
Effect of HIV-1 Tat and morphine on murine neural progenitors in vitro 
 To determine whether Tat1-86 and morphine affect the maturation of NPCs either 
independently or interactively, NPCs from embryonic mouse striata were treated with 100 
nM Tat1-86 ± morphine (500 pM) over a period of 48 h, with BrdU added for the final 12 h. 
Double-label immunostaining was performed following 12 h, 24 h and 48 h treatments for 
BrdU and three lineage specific markers, nestin, Sox2, and Olig2. Nestin and Sox2 are 
markers of uncommitted NPCs (Blumcke et al. 2001; Episkopou 2005; Gu et al. 2002; 
Nunes et al. 2003; Qu and Shi 2009), while Olig2 is a transcription factor expressed in 
more differentiated cells that develop largely into oligodendrocytes (OLs) and motor 
neurons (Masahira et al. 2006; Takebayashi et al. 2002). Treatment with Tat ± morphine 
for 12 h did not alter either the proportion of nestin+ (nestin+/Hoechst+) or Olig2+ 
(Olig2+/Hoechst+) cells, or the percentage of nestin+ or Olig2+ cells expressing BrdU (Fig. 
3.1 A and D, C and F). There were, however, significant effects on the subset of NPCs 
expressing Sox2. While neither morphine or Tat alone had any effect, both the percent of 
proliferating Sox2+/BrdU+ cells, and the total Sox2+ cell population were reduced when 
cells were exposed concurrently to Tat + morphine (Fig. 3.1 B and E). Since only Sox2+ 
cells were affected after 12 h, we hypothesized that the sensitivity of NPCs to Tat ± 
morphine might depend on their stage of differentiation, and that changes in the Sox2 cells 
might affect their progeny. We extended the experiments to 24 h and 48 h using markers 
for Olig2 (Fig. 3.2). At both 24 h and 48 h, the total Olig2+ population was reduced by Tat 
alone with no added effect of morphine (Fig. 3.2 C, D). The proliferating (Olig2+ / BrdU+) 
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population at 24 h was unaffected by either Tat or morphine alone, but Tat and morphine 
interacted to reduce BrdU uptake (Fig. 3.2 A). By 48 h, Tat alone, but not morphine alone, 
had reduced the proliferating, Olig2+ population. Tat and morphine interacted at this time 
point to further decrease BrdU uptake (Fig. 3.2 B). Thus, interactive effects of Tat and 
morphine were only observed on the proliferative behavior of Olig2+ cells, while Tat by 
itself affected cell populations. Naloxone partially reversed the interactive effects of 
morphine in proliferating cells, as the groups receiving Tat, morphine, and naloxone were 
not different from control, but also not different from the group co-exposed to Tat and 
morphine. It also appeared to reduce the overall numbers of Olig2+ cells when given 
concurrently with Tat and morphine. We conducted the additional experiments described 
below to understand these findings.  
 
Effect of naloxone on murine progenitors in vitro 
 Although naloxone partly or fully reversed the effects of morphine in most 
instances, naloxone exposure also decreased the percentage of cells expressing Olig2 when 
combined with morphine and Tat treatment (“a” in Fig. 3.2 D and E). We thus treated 
murine NPCs with naloxone alone for 12-48 h and compared the proportion of Olig2+ cells 
in untreated control and naloxone treated groups. There was no significant reduction in the 
Olig2+ population (Fig. 3.2 E), suggesting that naloxone by itself is not toxic to Olig2+ cells 
or their immediate progenitors. Instead, it might interfere with endogenous opioid signals 
under the specific condition of Tat and morphine treatment. Autocrine opiate signaling 
pathways are known to play pivotal roles in OL survival (Buch et al. 2007; Hauser et al. 
2009; Khurdayan et al. 2004; Knapp et al. 2001), and overall glial cell fate (Gorodinsky et 
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al. 1995; Kim et al. 2006; Persson et al. 2003). Naloxone might interfere with multiple 
opioid pathways that modulate proliferation and development of OL lineage specific 
progenitors under these experimental conditions.  
 
Effect of HIV-1 Tat and morphine on murine neural progenitors: proliferation vs. 
viability  
To determine whether cell death might contribute to the observed reductions in 
proliferating or total NPCs, we examined the viability of total NPCs at up to 48 h of 
exposure to Tat ± morphine using an ethidium-based viability assay. There was no 
significant cell death in response to any treatment at any time period measured by EthD-1 
fluorescence intensity (Fig. 3.3). 
 
Effects of HIV-1 Tat and morphine on neural progenitors in striatum  
 To assess the effect of HIV-1 Tat and morphine on NPCs in vivo, we utilized an 
inducible, tetracycline (tet) “on” system with doxycycline induction. Detection of Tat 
mRNA and protein in the brains of these mice, including the striatum, was previously 
reported by our group, (Bruce-Keller et al. 2008; Duncan et al. 2008; Fitting et al. 2010b; 
Hauser et al. 2009) and also shown here (Fig. 3.4 A-C). Pregnant dams received chow 
containing doxycycline from gestational day 15-16 through postnatal day 7 to activate the 
HIV-1 Tat transgene in fetal and neonatal mice. Reverse transcription PCR was performed 
to detect Tat mRNA expression in cortex and striatum of neonatal mice at P7 (Fig. 3.4 B). 
Evaluation of PCR band intensities confirmed that doxycycline delivered to dams induced 
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Tat mRNA expression in the cortex and striatum of Tat+, but not Tat- neonatal mice (Fig. 
3.4 C).  
 All mice used in experiments were male. Some mice received morphine s.c. at 
postnatal days 4–to-7 to assess whether co-exposure to HIV-1 Tat and morphine caused 
effects on NPCs in vivo similar to those seen in culture. There were several significant 
effects on proliferating cell populations. Morphine exposure and Tat induction 
independently reduced BrdU uptake in both Sox2+ and Olig2+ cells in the striatum, and in 
the overall population of striatal NPCs (Fig. 3.4 D). An interactive effect of morphine and 
induced Tat was seen in the Sox2+/BrdU+ population and in the overall population of 
BrdU+ cells (Fig. 3.4 D). We examined whether this might lead to changes in the overall 
populations of Sox2+ and Olig2+ cells. Morphine and Tat by themselves each reduced the 
percentage of the population that was Sox2+ or Olig2+ (Fig. 3.4 E); there was no interactive 
effect between them. Additionally, Tat alone, but not morphine alone, reduced the 
percentage of the population that was Olig2+; again there was no Tat and morphine 
interaction.  
  
Effects of HIV-1 Tat, HIVSF162, and morphine on proliferation of a human NPC line 
To validate our in vitro and in vivo results in a more clinically relevant system, we 
exposed human NPCs to HIV-1 Tat1-86, or to supernatant from U-937 monocytes infected 
with R5-tropic HIV-1SF162, with or without concurrent morphine. Before conducting 
experiments, we briefly characterized the hNPC cell line by co-localizing MOR, nestin, 
and/or Sox2 antigenicity. In accordance with previous reports (Breier et al. 2008), more 
than 95% of hNPCs expressed nestin and Sox2. Approximately 95% of hNPC also showed 
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MOR immunoreactivity, suggesting their potential as targets of opiate signaling (Fig. 3.5 A 
and B). Olig2 immunofluorescence was not detected in hNPCs (not shown). Since we used 
an R5-tropic HIV strain that preferentially uses C-C chemokine receptor type 5 (CCR5) as 
a co-receptor for viral entry, we co-localized CCR5 immunoreactivity in Sox2-
immunopositive NPCs to verify expression (Fig. 3.5 C).  
FACS analysis was performed after 12 h exposure to Tat ± morphine to assess the 
percentage of hNPCs in S-phase of the cell cycle, as an index of proliferation. We also 
tested the effect of HIV-1SF162 supernatant from infected cells that had been treated ± 
morphine. Due to their short cell cycle (Breier et al. 2008), hNPCs were treated with BrdU 
2 h prior to harvest. FACS analysis showed a significant reduction in S-phase hNPCs in all 
treatment groups (Fig. 3.5 D). Approximately 47% of control hNPCs incorporated BrdU. 
Both Tat and morphine independently caused a significant reduction in the proportion of S-
phase cells as compared to control, with no synergistic or additive effect of morphine (Fig. 
3.5 D, E). Interestingly, hNPCs exposed to HIV-1SF162 supernatant by itself also showed 
significantly reduced proliferation, and there was an additional reduction in their 
proliferation rate with combined morphine (Fig. 3.5 D, F). HIV-1SF162 utilizes CCR5 as a 
co-receptor for entry, and although the changes in NPC function are not likely due to 
infection, some effects might be due to viral proteins such as gp120 binding to CCR5 on 
hNPCs. To examine this question, the specific, non-signaling, CCR5 blocking antibody 
2D7 (Lee et al. 1999; Wu et al. 1997) was applied 1 h before exposure to viral supernatant. 
Compared to treatment with control mouse IgG, 2D7 immunoblockade partially reversed 
the anti-proliferative effect of HIV-1SF162 supernatant (Fig. 3.5 G).   
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p24 expression in hNPCs by FACS analysis and immunolabeling 
hNPC infection by HIV has been sporadically reported by other investigators 
(Lawrence et al. 2004; Mishra et al. 2010; Schwartz et al. 2007). We assessed hNPCs in the 
present study for the presence of p24 antigen with an antibody commonly used by other 
laboratories to study infective processes (Eugenin et al. 2011; Hahn et al. 2008; Lawrence 
et al. 2004).  hNPCs were exposed for 12 h to HIV-1SF162 infective supernatant, then fixed 
and either detached from the plate, stained with 7-AAD, immunolabeled with p24 
antibody, and subjected to FACS analysis (Fig. 3.6 A-C), or immunolabeled for fluorescent 
microscopic analysis of p24 within individual cells (Fig. 3.6 D, E). Immunoreactivity was 
most often observed in cells that were clearly pyknotic (arrowheads, Fig. 3.6 D, D’). This 
may represent non-specific binding of antibody to cell debris, or infection and subsequent 
death of hNPCs; our methods cannot distinguish between these two possibilities. 
Occasional hNPCs with a normal cellular and nuclear morphology, indicating viability at 
the time of fixation, were also p24+ (Fig. 3.6 E, E’). For FACS studies, hNPCs were fixed 
and immunolabeled with the same p24 antibody and Alexa Fluor 488–conjugated second 
antibody, followed by 7-AAD. Approximately 1 x 104 intact, 7-AAD+ cells were analyzed 
by a single laser (488 nm), two color fluorescence (585/42 band pass; 530/30 band pass) 
methodology that permits assessment of autofluorescence. Neither control (Fig. 3.6 B, C) 
nor experimental (Fig. 3.6 A) groups showed any evidence of autofluorescence. A p24+ 
signal was detected in 0.34% of the overall population (Fig. 3.6 A). Controls included p24 
labeling in untreated cells (Fig. 3.6 B) and non-specific IgG followed by second antibody 
in HIV-treated cells (Fig. 3.6 C); p24 was detected in 0.1% and 0.001% of the control 
populations, respectively. 
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Discussion 
 
NPCs are present throughout ontogeny, including in the adult brain, although the size 
of the NPC population is substantially reduced with age, as is their distribution and 
recruitment. We used both murine and human embryonic cultures, as well as an in vivo 
perinatal model, to determine the ability of HIV-1 Tat, or viral supernatant, to dysregulate 
the proliferation of NPCs, and to affect resulting cell populations in developing systems. 
Exposure to Tat or supernatant from HIV-1SF162-infected cells both reduced progenitor 
proliferation, although exposure time and developmental stage were critical variables. 
Morphine interacted with both Tat and infective supernatant to cause further dysregulation. 
Results suggest that HIV exposure, and co-exposure to opiates, elicit fundamental changes 
in NPC function that likely contribute to neurologic impairment in both pediatric and adult 
patients. Morphine by itself caused changes in the behavior of NPCs in mice exposed 
during the perinatal period that may be relevant to children exposed to morphine or heroin 
before birth.  
 
HIV-1 Tat and opiates alter proliferation/population dynamics of murine NPCs in 
vitro 
Previous studies have shown effects of HIV-1 Tat on the expansion, viability, and/or 
defined populations of fetal human or murine NPCs or glially-restricted progenitors in 
culture, without determining if cells at a particular stage of maturation might be selectively 
affected (Buch et al. 2007; Khurdayan et al. 2004; Mishra et al. 2010). We were especially 
interested to test whether opiate exposure might enhance Tat effects, since opiates are a co-
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morbid factor that can amplify CNS dysfunction, both in experimental models of HIV 
(Bokhari et al. 2011; Bruce-Keller et al. 2008; Fitting et al. 2010b; Hauser et al. 2006; Hu 
et al. 2005; Kumar et al. 2006; Zou et al. 2011) and in patients (Anthony et al. 2005; Bell et 
al. 2002; Byrd et al. 2011). Studies both in vitro and in vivo examined the striatum, an area 
that is rich in opiate receptors and extremely vulnerable to HIV-1-induced neuropathology 
(Berger and Nath 1997; Mirsattari et al. 1998; Nath et al. 2000; Nath et al. 2002). Murine 
NPCs derived from E14 striatum were characterized previously as a mixture of progenitors 
and very immature cells (nestin+, Sox2+, DCX+, Olig2+) (Hahn et al. 2010b). Most cells 
were actively proliferating and expressed MOR (Fig. 3.5) (Hauser et al. 2009).  
We distinguished between cells expressing nestin or Sox2, markers of relatively 
undifferentiated NPCs, and Olig2, a marker typical of developing OLs (Masahira et al. 
2006; Takebayashi et al. 2002). Tat and/or morphine had effects at specific stages of 
differentiation. As early as 12 h after co-exposure to morphine and Tat, the proliferation 
rate of Sox2+ cells was reduced (Fig. 3.1 B) and the total Sox2+ population was diminished 
(Fig. 3.1 E). With increasing time, Olig2+ proliferation was also affected, first by Tat and 
morphine co-exposure, and then by Tat alone, with combined Tat and morphine leading to 
an additive effect (Fig. 3.2 A, B). Since Tat by itself did not affect proliferation until 48 h, 
and did not affect viability (Fig. 3.3), it was surprising that Tat by itself reduced the 
percentage of total cells that expressed Olig2 at both 24 and 48 h (Fig. 3.2 C, D). A 
potential explanation that was not explored is that Tat may influence NPC lineage 
decisions, perhaps stalling cells at the Sox2+ stage, or increasing the production of GFAP+ 
or NG2+ cells. In keeping with this idea, an increase in the production of GFAP+ cells was 
noted in human progenitors exposed to HIV-1 (Peng et al. 2008).  
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Treatment with naloxone partially reversed morphine–Tat interaction in most in vitro 
studies. However, in the Olig2 population studies, treatment with naloxone decreased the 
percentage of Hoechst+ cells that expressed Olig2 (indicated by “a” in Fig. 3.1 and 2). This 
effect only occurred for Olig2+ cells, and not for nestin+ or Sox2+ cells. These results were 
reminiscent of in vivo studies with another non-selective opioid receptor antagonist, 
naltrexone, which was shown to modulate NPC proliferation in adult rodent hippocampus 
(Holmes and Galea 2002; Ra et al. 2002) and developing rat brain (Schmahl et al. 1989). 
However, we found that naloxone did not directly affect the Olig2+ population (Fig. 3.2 E). 
We have previously suggested that naloxone or naltrexone may interfere with endogenous 
opiate signaling pathways that modify the survival and development of OL lineage cells 
(Hauser et al. 2009; Knapp et al. 2001; Knapp et al. 1998). The present study suggests a 
more complex phenomenon, since naloxone reversal was only partial, and particularly 
impaired in the presence of combined Tat and morphine. CCR5, an HIV co-receptor, has 
well documented interactions with MOR, leading to bi-directional, heterologous cross-
desensitization (Chen et al. 2004; Chen et al. 2007; Suzuki et al. 2002; Szabo et al. 2002; 
Szabo et al. 2003). Tat is known to elevate the β-chemokine ligands that activate CCR5 
(RANTES, MIP-1α, and MIP-1β) in multiple cell types including NPCs (Hahn et al. 
2010b), which may interfere with naloxone activity through the above mechanisms.  
 
HIV-1 Tat and opiates alter proliferation/population dynamics of murine NPCs in 
vivo 
We used inducible HIV-1 Tat1-86 transgenic mice to model Tat and opiate exposure in 
vivo.  While all animal models of a human-specific disease have limitations, these mice 
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have been extensively characterized and shown to exhibit neurologic abnormalities 
associated with chronic HIV-1 exposure, including activation of microglia and astroglia 
(Bruce-Keller et al. 2008), dendritic damage and reduced spine density in striatal neurons, 
abnormal oligodendroglial phenotypes (Fitting et al. 2010b; Hauser et al. 2009), circadian 
rhythm abnormalities (Duncan et al. 2008), and behavioral changes (Fitting et al, 
submitted). Since our culture experiments used E14 tissue grown for 7 d in vitro, we 
performed in vivo studies at a similar time. Results may therefore have particular relevance 
to pediatric HIV patients, but may also pertain to the smaller population of progenitors in 
adult brain parenchyma.  
We focused on Sox2+ and Olig2+ cells, which are relatively abundant in striata as 
compared to nestin+ cells. In vivo results paralleled the tendency towards a decline in 
proliferation and progenitor populations seen in cultured cells, but there were notable 
differences. Of great interest, in mice exposed only to morphine (Tat- + Morph in Fig. 3.4 
D, E), BrdU incorporation was significantly reduced in both Sox2+ and Olig2+ cells, as well 
as in the overall Hoechst+ cell population. The Sox2+ population was also decreased in this 
group, although surprisingly the Olig2+ population was stable. Morphine alone did not 
affect these parameters in cultures. Previous studies of morphine and proliferation have 
been directed towards understanding the dynamics of neuron production, and it is clear that 
morphine reduces neuron generation in neonatal (Kornblum et al. 1987; Seatriz and 
Hammer 1993) and adult rodent brain (Arguello et al. 2008; Eisch et al. 2000; Kornblum et 
al. 1987). Similar to our results, Kornblum et al. (1987) found that morphine reduced 
proliferation in vivo, but had no effect on tissue dispersed in culture. They postulated an 
indirect mechanism for morphine-induced changes in progenitor dynamics; our data would 
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support that concept. Our studies modeled morphine exposure acutely to avoid issues of 
tolerance and dependence that occur during chronic opiate exposure.   
Similar to morphine, the effect of Tat alone was to decrease BrdU uptake into Sox2+, 
Olig2+, and total cells (Fig. 3.4 D), but in all cases Tat induction caused significantly 
greater reduction than morphine exposure (Fig. 3.4 D). The greater effect of Tat on BrdU 
uptake in vivo may reflect the longer Tat exposure time (12 d), as BrdU uptake in cultured 
Olig2+ cells was reduced after 48 h but not earlier. Both Sox2+ and Olig2+ populations 
were reduced by Tat alone (Fig. 3.4 E), probably due in part to decreased proliferation. As 
was true in cultures, the only interactive effect between morphine and Tat was on BrdU 
uptake. This was observed in Sox2+ and total cells, but not in Olig2+ cells, even though co-
exposure reduced BrdU uptake into Olig2+ cells in culture. Given the differences in timing 
and dosing of morphine, these somewhat different responses in culture versus in vivo are 
not surprising.  
We consider it likely that the observed effects of Tat, HIV and/or morphine on 
progenitors will modify the balance of glia and neurons in the CNS, but a different 
approach, including stereology, is required to determine exactly how mature populations 
are affected. Glial populations may be preferential targets, since production of both 
astroglia and oligodendroglia continues well into the postnatal period in both rodents and 
humans (Altman 1966; Chan et al. 2002; Price 1994; Skoff and Knapp 1991; Skoff et al. 
1976; Sturrock 1979; Webster and Astrom 2009). The present studies predict that OLs may 
be quite vulnerable to HIV-1 Tat, and this has been observed in the striatum of mature, Tat-
transgenic mice, especially when the mice are co-exposed to morphine (Hauser et al. 2009).  
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Tat, HIV-1SF162, and morphine alter proliferation of hNPCs 
Since HIV is a human specific disease, the results of our murine models were re-
evaluated in a human NPC line generated from 14-wk gestation human ventral 
mesencephalon. Over 95% of cells are immunopositive for nestin and/or Sox2, and many 
also expressed MOR and CCR5 (Fig. 3.5 A-C). Tat, HIV-1SF162-infective supernatant, and 
morphine all individually reduced proliferation after 12 h, with viral supernatant and 
morphine displaying additive effects (Fig. 3.5). Supernatant and Tat both decreased 
proliferation to the same extent. In general, these results are in accord with a previous 
report that 25-100 ng/ml Tat decreased human fetal progenitor proliferation (Mishra et al. 
2010). Isolated Tat effects were greater in that study, perhaps reflecting different cell 
derivations and culture conditions. Gp120 also was reported to reduce human (Okamoto et 
al. 2007) and mouse progenitor proliferation (Lee et al. 2011). A decrease in young 
neurons produced in the presence of Tat (Mishra et al. 2010) may also reflect an effect on 
cell fate, as hypothesized for certain of our findings. Cell heterogeneity may be an 
important consideration in our results, since all nestin+ or Sox2+ cells do not necessarily 
express equivalent amounts of functional MOR, and may not uniformly express molecular 
targets for Tat, such as α v β 5-integrin (Vogel et al. 1993), mannose (Liu et al. 2004) or 
NMDA receptors (Li et al. 2008), or the low-density lipoprotein receptor-related protein 
(Liu et al. 2000). The gradually increasing effects of Tat ± morphine during the exposure 
period may involve a change in receptivity of the cells with development. Interestingly, 
studies by another group, also using an R5 virus, showed an increase in progenitor 
production (Peng et al. 2011; Peng et al. 2008). While timing or culture variability might 
underlie the different outcomes, another critical difference may be the method for assessing 
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proliferation. BrdU uptake into individual cells after a 2 h pulse gives an immediate picture 
of DNA synthesis in individual cells. Studies by Peng et al. (2011 and 2008) assayed [3H]-
thymidine uptake into the population after 16 h, which reflects a combination of DNA 
synthesis, division, survival, and further differentiation over time. Those studies 
demonstrated that exposure to infected supernatant causes re-direction of progenitors 
towards an astroglial fate, a possibility also suggested by our findings and by others 
(Mishra et al. 2010). Although concurrent morphine exposure did not alter Tat effects on 
hNPCs, there was an additive effect of morphine and HIV-1SF162 supernatant (Fig. 3.5). 
Effects of supernatant by itself or with morphine may be due to multiple factors or 
interactions, since supernatant contains virions, multiple viral proteins, and 
cytokines/chemokines from infected cells.  
HIV-1 has been reported to infect hNPCs (Lawrence et al. 2004; Rothenaigner et al. 
2007; Schwartz et al. 2007). We performed FACS analysis and immunohistochemistry 
after 12 h exposure to infective supernatant to examine whether hNPCs in our system were 
infected. FACS analyses showed that < 0.04% of intact hNPCs were immuno-positive for 
p24 (Fig. 3.6 A), and we very occasionally detected cells with a viable morphology that 
appeared to be p24+ by immunocytochemistry (Fig. 3.6 E, E’). Although our experience 
does support to the concept that hNPCs can be infected by HIV-1, it was not a common 
event under our experimental conditions. Most progenitors in the brain appear to respond 
as bystanders to events triggered by infected cells.  
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Relationship to HIV Pathology in Humans 
Prior to the advent of anti-retroviral therapy, the prevalence, rate of onset, and severity 
of HIV-1-associated CNS disease in children was quite high as compared to adult patients 
(Mintz 1994; Schwartz et al. 2007; Schwartz and Major 2006). This is not surprising, since 
much of CNS development occurs after birth, and the immature brains of children or 
adolescents exposed to HIV are highly vulnerable to pathologic agents. Over-expression of 
excitatory amino acid receptors during periods of active synapse formation may in 
particular contribute to excitotoxic injury (Epstein and Gelbard 1999). CNS disease in 
pediatric HIV patients manifested as either a static or progressive encephalopathy, with 
classic symptoms that included delay or loss of major motor and mental milestones, as well 
as atrophy of cortical/subcortical regions and other abnormalities on CT scans (Drotar et al. 
1997; Epstein et al. 1988; Epstein et al. 1985; Schwartz and Major 2006; Tahan et al. 2006; 
Ultmann et al. 1985; Van Rie et al. 2007). In developed countries, the rate of HIV-1 
vertical transmission has been reduced to 1-2%, from 40% in 1995 (Buchholz et al. 2010; 
Van Dyke 2011). Treatment with CNS-penetrating drugs has, by most accounts, reduced 
the incidence of pediatric and adolescent HIV-associated encephalopathy by ≥ 50%, 
especially in cases of perinatal acquisition (Patel et al. 2009). It is currently estimated that 
10% of HIV+ children on cART therapy will show signs of CNS disease (Chiriboga et al. 
2005). The situation in resource-limited settings is quite different. According to a 2008 
estimate, 1,600 children per day become infected with HIV-1 worldwide, 90% of them in 
sub-Saharan Africa (UNAIDS 2009; UNAIDS 2010). In such regions, mother-to-child 
transmission of HIV via breastfeeding is common, even in infants not infected at birth, and 
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HIV-1 infection is still a major source of infant mortality (Becquet et al. 2009; Meyers et al. 
2007). 
In the context of pediatric HIV, reduced progenitor production and development are 
likely to have serious consequences. Reduced production of Sox2+ progenitors is expected 
to impact the populations of neurons and glia that derive from Sox2+ cells. Indeed, we find 
that immature, Olig2+ OLs are reduced in vivo, and others have reported lower neuron 
production, possibly through altered cyclin D1 and MAPK signaling (Mishra et al. 2010; 
Okamoto et al. 2007). Although the hypothesis that Tat exposure can alter lineage 
decisions in uncommitted progenitors remains to be fully tested, a proportional increase in 
astroglia might enhance interactions between astroglia and HIV-1 infected 
macrophages/microglia that are deleterious for developing neurons and neural circuitry 
(Blumberg et al. 1994). Our finding of significant Tat-morphine and HIV-morphine 
interactive effects is clinically relevant, given the high rate of opiate abuse in HIV patients, 
and the fact that morphine may initially be used to treat neonatal abstinence syndrome in 
children of opioid-maintained or non-maintained mothers (Bandstra et al. 2010; Colombini 
et al. 2008; Ebner et al. 2007; Jansson et al. 2009).  
Our results may also be relevant for the adult CNS. If the Tat effects, and morphine-Tat 
interactions that we observed also occur on adult progenitors, the predicted outcome would 
be fewer overall NPCs, a tendency towards increased astroglia at the expense of 
oligodendroglial production, and abnormal neural function. Importantly, neural precursors 
were reduced in human hippocampal slice cultures by HIV coat proteins and patient CSF 
(Krathwohl and Kaiser 2004b) and in gp120 transgenic mice (Lee et al. 2011; Mishra et al. 
2010; Okamoto et al. 2007). Neural precursors were also reportedly reduced in HIV 
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patients with neurological deficits as compared to HIV-1 infected individuals without 
neurological deficits and non-infected controls (Krathwohl and Kaiser 2004b).  
 
Summary 
 
Consistent findings that Tat and HIV reduce NPC production in a variety of model 
systems that assess maturation are compelling. By disrupting the proliferation of NPCs and 
their subsequent differentiation into mature glia and neurons, HIV infection may increase 
the severity of neurological deficits and impairment in pediatric and adolescent patients. 
Interactions between Tat/HIV and morphine may exacerbate neurologic problems in young 
HIV patients receiving opiates prescribed for neonatal abstinence syndrome, pain, or other 
valid reasons, as well as HIV-1+ adolescents experimenting with abused opiates. Evidence 
that some neurologic abnormalities in the pediatric HIV population may be reversible 
(McCoig et al. 2002) is encouraging from a therapeutic standpoint, and points to the need 
for full understanding of how HIV and opiates individually and interactively affect CNS 
progenitors. This is especially true in resource-limited environments, where the spectres of 
perinatal HIV infection and high rates of pediatric disability/mortality have not been 
diminished. 
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Figure 3.1 
 
 
Figure 3.1 Co-exposure to HIV Tat and morphine for 12 h alters the Sox2+ population and 
proliferation of Sox2+ cells in vitro. Neither the nestin+ (A, D) nor the Olig2+ (C, F) 
populations were affected by any combination of Tat, morphine, or naloxone treatment at 
12 h. However, both the percentage of the population that was Sox2+, and the proliferation 
of cells at this stage of differentiation were decreased in response to Tat and morphine co-
exposure (B, E). (* p<0.05, ** p<0.01, a <0.05 vs. control; with Duncan post-hoc test, n = 
4-6, Morph = Morphine (500 nM), Tat (100 nM), Nal = naloxone (1.5 µM)). 
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Figure 3.2 
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Figure 3.2 Effects of HIV-1 Tat ± opiates on the population and proliferation of Olig2+ 
cells, at 24 – 48 h in vitro. Interactive effects of morphine and Tat to reduce Olig2+ cell 
proliferation were observed at both 24 h and 48 h (A and B); Tat by itself also reduced 
Olig2+ proliferation, but only at the 48 h time point (B). Tat by itself reduced the percent of 
Olig2+ cells in the overall population, after both 24 h (C) and 48 h (D) of exposure; there 
were no additional effects of morphine co-exposure. Morphine by itself did not affect 
populations of Olig2+ cells, or their proliferation indices. Naloxone partially reversed the 
effect of morphine in both A and B; the percentage of Olig2+/BrdU+ cells in the 
Morph+Tat+Nal groups was not different from the control, or from the Morph+Tat 
treatment group at the same exposure time. However, naloxone did not reverse the 
interactions between morphine and Tat in C and D (indicated as “a”). This suggested that 
naloxone might directly affect the Olig2+ population, but this was not the case at 12 - 48 h 
exposure (E).  Morph, Morphine (500 nM); Tat, HIV-1 Tat1-86 (100 nM); Nal, naloxone 
(1.5 µM); * p < 0.05, ** p < 0.01, *** p < 0.001, a p < 0.05 vs. control; ANOVA with 
Duncan’s post-hoc test, n = 4-6. 
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Figure  3.3 
 
 
 
 
 
 
 
Figure 3.3 Neither Tat nor morphine has a significant effect on NPC death. There is no 
difference in the ethidium homodimer-1 (EthD-1) fluorescence intensity, measured in 
arbitrary fluorescence units, between any treatment group at 12-48 h of treatment time, 
indicating no increase in cell death. The dotted line indicates the signal in empty wells. 
Morph, Morphine (500 nM); Tat, HIV-1 Tat1-86 (100 nM); Nal, naloxone (1.5 µM).  
81 
 
Figure  3.4 
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Figure 3.4 Pre- and neonatal Tat and/or morphine exposure reduces proliferation in the 
neonatal striatum. HIV Tat1-86 was induced via doxycycline delivered sequentially through 
placenta and lactation (A and B); Tat mRNA transcription was detected by RT-PCR in both 
cortices and striata of 7 d pups (C).  All dams received the same chow so that both Tat+ and 
Tat- pups were exposed to doxycycline. 12 d Tat induction and 4 d of s.c. morphine 
injections significantly reduced overall proliferation (BrdU+), and also reduced 
proliferation in Sox2+ (undifferentiated progenitors) and Olig2+ cells. Additive effects of 
Tat and morphine were observed in Sox2+/BrdU+ cells and in the overall BrdU+ population 
(D). Changes in progenitor proliferation appear to affect the overall populations of Sox2+ 
and Olig2+ cells in the neonatal striatum (E). (* p < 0.05; ** p < 0.01; § p < 0.05, Tat- vs. 
all other groups, Duncan’s post-hoc test, n = 6-8). DOX, doxycycline. 
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Figure  3.5 
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 Figure 3.5 Effect of Tat or HIV-1SF162 supernatant ± morphine on proliferation of human 
ReNcell VM NPCs. Double-immunolabeling confirmed that 95% of hNPC were nestin+ 
and Sox2+ positive, and that 95% also showed immunoreactivity for MOR and CCR5 (A-
C). The colors representing neural precursor makers are separated in the lower panels (A’: 
nestin (green), nuclei (blue); A’’: MOR (red), nuclei (blue); B’: Sox2 (green); B’’: MOR 
(red), nuclei (blue); C’: Sox2 (green); C’’: CCR5 (red), nuclei (blue)). The presence of 
CCR5 on hNPCs suggested that effectors such as gp120 and 　-chemokines, released in 
response to Tat or contained in the viral supernatant, might affect the behavior of hNPCs 
(C). FACS analyses (D) were performed after 12 h treatment with the Tat, virus, or 
morphine combinations indicated by the histograms in E-G, with BrdU added during the 
last 2 h to label S-phase cells. Exposure to supernatant from HIV-1SF162-infected monocytes 
(E), Tat (F), and morphine (E and F) all decreased the proportion of hNPCs in S-phase 
compared to control (§ p < 0.05, compared to all other groups).  BrdU incorporation was 
additively reduced in cells treated with a combination of HIV-1SF162 supernatant and 
morphine (E). There was no interactive effect of Tat and morphine (F). A CCR5 blocking 
antibody (2D7) reduced, but did not abolish, the effect of HIV-1SF162 supernatant (G), 
suggesting that BrdU uptake was sensitive to multiple factors in the supernatant, some of 
which interact with CCR5. (§ p < 0.05, compared to all other groups; ** p < 0.01, one-way 
ANOVA, Duncan’s post-hoc test, n = 4-7; Morph, Morphine (500 nM); Tat, HIV-1 Tat1-86 
(100 nM); Nal, naloxone (1.5 µM); SF162, supernatant from U937 monocytes infected 
with HIV-1SF162 (supernatant diluted to 500 pg p24 per well); CCR5 Ab, antibody 2D7 (2 
μg/ml); mIgG = monoclonal mouse IgG (2 μg/ml).    
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Figure 3.6 
 
 
 
 
 
86 
 
  
 
 
 
 
Figure 3.6 Detection of p24 on hNPCs by FACS and fluorescent microscopy.  p24 
immunolabeling intensity was assessed on approximately 1 x 104, 7-AAD+ cells using a 
single laser (488 nm) and two color fluorescence emission (585/42 band pass; 530/30 band 
pass) FACS approach (A-C). A very small percentage (0.33%) of hNPCs exposed to 
supernatant from HIVSF162-infected monocytes were p24+ (A). Labeling indices in control 
groups, which included untreated hNPCs immunolabeled for p24 (B) and HIV-treated 
hNPCs exposed to control IgG and fluorescently-labeled second antibody (C), were 0.1% 
and 0.001%, respectively, suggesting that a portion of the p24 labeling was specifically 
related to antigen expression. Autofluorescence (585 > 530 signal) was not detected in any 
of the samples. FACS diagrams shown are representative of n=3 separate experiments. 
When individual cells were examined, p24 signal was not detected in untreated hNPCs (D, 
phase contrast; D’, fluorescence). p24 immunoreactivity was associated with two groups of 
cells in cultures exposed to HIV-1SF162 supernatant (E, phase contrast; E’, fluorescence). 
The first group was clearly pyknotic (arrowhead in E and E’). This staining may be non-
specific, or may represent infected hNPCs that have subsequently died; our methods cannot 
distinguish between these possibilities. Other p24+ cells, observed very infrequently, had a 
viable phenotype (arrow in E and E’).    
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Figure 3.7 
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Figure 3.7 Overview of the proposed effects of HIV-1SF162 and/or morphine on NPCs in 
the striatum during the perinatal period. Both the intermediate filament nestin and the 
transcription factor Sox2 identify undifferentiated and self-renewing NPCs in the 
developing CNS, although nestin and Sox2 expression do not entirely overlap. Sox2 
expression is maintained in immature cells destined to become neuroglia (glial-restricted 
precursors; GRPs) but is lost in immature cells destined to become neurons (neural-
restricted precursors; NRPs) (Ellis et al. 2004). GRPs further differentiate into astroglia and 
oligodendroglia; the transcription factor Olig2 is expressed in precursors destined to 
become oligodendroglia. Our studies show that HIV-1 Tat, HIV-1SF162, and morphine all 
affect the proliferation of certain subtypes of progenitors (red lettering). Morphine and Tat 
reduce the proliferation of Sox2+ progenitors and immature Olig2+ oligodendrocytes in the 
mouse brain and in vitro, and have an additive effect that reduces proliferation even further. 
Proliferation of human Sox2+/nestin+ NPCs is similarly reduced by Tat, morphine, and 
infective HIV-1SF162 supernatant, and an additive effect between HIV-1SF162, and morphine 
reduces proliferation further.  Reduced NPC and GRP proliferation is associated with 
changes in cell populations (blue lettering). We specifically measured a reduction in Sox2+ 
cells with morphine or Tat exposure, and in Olig2+ cells with Tat exposure. Taken as a 
whole, the findings support a model where the proliferation of both NPCs and GRPs is 
significantly reduced by morphine or HIV, with interactions that compromise progenitor 
production even further. While the HIV-1 Tat protein clearly reduces proliferation by itself, 
effects of HIV supernatant may also reflect other viral proteins such as gp120 (Lee et al. 
2011) or numerous secreted factors present in the medium. Reduced proliferation predicts 
an overall reduction in populations of progenitors, which was observed. Continued effects 
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on proliferation indices are likely to disturb the overall balance of glia and neurons in the 
brain, a prediction that remains to be tested.  (Note that arrows and cartoons done in grey 
represent hypothesized outcomes for which we have no direct experimental evidence.) 
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Chapter 4 
Sex Influences the Effects of Long-term HIV-1 Tat Exposure in the Striatum: 
Do Changes in Inflammation and Cell population Affect Behavior? 
 
Introduction 
 
Epidemiology of neurocognitive disorders in HIV 
 The introduction of combination antiretroviral therapy (cART) has resulted in 
dramatic declines in the  prevalence of HIV associated dementia (HAD) and mortality of 
HIV infected individuals, while simultaneously, the overall proportion of HIV-associated 
neurocognitive disorders (HAND) have increased  in these patients (McArthur et al. 2010). 
For instance, the prevalence of neurolocognitive disorders is more frequent in developing 
countries (Nakasujja et al. 2005; Wong et al. 2007) and there is a great possibility that these 
neurocognitive disorders and impairments become the most common types of dementia 
among young-age people globally (Wright et al. 2008). Some clinical reports suggest that 
HAND can be diagnosed in HIV infected individuals; even though they have a history of 
prolonged aviremia with high adherence to cART (Cole et al. 2007). Regardless of cART 
usage, neurological insults and injury by HIV-1 might continue to occur in some patients 
(Robertson et al. 2007). HAND can be diagnosed with broad spectrum symptoms ranging 
from asymptomatic neurocognitive impairment (ANI), to minor neurocognitive disorders 
(MND), to HIV associated dementia (HAD), because HAND is a progressive disease with 
different intensity of CNS involvement and symptoms in its development. Approximately, 
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40-60% of HIV/AIDS patients can be categorized in one of these diagnoses (Ellis et al. 
2007; McArthur et al. 2010).  
ANI is the mildest form of HAND and 30% of HIV infected individuals under 
cART belong to this group. These individuals with ANI are more likely to develop the 
more severe forms of HAND (Ellis et al. 2007). ANI is characterized by a number of 
criteria, including measurable neurocognitive impairment without recognition by the 
patients and without impact on day-to-day function. Next, MND is a more severe form of 
neurolcognitive impairment than ANI, and was often identified in 20 to 30% of HIV 
infected adults in pre-cART era (Janssen et al. 1989; McArthur et al. 2010; Sacktor et al. 
2002). These individuals usually self-report having impaired cognitive or behavioral 
deficits. Such impairments can include a reduction in attention/concentration, mental 
slowing, abnormal memory along with other cognitive functions, slowed or uncoordinated  
movements, apathy, personality change, depression, irritability and mood swing (McArthur 
et al. 2010). These abnormalities typically can cause mild impairment in work, or 
negatively affect activities of daily living. MND is known to be associated with shortened 
survival, reduced adherence with antiretrovirals, as well as worse employability, and 
increased prevalence of HIV encephalitis in patients from pre-cART period (Cherner et al. 
2002; Hinkin et al. 2002; Mayeux et al. 1993; Sacktor et al. 1996). Finally, the prevalence 
of HAD is rare in cART-treated individuals, approximately 2 to 8% of frequency is still 
estimated (McArthur et al. 2010).                     
According to previous clinical studies, the prevalence of neurocognitive disorders 
in HIV infected patients is high in both those complaining of cognitive impairments (84% 
of complaining HIV+ patients) and those without complaints (64% of asymptomatic HIV+ 
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patients) despite suppression of viremia with cART (Simioni et al. 2010). The high 
prevalence of neurocognitive disorders and impairments in aviremic, cART-treated 
individuals suggested that many anti-retroviral medicines may fail to reverse neurological 
damage, even though cART lengthens the survival (McArthur et al. 2010). Therefore, 
HAND has become a significant economical and psychological burden to persons living 
with HIV infection and places excessive damage on the health care system. What was once 
a uniformly fatal illness is now a chronic disease requiring long-term medical management 
(Tozzi et al. 2005). 
 
Basal ganglia is especially vulnerable to damage from HIV 
 The complications of HAND, mentioned above, are tightly associated with 
neuropathological changes within subcortical regions of the brain, especially the basal 
ganglia, which also retains the major brunt of the infection in the brain (Berger and Nath 
1997). These subcortical changes result in cognitive and motor dysfunction such as mental 
slowing, memory loss, difficulties in complex tasks, as well as motor disorders (Simioni et 
al. 2010; Tozzi et al. 2005). Affected individuals can also present with behavioral 
abnormalities, such as apathy, a decrease in spontaneity, and mood swings. In addition, the 
incidence of depression and anxiety are more prevalent in HIV infected individuals with 
HAND (Simioni et al. 2010). The reasons for regional vulnerability of the basal ganglia for 
the associated neuropathological features of HAND are still elusive.  HIV-1 virus was 
found in the basal ganglia in early infection (Ances and Ellis 2007; Berger and Nath 1997; 
Kumar et al. 2007). Before the introduction of cART, multinucleated giant cells, microglial 
nodules, HIV-infected microglial cells, and infiltrating macrophages were often detected in 
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the basal ganglia compared to other regions within the brain (Navia et al. 1986). These 
pathological abnormalities were most common within the putamen and caudate in the basal 
ganglia (Koutsilieri et al. 2001; Navia et al. 1986). Paralleling with abnormatlities in these 
regions, the atrophy of subcortical brain is often detected in HIV infected individuals in 
pre-cART era. Even in post-cART era, this pattern of atrophy was also consistent with 
motor dysfunction found in HIV patients with HAND (Becker et al. 2011; Kuper et al. 
2011). Neuroimaging studies in pre- and during cART era have indicated that dopamine 
transporters and metabolites were abnormal in HAD patients compared with asymptomatic 
individuals (Berger et al. 1994; Chang et al. 2008; Kramer and Sanger 1990; Wang et al. 
2004). Furthermore, the basal ganglia are where HIV proteins Tat and gp120 were 
prominently detected in patients with HIV encephalitis. The proteins can be detected in 
glial cells, extracellular matrices, perivascular compartments, and in close proximity to 
neurons (Hofman et al. 1994; Kruman et al. 1998). These proteins thus have the 
opportunity to interact with neuronal cell bodies, dendrites, and synaptic terminals (Nath et 
al. 2000). 
  
Glia associated neuropathogenesis in HIV 
The progression of HAND may be associated with chronic inflammation due to 
low-level viral replication in the CNS because many cART medicines have poor 
permeability through BBB. Despite suppression of viremia due to cART systemically, the 
abnormal immune activation of microglia/macrophages triggered by HIV is persistently 
remained in the CNS (Woods et al. 2009). Productive HIV infection seen within the basal 
ganglia thought to be due to microglia and macrophages (Everall et al. 1995; Jordan et al. 
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1991; Speth et al. 2005). Studies with in situ polymerase chain reaction and laser capture 
dissection microscopy have confirmed that productive infection occurs within perivascular 
macrophages and microglia in brain parenchyma (Williams et al. 2001). Non-productive 
HIV infection has also been detected in astrocytes (Takahashi et al. 1996; Thompson et al. 
2004), and this infection is CD4 independent, because CD4 is not normally expressed on 
astrocytes (Di Rienzo et al. 1998; Ma et al. 1994).  There have been some reports that low 
numbers of HIV-infected astrocytes might contribute to the disruption of the blood-brain-
barrier in HIV infected CNS (Eugenin and Berman 2007; Eugenin et al. 2011). The toxicity 
of HIV, especially the apoptotic cell signaling molecules, might be amplified by gap 
junctions in astrocytes, even under the condition of minimal HIV infection in these cells 
can result in significant damage in CNS, because the disruption of the BBB allows massive 
numbers of  macrophages to infiltrate into CNS (Eugenin and Berman 2007; Eugenin et al. 
2011). In addition, robust upregulation of chemokines and cytokines in the basal ganglia 
also suggests that neuronal dysfunction and injury in progressive HAND may be due to 
abnormal cytokine production by these astrocytes and microglia (Suzuki et al. 2011; 
Turchan-Cholewo et al. 2009a; Turchan-Cholewo et al. 2009b). 
 Replication of HIV in infected microglia/macrophages results in the release of HIV 
proteins such as gp120 and Tat. In addition the release of viral proteins accompanied by the 
secession of cellular gene products, including proinflammatory cytokines such as tumor 
necrosis factor-α (TNF-α), as well as eicosanoids, nitric oxide (NO), platelet-activating 
factor (PAF), quinolinic acid, and extracellular matrix-degrading proteases (Adamson et al. 
1999; Griffin 1997; Heyes et al. 2001; Patton et al. 1998; Smith et al. 2001; Vos et al. 
2000; Wesselingh et al. 1997; Yong et al. 1998). gp120 and Tat shed from infected 
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microglia can bind to and impair the function of neurons and astrocytes, causing  them to 
secrete  inflammatory cytokines/chemokines, which can activate adjacent microglia and 
astrocytes in the early asymptomatic stage of HIV infection.  In addition, much evidence 
points to the role of  activated microglia as a chronic source of multiple neurotoxic factors, 
including TNF-α, interleukin-1β (IL-1β), NO, and reactive oxygen species (ROS), driving 
progressive neuron damage with opiate exposure (Bruce-Keller et al. 2008; El-Hage et al. 
2008b; Turchan-Cholewo et al. 2009a). Furthermore, microglia are known to be 
chronically activated by a single or chronic exposure to disease proteins, oxidative stress, 
and cytokines/chemokines, this characteristic of microglia could contribute to HIV 
neuropathogenesis (reviewed in Lull and Block 2010). Finally, pro-inflammatory factors 
can generate more reactive astrocytes and chronically activated microglia, which may 
induce functional damage to adjacent neurons. Taken together, the HIV infected or 
activated macrophages, microglia, and astroglia up-regulate release of pro-inflammatory 
cytokines/chemokines, which probably leads damage neurons and circuitry systems and 
lead HIV related neurological disorder and impairments.  
 
HIV associated neurocognitive disorders in sex differences  
 The incidence of HIV is higher in men than women (75% men vs. 25% women) in 
all ethnic groups in the United States and Europe (CDC 2009; UNAIDS 2009). For this 
reason, it is not surprising that studies of neurocognitive deficits and impairments in HIV 
are mainly based on studies focusing on men. According to recent reports, 51% of people 
HIV positive population in worldwide are estimated to be women (UNAIDS 2010). The 
availability of antiretroviral treatment in women is higher than or equal to that of men in 
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worldwide (UNAIDS 2010). However, the proportion of HIV-infected individuals 
receiving antiretroviral therapy was still low in low- and middle-income countries. Only  
36% of HIV positive people received antiretroviral therapy in low- and middle-income 
countries (UNAIDS 2010), compared to 70% of the HIV positive population receiving 
antiretroviral therapy in the United States (CDC 2009). 
 There have been some reports that women might be more vulnerable to the 
development of HIV-associated neurocognitive deficits or impairment than men. However, 
these studies in some cases have been inconclusive and differ greatly depending on 
outcome measures. For instance, early studies by the AIDS in Europe Study Group found 
that the risk of HIV-associated neurocognitive complications (termed as AIDS dementia 
complex (ADC) at that time) in Europe during pre-cART era were two-times higher in 
women than men (Chiesi et al. 1996). On the other hand, there also have been reports that 
the risk of neurocognitive complications among men and women was similar to rates found 
among men in the United States, Europe and Australia, where availability of cART are well 
established (Robertson et al. 2004; Wojna et al. 2006), as well as in more resource-limited 
counties such as Puerto Rico and India (Bouwman et al. 1998; Gupta et al. 2007). 
However, there have been some concerns that there are numerous immeasurable factors 
that may make sex studies difficult to assess accurately. For example, globally HIV 
infected women live under relatively impoverished conditions. This accompanied by low 
literacy levels, high injection drug abuse rate, poor mental health, cultural barriers to health 
care services, several relevant genetic risk factors and low social status compared men with 
HIV, which may significantly influence the diagnosis of neurocognitive disorders in HIV 
positive women (Basso and Bornstein 2000; Farinpour et al. 2003; Maki and Martin-
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Thormeyer 2009). Therefore, additional and controlled studies may be required to address 
the possibility of sex differences in susceptibility to HIV associated neurocognitive deficits 
and impairments.  
 
Material and Methods 
 
Animals, husbandry and general procedures 
GFAP-driven, doxycycline-inducible HIV-1 IIIB Tat1-86 transgenic mice were 
generated as described in Chapter 3 above. Genotyping was confirmed by PCR and the 
method is mentioned in Chapter 3 material and methods. In this study, independent sets of 
6-8 mice were utilized in each group and included female Tat-, female Tat+, male Tat-, and 
male Tat+. Mice were treated with doxycycline in specifically formulated chows (Harlan 
Laboratories, Inc. Indianapolis, IN) with daily dosages of 6 mg/kg for a period of 3 months. 
These animals were allowed to reach to chows ad libitum. The doxycycline treatment was 
started at 3 months of age and preceded until mice were 6 months old. For control groups 
in grip strength test, open field test and light/dark box test, one cohort of mice received 
normal chows until they reached to 6 month old.  
 
Accelerating rotarod assay  
An accelerating rotarod test, which is sensitive to measures of balance, 
coordination, and motor control, was used to evaluate motor performance in groups of Tat 
transgenic mice mentioned above. Rotarod testing began after one week of doxycycline 
treatment (around 13 weeks old), and was performed once a week (from the first week to 
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the fourth week). After four rounds of testing within the first month of doxycycline 
treatment, this behavioral test was paused for one month without removal of doxycycline. 
This behavioral test was resumed and applied weekly to mice in the third month of 
doxycycline treatment (from the ninth week to the twelfth week). Independent, age-
matched mice were utilized in other behavior tests. The Rotamex-5 treadmill (Columbus 
Instruments, Columbus, OH) consists of a 3.0-cm diameter cylindrical treadmill connected 
to a computer-controlled stepper motor-driven drum, which can be programmed to operate 
in a defined acceleration mode (Rotamex-5, Columbus Instruments). 4 different groups, 
female Tat-, female Tat+, male Tat- and male Tat+ mice with doxycycline treatment, were 
housed 2–4 to a cage and were tested weekly at 13–16 weeks and 21-24 weeks of age. On 
the test day, mice were moved to the testing room and allowed to habituate for 60 min 
before testing. All mice in this experiment were naïve to the rotarod apparatus until the first 
test day at week 13. Each mouse was placed on the rubber covered rods to evaluate rotarod 
performance. On a given trial, four mice were placed on the cylinder, one mouse in each 
compartment. The accelerating rotarod was set to accelerate gradually from 1 to 40 rpm, 1 
rpm increase per 15 s, for each trial. The starting speed was 1 rpm, and the total time of 
each trial was 400 s. Acceleration continued until either 40 rpm was reached or the last 
animal was unable to perform the running response and had fallen to the padded surface. 
When the animal fell off the rotating drum, individual sensors at the bottom of each 
separate compartment automatically record the amount of time (in seconds) spent on the 
treadmill. The time spent on the treadmill was recorded for each successive trial, and a 
score of one trial per week was analyzed (reviewed Liu et al. 2010).  
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Forelimb grip strength test 
The apparatus is comprised of a push-pull strain digital force gauge, Chatillon® 
DFE II grip strength meter (AMETEK’s Test & Calibration Instruments (TCI), Largo, 
Florida USA). Mice were housed 2–4 to a cage and were tested at 6 months of age. On the 
test day, mice were moved to the testing room and allowed to habituate for 60 min before 
testing. Each mouse was weighed before forelimb grip strength test. A forelimb grip 
pedestal was used as the grip bar. The mouse was held near the base of its tail and lowered 
toward the bar until it gripped the bar with both forepaws. The mouse was then gently and 
steadily pulled directly away from the bar until the bar was released. Peak force 
disturbance was automatically registered in grams-force (gf) by the apparatus (Grip 
Strength Meter 2.66, AMETEK’s Test & Calibration Instruments (TCI)). Data were 
automatically recorded, and 5 trials per mouse were given in quick succession. The force of 
resistance was measured in a single 5-trial session and the strongest measurement was 
collected as the score (reviewed by Crabbe et al. 2003). The presented scores (gf) in grip 
strength were normalized by mouse weights (g) for statistically comparing control and all 
other groups. 
 
Open field test 
All groups of transgenic mice, including female Tat-, female Tat+, male Tat- and 
male Tat+ mice with/without doxycycline treatment, were housed 2–4 to a cage and were 
tested at 6 months of aged. On the test day, mice were moved to the testing room and 
allowed to habituate for 60 min before testing. Prior to the evaluation, animals were 
habituated to the box for 1 min. Mice were individually placed at the center of a clean open 
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field apparatus (30 × 30 × 15 cm, divided into nine squares, Med Associates Inc., St. 
Albans, VT, USA). The observed parameter, number of squares crossed (locomotor 
activity) was automatically recorded for 10 min (Burger et al. 2005; Ramezani et al. 2011). 
The data in open field test (percent of total travel distance in 10min, Fig. 4.2 A, Table 4.1 
A) indicate that the scores from 6 month old with 3 month doxycycline treatment were 
normalized by the scores from control age-matched groups without doxycycline treatment.   
 
Light-dark Transition Model of Anxiety 
 All groups of transgenic mice, including female Tat-, female Tat+, male Tat- and 
male Tat+ mice with/without doxycycline treatment were, housed 2–4 to a cage and were 
tested at 6 months old. On the test day, mice were moved to the testing room and allowed 
to habituate for 60 min before testing. The light-dark box was adapted from the originally 
described apparatus (Crawley and Goodwin 1980). Two equally sized compartments (30 
cm x 30 cm x 15 cm) were separated by a black plastic partition with an opening in the 
middle to allow for light-dark transitions (Med Associates Inc., St. Albans, VT, USA). The 
box was enclosed in a sound attenuating box equipped with overhead lighting and fan 
ventilation. Each mouse was tested by locating it in the center of the white area, facing to 
the dark one, and was allowed to explore the novel environment for 10 min. The system 
was interfaced with Med Associates software (Med Associates Inc.) enabling automatic 
measurement of activity using a set of 16 infrared beam sensors along the X-Y plane. The 
observed parameter, number of squares crossed (locomotor activity), was automatically 
recorded for 10 min (modified from Malmberg-Aiello et al. 2002). The data in light-dark 
box test (Fig. 4.2 B, Table 4.1 B) indicate that the percent of travel distance in dark side 
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box from 6 month old with 3 month doxycycline treatment were normalized by the percent 
of travel distance in dark side box from control age-matched groups without doxycycline 
treatment. 
 
Immunohistochemistry and quantification 
 For immunohistochemistry (IHC) studies, mice were deeply anesthetized with 
isoflurane (Baxter, Deerfield, IL, USA) prior to perfusion with 4% paraformaldehyde (pH 
7.4, Sigma-Aldrich Co., St. Louis, MO, USA). After perfusion, brains were removed and 
post-fixed in fresh fixative overnight. Brains were hemisected, rinsed several times in 15 
mL changes of phosphate-buffered saline (PBS) and left overnight in 15 mL of PBS.  
Brains were then cryopreserved through graded sucrose solutions (20 and 30%), embedded 
in Tissue Tek OCT compound (Sacura Finetek, Torrance, CA, USA), and stored at –80˚C. 
10 µm frozen sections containing the striatum were thaw-mounted on SuperFrost Plus 
slides (VWR Scientific, West Chester, PA, USA) and processed for immunostaining. The 
brains from female Tat-, female Tat+, male Tat- and male Tat+ mice with doxycycline 
treatment were serially cut and numbered and ordered and stored -80˚C until use. For in 
vivo studies, to assess proportional numbers of specific cells in the striatum, single or 
double immunostaining was performed on 10 µm frozen brain sections including striatum. 
Primary antibodies were utilized directed against Iba-1 (1:200, Wako, Osaka, Japan), 3-
nitrotyrosine (3-NT, 1:100, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), NeuN 
(1:200, Millipore, Temecula, CA, USA), Olig2 (1:100, Immuno-Biological Laboratories, 
Minneapolis, MN, USA), and Sox2 (1:200, R&D Systems, Inc., Minneapolis, MN USA). 
Tissue sections on slides were rehydrated with 1x PBS (pH 7.4, Invitrogen Corp., Carlsbad, 
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CA, USA) for 10 min at room temperature. For intracellular markers, tissue sections were 
permeabilized with 0.2% Triton X-100 in phosphate-buffered saline containing 1% bovine 
serum albumin (Sigma-Aldrich) for 30 min. For double immunostaining, individual 
primary antibodies were sequentially applied and incubated overnight at 4ºC in humid 
chamber; and host-matched fluorescent-conjugated secondary antibodies were applied for 
visualization 1 hour at room temperature (Invitrogen Corp., Carlsbad, CA, USA). 
Immunostained tissues were finally incubated with Hoechst 33342 dye (0.5 µg/ml, 8 min, 
RT) to identify nuclei (Invitrogen), then mounted in ProLong Gold anti-fade reagent 
(Invitrogen) and dried for 8 h in the dark. To assess the proportion of microglia cells, 300–
350 Hoechst+ cells were selected randomly in one side of the striatum to assess the 
presence of Iba-1 in striata under oil immersion at 63× using a Zeiss AxioObserver system 
with an integrated MRM camera system (Carl Zeiss, Inc., Thornwood, NY, USA, n = 6-7). 
To determine the relative activation state of microglia in the striata, an independent group 
of 200 Iba-1+ cells were randomly selected per striatum and assessed for the 3-NT 
expression. To verify the proportion of neural progenitors and immature oligodendrocytes 
in the striata, 300–350 Hoechst+ cells were selected randomly per striatum and assessed for 
Sox2 and Olig2 expression, respectively (n = 6-7).  
 
NeuN immunoblots and analysis 
In vivo NeuN expression was examined by immunoblotting. Striata were harvested 
and homogenized with T-PER Tissue Protein Extract Reagent (Thermo Scientific, 
Pittsburgh, PA, USA), including a protease inhibitor cocktail (Roche, Indianapolis, IN, 
USA). Homogenized tissue lysates were centrifuged; the supernatants were transferred into 
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new tubes and then stored at -80ºC until use. Protein concentration was measured using the 
BCA protein assay (Pierce, Rockford, IL). Duplicate samples of 20 µg total protein were 
loaded per well onto 10% Tris–HCl Ready Gels (Bio-Rad Laboratories, Hercules, CA) 
using Precision Plus Protein Dual Color Standards (Bio-Rad; MW range: 10–250 kDa) to 
monitor protein transfer and molecular weight. Proteins were transferred to Hybond-P 
PVDF membranes (Amersham Biosciences, Piscataway, NJ, USA), probed with mouse 
monoclonal anti-NeuN (1:1000, Millipore) and anti-GAPDH (1:2500, Abcam, Cambridge, 
MA, USA). Host-matched IRDye® Infrared Dyes conjugated secondary (LI-COR 
Biotechnology, Lincoln, Nebraska) were applied to visualize each protein band. Protein 
bands were detected on an Odyssey® Infrared Imaging System and their intensity were 
analyzed by Odyssey 2.0 software (LI-COR). The intensities of two NeuN bands in each 
sample were combined to analyze. To assess changes in NeuN, the combined band 
intensities were normalized with the intensity of the respective GAPDH band.  
 
Nissl staining 
In addition to NeuN immunohistochemistry, we analyzed Nissl stainined tissues in 
order to estimate the total neuron number in striatum. Nissl staining was performed on 50 
µm brain coronal sections were taken serially through the striatum based on stereotaxic 
coordinates (3rd ed., Academic Press, Orlando, FL, 2008). Sectioning was performed with 
vibrating blade microtome (Leica VT1200S, Leica, Nussloch, Germany). Sections were 
prepared in ice-cold PBS (Invitrogen) and each section was stored in 48-well plates by 
serial order with cryoprotectant solution (25% of glycerin: 25% of ethylene glycol: 50% of 
0.1 M phosphate buffer) until use. The Nissl staining was performed as described by 
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Davenport, H.A. (1960) (Davenport 1960). Briefly, free floating brain sections were 
mounted on chrom-gelatin coated slides serially and were dehydrated at room temperature 
until completely air dried. Brain sections were submerged in water for rehydration for 10 
min and then underwent 70, 95, and 100% ethanol submersions for dehydration. The brain 
tissues were stained for 6 min with 0.5% cresyl violet (Sigma–Aldrich Co., St. Louis, MO, 
USA). After rinsing in water, the sections were submerged in 70% ethanol in 0.34 M acetic 
acid for 2-3 sec, and then submerged in 95% followed by 100% ethanol for 5 min each. 
Finally, the sections were dehydrated with xilene for 10 min. The sections were mounted 
and sealed under coverslips for analysis.  
 
Stereology 
 For stereology, 50 µm free-floading sections were prepared from fixed brains, as 
described in IHC section above. After Nissl staining was performed on these brain sections, 
total numbers of Nissl+ neurons in the striata were estimated using the optical fractionator 
method (West et al. 1991), with assistance from a computerized stereology system 
(Stereologer, Systems Planning and Analysis, Alexandria, VA). Every fifth section was 
selected from the total number of sections through striatum in a systematic-random 
manner, and 12 sections per sample were generated. The sampling fractions were: (1) 
section sampling fraction (ssf), the number of sections sampled divided by the total number 
of sections for each striatum; (2) area sampling fraction (asf), the area of the sampling 
frame divided by the area of the x-y sampling step; and (3) thickness sampling fraction 
(tsf), the height of the disector divided by the section thickness. Each reference space was 
outlined at low power (x5), and cells were counted using a high magnification (x100, oil-
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immersion) objective. Nissl+ neurons in striata were counted using the optical fractionator 
method in combination with the disector principle and unbiased counting rules (Mouton 
2002). Since Nissl staining detects both neurons and glia in striata, Nissl+ neurons were 
distinguished from glia and identified by their characteristics for unbiased stereological 
counting. Neurons cells were distinguished by relatively a large oval shape nucleus, the 
presence of dark, coarsely stained Nissl substance in the cytoplasm, and lightly stained 
proximal segments of dendritic processes. In contrast, glial cells contain less endoplasmic 
reticulum and have relatively dark, tight and small nucleus (Fitting et al. 2010a; Sherwood 
et al. 2006). In counting of neurons, astrocytes and oligodendrocytes, and microglia were 
excluded without distinguishing among them. A guard volume of 2.0 mm was used during 
cell counting to avoid sectioning artifacts, including lost caps and uneven section surfaces. 
Criteria for counting cells required that cells exhibited positive chemical- and immuno-
reactivity and morphological features consistent with each cell type. Cells were counted on 
the left hemispheres. After Hoechst staining was applied on 50 µm free-floading sections, 
the Cavalieri principle was applied to measure the volume of the striata. The slides were 
viewed by using a Zeiss AxioObserver system with an integrated Sony 3CCD Exwave 
HAD camera system (Carl Zeiss, Inc., Thornwood, NY)  
 
Statistical analysis 
Linear regression was also performed followed by t-test among groups using 
GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA). Statistical analyses were done 
by one way and main effect analysis of variance (ANOVA) followed by Duncan’s post-hoc 
testing using Statistica 6.0 software (Statistica, Tulsa, OK).  
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Results 
 
Accelerating rotarod assay 
To examine whether the long-term induction of Tat in transgenic mice affects motor 
skill in a sex-dependent manner, the accelerating rotarod assay was performed in all groups 
of mice, female Tat-, female Tat+, male Tat- and male Tat+. During 3 months of 
doxycycline exposure, all mice used in this study performed the rotarod test once a week 
during week 1-4 and 9-12. The accelerating rotarod test is a forced performance test based 
on a rotating rod with forced motor activity to evaluate basic gait, balance and coordination 
and duration on rod and maximum speed can be measured (Jones and Roberts 1968). 
Female Tat-, female Tat+, and male Tat- groups showed the obtaining motor skill by the 
repeated rotarod tasks and reached their maximum performance at 12 weeks, as measured 
by an increase in the duration of time spent on the rotarod (Fig. 4.1 A). Three groups of 
mice maintained balance on the rotarod with the maximum latency, around 300-352 sec 
(Fig. 4.1 A), and rotation speeds reached the highest rotation speeds of 21-24 rpm before 
falling by 12 weeks. Interestingly, female Tat+ mice showed different and slow in obtaining 
motor skill compared female Tat- group, even they finally gained the motor skill as much 
as female Tat- group at the end of 12 week doxycycline exposure (* P<0.05; linear 
regression, t-test, n = 6, Fig. 4.1 A).  In contrast, male Tat+ mice significantly had more 
difficulty to maintain balance on the rotarod and/or obtaining motor skill after 12 weeks of 
doxycycline administration compared to all other groups (Fig. 4.1 A, § p<0.001; linear 
regression, t-test, n = 6, Fig. 4.1 A). The maximum time of male Tat+ group only reached 
less than 200 sec (Fig. 4.1 A), and their highest rotation speeds in male Tat+ mice groups 
107 
 
only reached around 14 rpm. In fact, the Tat+ mice did not show any acquisition of the task, 
as the slope of their performance measure was not different from 0 (Fig. 4.1 A). The data 
showed a clear indication of sex differences in the accelerating rotation tasks. Therefore, 
this data might indicate that motor skill/balance and/or the ability to learn a motor task are 
more significantly vulnerable to HIV-1 Tat exposure in male than in female. 
 
Forelimb grip strength 
Forelimb grip strength test was performed in all 8 groups of mice with/without 3 
month doxycycline treatment groups. Reduction or abnormality in grip strength indicates 
inappropriate neuromuscular functioning or motor deficits in the brain. Since our 
transgenic mice almost exclusively express HIV-1 Tat1-86 in their CNS, the test could be 
utilized to assess whether long-term induced Tat might cause motor deficits in their CNS 
that can affect strength of forelimbs in sex specific manner. 4 groups of 6 month old mice 
without doxycycline exposure showed no significant difference in forelimb grip strength, 
based on their sex or genotype difference of Tat transgene, after normalizing by their 
weight (Fig. 4.1 B). Doxycycline exposure to 12 weeks induced significant differences 
resulted to sex and transgene expression. Importantly, doxycycline by itself did not appear 
to influence on forelimb grip strength since female Tat-, female Tat+ and male Tat- mice 
had similar strength. Tat expression significantly reduced grip strength only in female Tat+ 
mice (§* p<0.05, control male Tat- vs. male Tat- with doxycycline treatment, one-way 
ANOVA, Duncan’s post-hoc test, n = 6, Fig. 4.1 B). Male Tat+ mice also showed the 
weakest grip strength among the groups with doxycycline treatment (**, p<0.01, one-way 
ANOVA, Duncan’s post-hoc test, n = 6, Fig. 4.1 B). This result suggests an interactive 
108 
 
effect of sex and Tat induction, since Tat+ mice with doxycycline showed significant 
reduction in forelimb grip strength compared to other groups. Therefore, similar to rotarod 
test in gaining motor function, males were more affected by HIV-1 protein Tat than 
females in forelimb grip strength.  
  
Open-field test 
 To examine whether the locomotor activity during exploration of a novel 
environment may be affected by long-term induction of Tat in male and/or female mice, an 
open-field test was performed in all groups of mice including after 3month Tat induction. 
The open field test and light/dark box test can measure a tendency to explore novel 
environments. Depressed or anxious animals in this test will show reduced traveling 
distances in open field if they lose their will to seek novel environment (Cryan and Holmes 
2005; Wallace et al. 2008). The distance traveled in 10 min was significantly reduced in 
both male and female Tat+ mice, to the same extent after normalization by age-matched 
groups without doxycycline exposure (** p<0.01, *** p<0.001, One way ANOVA, 
Duncan’s post-hoc test, n=6-7, Fig. 4.2 A, Table 4.1 A). Interestingly, there was no sex 
specific effect. Results suggest that long-term exposure to HIV-1 Tat reduced locomotor 
activity and/or exploring behavior independent of sex.  
 
Light/dark box test 
 A standard light/dark box test was performed to examine whether HIV-1 Tat 
expression in mouse CNS induced the anxiety-related behavior in these mice and whether 
there were sex dependent factors. In rodent behavior studies, increased time spend or travel 
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distance by freely ambulating in dark side box has been taken as an indication of enhanced 
anxiety in previous numerous studies with anxiogenic or anxiolytic treatment (Bourin and 
Hascoet 2003). The Tat induction by doxycycline treatment did not increase the travel 
distance in dark side of female Tat-, femalr Tat+ and male Tat- mice (Fig. 4.2 B, Table 4.1 
B). However, age matched male Tat+ mice after Tat induction showed significantly 
increased anxiety-like behavior, since Tat+ males showed significantly increased travel 
distance in dark side compared to any other groups. (* p<0.05, one-way ANOVA, 
Duncan’s post-hoc test, n = 6, Fig. 4.2 B and C, Table 4.1 B). Since the only the group 
showed increased travel distance/time on dark side after Tat induction were male Tat+ 
mice, male mice may be more vulnerable to the anxiogenic effects of HIV-1n Tat exposure. 
 
Effects of long-term Tat induction on the proportion of microglia and their 3-NT 
immunoreactivity 
Since microglial activation has been detected in CNS from the broad spectrum of 
HAND patients (Anderson et al. 2003; Glass et al. 1995; Gray et al. 2001; Patton et al. 
1996; Tyor et al. 1995), the effects of long-term doxycycline treatment on sex-specific 
microglial activation was determined in the striata of Tat- and Tat+ after 3 month 
doxycycline treatment. Firstly, the proportion of microglia was quantified in the striata 
from all groups by performing Iba-1 immunohistochemistry as described in the Materials 
and Methods. Blinded cell counts revealed that the percent of Iba-1+ cells in total cells in 
striata were equivalent in Tat- males and Tat+ females (Fig. 4.3 A). However, long-term Tat 
induction caused significant increases in the proportion of Iba-1+ cells in both Tat+ females 
and Tat+ males without sex difference. Increases were similar in both male and female Tat+ 
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mice (** p<0.01, *** p<0.001, one-way ANOVA, Duncan’s post-hoc test, n = 6, Fig. 4.3 
A).  
We next determined whether microglial activities in male mice have a different 
level of those of female mice, the extent of Iba-1 and 3-NT co-localization was examined 
by double labeling immunihistochemistry. Since 3-nitrotyrosine is a product of tyrosine 
nitration mediated by reactive nitrogen species such as peroxynitrite anion and nitrogen 
dioxide. Among CNS cells, activated microglia are considered as a major cell mainly 
releasing reactive nitrogen species. 3-NT immunoreactivity has been used to identify 
inflammatory cells as a marker of reactive nitrogen species-induced oxidative stress (Ryu 
and McLarnon 2006; Shavali et al. 2006; Shishehbor and Hazen 2004; Zhang et al. 2005). 
Tissue sections from mouse brains were processed to detect both Iba-1 and 3-NT 
immunoreactivity as described in Materials and Methods, and control sections, incubated 
with secondary antibodies only, were inspected to verify the specificity of the antibodies 
and to determine the pattern of co-localization. Female and male Tat- treated with 
doxycycline did not show significant difference in the percentage of Iba-1+ cells that 
expressed 3- NT, suggesting that doxycycline by itself had no effect on this parameter (Fig. 
4.3 B). However, long-term Tat-induction significantly increased the proportion of 3-NT 
immunoreactive microglia in both female Tat+ and male Tat+ groups (* p<0.05, *** 
p<0.001 one-way ANOVA, Duncan’s post-hoc test, n = 6, Fig. 4.3 B). Importantly, there 
was a significant effect of sex in the proportional reactivity of microglia, since 
doxycycline-induced male Tat+ mice had a significantly higher proportion in cells being 3-
NT staining within microglia compared with female Tat+ mice that also received 
doxycycline (** p<0.01 one-way ANOVA, Duncan’s post-hoc test, n = 6, Fig. 4.3 B).  
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Effects of long-term Tat induction on the expression of NeuN in striatum  
The NeuN antibody is well known to have high specificity to a neuron-specific 
nuclear protein and has been widely used to identify the loss or reduced number of 
neuronal cells in various studies of HIV neuropathogenesis and other situations including 
normal neuronal cell counting (Dou et al. 2003; Everall et al. 2002; Mullen et al. 1992; 
Zujovic et al. 2000). It was recently shown that NeuN corresponds to Fox-3 (Feminizing 
locus on X-3 or hexaribonucleotide-binding protein 3) containing an RNA recognition 
motif and binds specifically to an RNA element for mRNA splicing (Kim et al. 2009). Fox-
3 is one of a family of mammalian homologues of C. elegans Fox-1, a gene involved in sex 
determination. Fox-1 family consists of Fox-1, Fox-2 and Fox-3, and they also known to 
have an RNA recognition motif. Even estimated sizes of all these Fox proteins are about 
46kDa in size, mouse monoclonal NeuN antibody recognize two bands in 46 and 48kDa 
size (Mullen et al. 1992) due to alternative splicing Fox-3 pre-mRNA (Kim et al. 2009). To 
assess the effect that long-term Tat induction might have on the number of neurons in the 
striatum, the proportional number of NeuN+ cells was counted in striata of age matched 
female Tat-, female Tat+, male Tat- and male Tat+ after 3 month doxycycline treatment. In 
both female and male Tat- mice, the proportion of total (Hoechst+) cells expressing NeuN 
was same (Fig. 4.4 A). Long-term Tat induction significantly decreased the proportion of 
NeuN+ cells in both female and male Tat+ mice compared to their respective controls 
(***p<0.001, one-way ANOVA, Duncan’s post-hoc test, n = 6, Fig. 4.4 A). Furthermore, 
the effect on NeuN was significant in male than in female (**p<0.001, one-way ANOVA, 
Duncan’s post-hoc test, n = 6, Fig. 4.4 A). We also confirmed the reduction of NeuN by 
performing an immunoblot analysis of all groups. NeuN was detected as two bands at 
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approximately 42-kD and 48-kD (Fig. 4.4 D), as mentioned previous studies (Kim et al. 
2009; Mullen et al. 1992).  The intensity of NeuN bands significantly reduced only in the 
tissue lysates from male Tat+ mice compared to other groups (Fig. 4.4 B and C). Although 
there was a tendency for reduction in intensities of NeuN bands in the female Tat+ group; it 
did not reach statistical significance. Taken together, our results showed that long-term Tat 
induction significantly reduces the proportion of total NeuN cells in striatum and overall 
NeuN levels are reduced in male Tat+ mice but not in female Tat+ mice.  
 
Stereological analysis of Nissl+ neurons in striatum and striatial volume after long-
term Tat induction  
 Although our results showed a significant reduction in NeuN+ cells in Tat 
transgenic mice, there have been reports that decreased NeuN+ cells means the depletion of 
NeuN protein level or loss of protein antigenicity by neuronal injury rather than neuronal 
cell death or loss (Collombet et al. 2006; Unal-Cevik et al. 2004). We performed unbiased 
stereological estimation of total neuron number (Nissl+) and the volume in the striata of 
female Tat-, female Tat+, male Tat- and male Tat+ mice after 3 months doxycycline 
treatment. Nissl histochemical staining has been commonly utilized to quantify the number 
of neurons in all brain regions in numerous stereological studies (Cyr et al. 2005; Fitting et 
al. 2010a; Fitting et al. 2008; Nielsen et al. 2009). Since Nissl staining in brain can detect 
both neurons and glia, morphological identification was required between Nissl+ neurons 
and glia for counting cells. Neurons were recognized by their larger, pale and oval nuclei 
surrounded by darkly cytoplasmic stained in their Nissl bodies. In contrast, glia, including 
astrocytes, oligodendrocytes and microglia, were identified with relatively smaller size of 
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their dark, tight and round nucleus with lack of stained cytoplasm (Fitting et al. 2010a; 
Sherwood et al. 2006). All Nissl+ glia were eliminated from counting in unbiased 
stereological estimation of total neuron number by morphological identification mentioned 
above. The unbiased stereological estimation in total Nissl+ neuron showed that female 
mice had higher numbers of neurons than males did (* p<0.05, two-way ANOVA, 
Duncan’s post hoc test, N=3, Fig. 4.5 A). There was no significant difference in the 
estimated striatal volume from any groups (Fig. 4.5 B). In summary, female mice naturally 
had higher numbers of neuron in their striata than did male mice in striata. Striatal volumes 
were similar and unchanged by Tat expression, suggesting different cell density. Since 
long-term Tat induction did not affect either neuron number or striatal volume, the loss of 
NeuN imminoreactivity in striata with Tat induction is likely to be the reduction of NeuN 
expression rather than loss or death of striatal neurons in striata. 
 
Effects of long-term Tat induction on the population of neural progenitor cells and 
oligodendrocytes in adult striata 
 Since one of our main interests has been the effect of HIV-1 Tat t on neural 
progenitor cells, we also examined the population of Sox2+ cells in adult striata from 4 
different groups mentioned above, after 3 month doxycycline treatment. HIV-1 Tat 
induction caused significantly decreased the populations of Sox2+ cells in the striata of both 
Tat+ females and Tat+ males, but there were no significant differences due to sex (Fig. 4.6 
A, * p<0.05; ** p<0.01; one-way ANOVA or two-way ANOVA, Duncan’s post hoc test, 
N=6-8). Similarly, Olig2+ oligodendrocytes equally decrease in the striata both Tat+ 
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females and Tat+ males (Fig. 4.6 B, * p<0.05; ** p<0.01; one-way ANOVA or two-way 
ANOVA, Duncan’s post hoc test, N=6-8)  
 
Discussion 
 
cART has dramatically improved survival rates over the past decade, and has 
decreased the incidence of HIV-1 associated dementia (HAD), but neurocognitive 
impairments still remain in high prevalence and affect up to 60% of HIV-infected people 
(Ellis et al. 2007; Wojna et al. 2006) and have shown no decline (Dore et al. 2003; 
Lawrence and Major 2002; Sacktor et al. 2001). These phenomenon might be the reflection 
of  low blood brain barrier (BBB) permeability of many cART medicines, which may 
contribute to higher viral loads in the CNS compared to peripheral immune system 
(Gonzalez-Scarano and Martin-Garcia 2005; Sacktor et al. 2001). Although the prevalence 
of neurocognitive impairments in HIV infected population was rapidly increased along 
with acquired immunodeficiency syndrome (AIDS) and HIVE in (Antinori et al. 2007; 
Grant et al. 1995; Heaton et al. 1995; Woods et al. 2009), but relatively little is known 
about whether sex can influence the prevalence and characteristics of neurocognitive 
dysfunction in HIV positive patients. 
 Whether or not the occurrence of HAND has sex bias in HIV positive patients has 
not been conclusively determined. Furthermore, it has been quite a challenge to design and 
develop animal models for studying in development of HAND. Several animal models 
have been generated for use in understanding the mechanisms in the development of HIV 
associated neurocognitive deficits. Transgenic mice expressing HIV-1 gp120 in glial cells 
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showed age-related impairments in open field activity and spatial reference memory at 12 
month old (D'Hooge et al. 1999), while 3 month old animal didn’t show any changes in 
their behaviors. Even simian immunodeficiency virus is different from HIV-1, infection of 
this virus in macaque monkeys showed impairments in various cognitive and neuromotor 
deficits (Bokhari et al. 2011; Cheney et al. 2008). Intracrebral inoculation of HIV-infected 
human monocytes in severe combined immunodeficient mice also resulted in cognitive 
impairment and motor deficits (Avgeropoulos et al. 1998).  
 Inducible HIV-1 Tat1-86 transgenic mice were utilized to determine if sex can 
influence to develop symptoms of neurocognitive deficit/impairments by HIV-1 Tat protein 
induction in CNS and to begin to uncover the underlying mechanisms. HIV-1 Tat1-86 
transgenic mice have been used in numerous studies from our labs for understanding HIV 
neuropathogenesis. For instance, doxycycline-induced Tat expression induced the 
activation of microglia and astroglia (Bruce-Keller et al. 2008), which resulted in dendritic 
abnormality and reductions in spine density of neurons, and structural alterations of OLs in 
the striatum (Fitting et al. 2010b; Hauser et al. 2009). HIV-1 Tat induction in these mice 
also resulted in circadian rhythm abnormalities and sensory changes (Duncan et al. 2008).  
These results in Tat transgenic mice seem to be correlated with neuropathogenesis in HIV 
patients showing neurocognitive disorders and impairments. Therefore, they are a 
reasonable animal model to study sex differences in development of HAND-like deficits. 
For the diagnosis of neurocognitive disorders and impairments in HIV positive 
patients, a battery of tests are usually performed to assess cortical and subcortical functions 
known to be affected by HIV infection.  The cognitive field tests typically include 
executive functions, episodic memory, speed of information processing, motor skills, 
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attention/working memory, language, and sensoriperception (McArthur et al. 2010; Woods 
et al. 2009). Individual tests would require a comparison in performance to the mean of a 
equivalent HIV uninfected group as a control.  In terms of assessing subcortical 
dysfunctions, severe motor impairments, such as chorea, myoclonus, dyskinesia, and 
dystonia, were not frequently observed in most of HIV positive population (Mirsattari et al. 
1998; Woods et al. 2009). Subtle neurocognitive motor abnormalities such as slowed 
movement and slowed information processing can be frequently detected in older aged 
adult HIV patients along with other motor impairments (Valcour et al. 2008); even when 
they were under the cART. Different behavior tests, such as gait velocity (Robertson et al. 
2006), handgrip strength (PrayGod et al. 2011; Rabeneck et al. 1998), finger tapping 
(Heaton et al. 1995), and manual dexterity with grooved pegboard (Carey et al. 2004; 
Wojna et al. 2006) can be used to detect these subtle symptoms of motor deficits in HIV 
positive patients. Gait velocity test usually was applied to HIV-1 positive patients in severe 
stage of HAND, while most of tests are based on the psychomotor speed tests, which are 
limited to motor skill of the upper body and associated with attention and procedural 
learning in human subjects, since these tests are often applied to HIV positive patients with 
subtle motor deficits. These tests are designed to examine the condition of human subjects, 
and cannot be exactly equated with animal behavior tests. However, the present study 
shows that some well-characterized animal behavior tests applied to access our HIV-1 Tat 
transgenic mouse model to detect a spectrum of motor deficits and disorders. The rotarod 
test/grip strength test were performed to assess subcortical motor deficits, while open-field 
test and light/dark box test were applied to our animal model to assess the aspect of rodent 
behavior that has been linked to mental status of humans.  
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The accelerating rotarod test is a forced performance test based on a rotating rod 
with forced motor activity to evaluate basic gait, balance and coordination tightly 
associated with the function of the basal ganglia (Jones and Roberts 1968). The grip 
strength test is also a forced assessment which is widely used in conjunction with the 
rotarod test, since a normally coordinated rodent will show a low score with low strength of 
forelimbs in the basal ganglia affected by neurodegenerative diseases (Prodoehl et al. 
2009). Long-term Tat induction resulted in a significant transgene-sex interaction. Male 
Tat+ mice had difficulty in obtaining the rotarod motor skill over the course of 12 weeks 
compared to all other groups. Interestingly, female Tat mice also showed some difficulty to 
acquire motor skills as shown by the slight, but significant difference in linear regression 
analysis compared to female Tat- mice (Fig. 4.1 A). When the results normalized by their 
own body weight, male Tat+ mice showed significant reductions in forelimb grip force 
strength compared to all other groups with doxycycline and were the only group in which 
doxycycline treatment caused reduced grip strength versus controls (Fig. 4.1 B).  
 Symptoms of HIV related neurocognitive disorders are likely to be accompanied by 
abnormal mental health conditions such as anxiety, depression or other mood disorders in 
HIV infected individuals. Thus, neuropsychological tests may be performed simultaneous 
to cognitive tests. Therefore, we hypothesized that long-term Tat induction might also 
induce neuropsychological impairments in transgenic Tat+ mice in a sex specific manner. 
The rotarod test and grip strength test are “forced” performance tests, while the open field 
test and light/dark box test can be used in rodents as qualitative and quantitative measures 
of general locomotor activity and willingness to explore, an indication of mental or 
neuropsycological status (Lalonde and Strazielle 2008; Stanford 2007). The open field test 
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and light/dark box test are based upon the rodent's conflict between an innate aversion to 
exposed spaces and a tendency to explore novel environments (Cryan and Holmes 2005; 
Wallace et al. 2008). In the open field test, depressed or anxious animals will show reduced 
traveling distances in an unrestricted environment, reflecting their loss of exploring new 
noble environment. In the dark/light box condition, depressed or anxious animals will tend 
to spend more time in exploring noble environment in the dark side (Bourin and Hascoet 
2003). Both behavior tests were only conducted in short time period (5-10 min), so that the 
animals in these tests do not lose their novelty to new environment by habituation. 
Interestingly, our results showed that an altered neuropsychological status varied between 
sexes varied according to the behavioral test being performed. Long-term Tat induction 
significantly attenuated the distance of exploratory activity in an open field in both female 
and male mice, with no effect of sex (Fig. 4.2 A) In the light/dark box test, only male Tat+ 
transgenic mice showed significantly increased time and activities in the dark  versus 
control (age matched male Tat+ unexposed to doxycycline). All other groups, including 
Tat+ females, were not different from their respective control group without doxycycline 
administration (Fig. 4.2 B).   
All together, our HIV Tat transgenic animal model showed that Tat induction 
resulted in significant changes in psycho-behavioral status. Open-field exploratory 
behavior was reduced in both sexes; whereas male mice showed preference to stay in dark 
conditions, perhaps indicating a sex-specific component of anxiety.  Therefore, our results 
may mean an underlying sex difference in the vulnerability to certain neurocognitive and 
psychological disorders in HIV infected individuals. It has been difficult to study human 
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subjects under controlled condition, but our result suggested that sex should be considered 
as an important variable.  
 Based on our behavior test results, multiple evaluations were performed in tissues 
from these mice to determine whether CNS cells were affected by long-term Tat induction 
in sex specific manner. Such changes might be involved in the development of sex specific 
behavioral abnormalities. Microglial activity and their inflammation in vivo became the 
first evaluation target in this studies, since previous studies in our laboratory strongly 
suggested that Tat can induced changed in microglial numbers and reactivity (Bruce-Keller 
et al. 2008; Fitting et al. 2010c; Gupta et al. 2010; Hahn et al. 2010b; Suzuki et al. 2011). 
Increased number of microglia and enhanced microglial reactivities significantly increase 
the inflammatory stress on neurons as direct effects or secondarily through microglial 
activation (Bruce-Keller et al. 2008; Suzuki et al. 2011; Zou et al. 2011). Data from the 
present study also showed that the overall proportions of microglia in striata were increased 
to a similar extent by long-term Tat induction in both sexes. However, when we assessed 
the reactive properties of microglia by assaying for 3-NT expression we noted that it can be 
influenced by the sex of animals. Long-term Tat expression appeared to enhance 3-NT 
expression in microglia significantly in male mice. Dysregulated macrophages/microglia in 
CNS, which over-produce various proinflammatory cytokines/chemokines, are frequently 
detected in autopsy studies of the basal ganglia from chronic HIV infection (McArthur et 
al. 2010; Pereyra et al. 2009). Therefore, our finding that the striata of male Tat+ mice have 
more elevated microglial population with increased 3-NT immunopositivity suggest that 
the neurons in male mice striata may be even more vulnerable to the stress from microglial 
reactivity than those in female mice. This implies that a similar, sex-related vulnerability 
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may occur in the CNS of HIV positive patients. There have been some studies that sex 
hormones might play an important role in microglial cytokines/chemokines secretion. For 
example, estrogen may modulate immune responses of microglia by leading micriglia in 
female mice to release greater anti-inflammatory cytokines than microglia in male mice, 
even though the increased proportion of microglia were similar in both sexes after exposure 
to Tat and/or opiates (Bruce-Keller et al. 2007). The underlying mechanism and 
relationships between microglia activation and sex-specific vulnerability of the CNS are 
still correlative and further studies are required to show direct, causal links. 
Neurons are considered a major target of the HIV-1 Tat protein. Previous in vivo 
studies indicated that certain HIV-1 proteins, including Tat and gp120, are neurotoxic, 
since not intended secondary/bystandard effects can induce cell loss, low neuronal integrity 
in synapses, caspase-3 activation, mitochondrial hyperpolarization and dendridic spine loss 
in parallel with macrophage/microglia activation (Everall et al. 2002; Ratai et al. 2010; 
White et al. 2011). Due to neuronal injury or loss, subcortical brain atrophy (Castelo et al. 
2007; Cohen et al. 2010) can frequently be detected by resonance imaging in HIV infected 
individuals, even these patients are in the cART. We utilized a NeuN antibody to identify 
the proportional number of neuronal cells in the striata of transgenic mice, because we 
thought the loss of neurons could be basis of behavior changes. In our transgenic mice that 
the proportion of NeuN+ neurons in striata was significantly decreased after 3 month of 
HIV-1 Tat induction. There was also the effect of sex-Tat interaction to reduction in NeuN+ 
cell population; male Tat+ mice proportionally lost more striatal NeuN+ cells than females 
did under same period of Tat induction. Immunoblotting with NeuN antibody was also 
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performed to semi-quantitatively compare the expression levels of NeuN protein in striatal 
lysates from those animals. 
 As the lysates from male Tat+ mice striata showed more reduction in the intensity of 
NeuN bands compared to those from female Tat+ mice, the pattern of reduction in NeuN 
immunoreactuvity were quite similar to the proportional counting reuslts. Nearby 50% with 
the NeuN signal lost in both measurements, this seemed like a tremendous amount of cell 
loss, and we hypothesized that long-term induction might cause the depletion of NeuN 
expression in neurons, rather than 50% neuron death in the striata. To assess the 
hypothesis, unbiased stereological techniques were applied to estimate neuron number in 
strata and striatal volume all groups. Comparable to previous reports (Cyr et al. 2005; 
Oorschot 1996), we measured neuron number in the striata to be approximately 1.8 million 
cells in females and slight, but significantly less in males. Furthermore, prolonged Tat 
induction didn’t affect the total neuron number in the striatum or the striatal volumes in any 
groups. Thus, in agreement with previous data after 10 days of doxycycline treatment in 
these transgenic mice, long-term Tat induction did not result in neuron death (Bruce-Keller 
et al. 2008). Based on stereological measurements, we believed now that the striatal neuron 
population is not reduced by long-term Tat expression, but that Tat induces neuron damage 
and interferes with production if NeuN or its antigenesity by unknown mechanism. 
Although NeuN has been utilized as a neuronal specific marker for over a decade; the 
NeuN protein was only recently identified as Fox-3, a new member of the Fox-1 gene 
family of RNA splicing factors (Kim et al. 2009; Kim et al. 2011). Therefore, the underling 
mechanisms of 1) how induction of Tat causes altered expression of NeuN, or 2) how an 
altered level of NeuN could affect neurons, 3) how many other environmental cues (i.e. 
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inflammatory factors from microglia/astrocytes) would be involved in NeuN associated 
pathogenesis are still required further studies.  
Since one of our interests was how HIV-1 can affect NPCs in CNS, especially in 
striata, we also examined whether long-term induction of HIV-1 Tat alters the population 
of NPCs and oligodendrocytes in striata. The population of Sox2+ and Olig2+ cells in 
striatum were significantly decreased by 3 month induced Tat expression in all Tat+ 
transgenic mice groups. There was no sex specific manner in the decline of either cell type. 
According to previous reports,  HIV-1 proteins such as Tat (Mishra et al. 2010), gp120 
(Okamoto et al. 2007) can alter the proliferation of NPCs both in vitro and in the 
hippocampus and may result in differentiations more toward astrocytes and less toward 
neurogenesis (Krathwohl and Kaiser 2004a; Tran and Miller 2005).  The reduction in NPCs 
seen here is in line with those results and our results from Chapter 3.in neonatal animal. 
There have been some suggestions that cytokine/chemokines secreted from 
microglia/macrophage induced by HIV-1 or its proteins might increased proliferation of 
NPCs (Gong et al. 2006; Peng et al. 2008), however, these studies had limitation that those 
experiments were short term condition of exposure and were also in vitro on isolated cells. 
Since long-term induction of Tat in CNS in our transgenic mice resulted in significant 
increase the activity of microglia, the survival or production of both NPCs and OLs can be 
secondarily affected by these activated microglia, which would produce not only pro-
inflammatory cytokine/chemokines but also nitro-oxidtive stress (Das and Basu 2008; 
Whitney et al. 2009). The long-period exposure to these multiple factors and HIV-1 Tat 
might decrease the population of NPCs by inducing fast turn-over of NPC proliferation or 
promoting quiescence of NPCs, since in preliminary studies, still in progress, we couldn’t 
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detect any proliferation of NPCs in adult striata by BrdU administration. Our experiment 
suggested that long-term Tat induction in CNS significantly decreases populations of NPCs 
and OLs as one of evidence of HIV neuropathogenesis. The depletions of NPC and OL 
populations correlate with altered motor and psychological behavioral test changes in our 
transgenic mice, but we cannot, of cause, conclude that there is a cause of relationship.             
  
 In conclusion, the data in this thesis support the hypothesis that HIV-1 Tat protein, 
produced by chronic replication of HIV in CNS, could play a significant role in the 
development of neurocognitive disorders in HIV patients, perhaps by induction of 
pathological microglial activation in the striatum. Data also show in this model that sex 
may affect the vulnerability in developing behavioral deficit/impairments with males, being 
significantly more affected in several standard rodent tests. Our data also suggested that 
sex-related changes in microglial activity may cause the depletion of NeuN immune 
reactivity in males, which is more affected than that is in females. In other measures, NPCs 
and OLs were reduced similarly in Tat+ males and females. At present, we can only say 
that depletion of NeuN+ neurons and enhanced microglial reactivity correlate with sex 
related behavioral changes. A cause-and-effect relationship remains to be established in 
later studies. 
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Figure 4.1 Long-term Tat expression in transgenic mice revealed a sex difference in Tat 
effects on motor activity and grip strength. Four different groups (female Tat+ and Tat-, 
male Tat+ and Tat-) were fed chow containing doxycycline continuously for 12 wk to 
induce Tat expression in vivo. (A) Rotarod results. There was no difference between these 
four groups after 1 wk of doxycycline exposure. However, long-term induction of HIV-1 
Tat by 3 month doxycycline administration caused significant difficulty in obtaining motor 
skill in the male Tat+ group compared to all other groups. (B) Grip strength results. To 
compare and normalize the effects of long-term Tat induction in vivo, a matching set of 4 
groups with normal chow feeding were separately prepared.  After 12 wk, when all mice 
were 6 month old, a grip strength test was performed. There was no difference due to sex 
or genotype without doxycycline exposure. However, the long-term exposure to HIV-1 Tat 
caused significantly decreased forelimb grip strength in the male Tat+ group compared to 
all other groups (§ p<0.05; ** p<0.01, male Tat+ vs. all other groups with DOX, Duncan 
post-hoc test, N=6-8). Based on these behaviors, we suggest that long term Tat exposure 
affects mice in a sex-specific manner, with effects on male mice that are not observed in 
female mice. DOX, doxycycline. 
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Figure 4.2 
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Figure 4.2 The effect of long-term Tat exposure on locomotor activity and anxiogenic-like 
behavior of adult transgenic mice. Open-field tests and light/dark box tests were applied to 
two sets of 4 different groups (female Tat+ and Tat-, male Tat+ and Tat-, with/without 
doxycycline treatment) were tested at 6 month old. A matching set of 4 groups with feeding 
normal chow at 3 month old were separately prepared and tested to normalize the data from 
other groups mentioned above. (A) Open field test results. There was a difference in 
locomotor activity due to sex, even in groups that did not receive doxycycline treatment. 
Long-term Tat induction significantly reduced locomotor activity in both sexes. (B)  
Light/dark box results. Long-term Tat exposure selectively induced anxiogenic-like effects 
in the male Tat+ group compared to all other groups. (C) Representative diagrams of 
light/dark box results. Tat+ males showed significantly increased travel distance in dark 
side compared to any other groups. Based on these behaviors, we suggest that long term 
Tat exposure affects mice in a sex-specific manner. By most measures, male mice are 
adversely affected by Tat induction in comparison to female mice. (* p<0.05; § p<0.05, 
female Tat- vs. all other groups, Duncan’s post hoc test, N=6-8.) DOX, doxycycline. 
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Figure 4.3 
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Figure 4.3 Long-term Tat expression in transgenic mice revealed a sex difference in Tat 
effects on microglial populations and their activities in adult striatum. The brains were 
harvested from four different groups (female Tat+ and Tat-, male Tat+ and Tat-), with 12 wk 
Tat induction by doxycycline in vivo. The effects of long-term Tat exposure on the 
microglial population in adult striata were examined by multiple immunohistochemistry. 
There was a significantly increased population of Iba-1+ cells in both male and female Tat+ 
groups compared to their Tat- control (A). Although there was no sex difference in Tat 
effect on Iba-1+ cells, long-term exposure to HIV-1 Tat did induce a significant increase in 
the activity of microglia in the male Tat+ group compared to all other groups, based on the 
expression of 3-nitrotyrosine (3-NT+) (B). Based on these results, we suggest that long 
term Tat exposure affects mice in a sex-specific manner, with effects on male mice that are 
not observed in female mice. (* p<0.05; ** p<0.01; *** p<0.001; § p<0.05, female Tat- vs. 
all other groups, Duncan’s post hoc test, N=6-7.) DOX, doxycycline. 
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Figure 4.4 Effects of long-term Tat induction on the population of NeuN+ cells and NeuN 
immunoreactivity in adult striatum. NeuN immunohistochemistry were performed on the 
brain sections including striata from 4 different groups (female Tat+ and Tat-, male Tat+ and 
Tat-) with doxycycline treatment at 6 month old for NeuN+ cell counting. HIV-1 Tat 
induction for 12 wk caused significantly decreased the population of NeuN+ cells in the 
striata of both female and male Tat+ mice. There was a significant sex effect, as the effect 
in Tat+ males was significantly greater than in all other groups (A). Immunoblots were 
performed with NeuN antibody to measuring any alteration in the level of NeuN in the 
striata after long-term Tat induction. Striata were dissected and harvested from 
independently prepared 4 different groups (female Tat+ and Tat-, male Tat+ and Tat- with 
DOX treatment at 6 months old) for immunobolting. The intensity of bands was 
significantly decreased by Tat exposure only in tissue lysates from male Tat+ mice (B, C). 
(* p<0.05; ** p<0.01; *** p<0.001, one-way ANOVA or two-way ANOVA, Duncan’s 
post hoc test, N=6-8.) DOX, doxycycline. 
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Figure 4.5 
 
Figure 4.5 Effects of long-term Tat induction on total number of Nissl+ neurons in 
transgenic mouse striata and the volume of striata. The brain sections including striata from 
4 different groups (female Tat+ and Tat-, male Tat+ and Tat-) with doxycycline treatment at 
6 month old for stereological estimation of  Nissl+ neuron numbers. Unbiased stereological 
estimates showed that total neuron number (Nissl+) were higher in female mice than in 
male mice; there was no effect of Tat on Nissl+ neurons (A). Furthermore, doxycycline 
induced Tat didn’t alter the estimated striatal volume in any group (B). Based on these 
results, we suggest that long term Tat exposure might affect expression level of NeuN in 
the neurons of male Tat+ mice, without actual loss of neurons or a change in volume of the 
striatum. (* p<0.05, two-way ANOVA, Duncan’s post hoc test, N=3.) DOX, doxycycline. 
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Figure 4.6 
 
 
 
Figure 4.6 Long-term effect of Tat expression in transgenic mice on the population of 
neural progenitor cells and oligodendrocyts in adult striata. HIV-1 Tat induction by 12 wk 
doxycycline administration caused significantly decreased populations of Sox2+ cells in the 
striata of both Tat+ males and Tat+ females, but there were no significant differences due to 
sex (A, * p<0.05; ** p<0.01; one-way ANOVA or two-way ANOVA, Duncan’s post hoc 
test, N=6-8). Similarly, Olig2+ oligodendrocytes equally decrease in the striata both both 
Tat+ females and Tat+ males (B, * p<0.05; ** p<0.01; one-way ANOVA or two-way 
ANOVA, Duncan’s post hoc test, N=6-8). DOX, doxycycline. 
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Table 4.1 Measurements of activity in open field and light/dark box tests 
A.     
Open field test 
Travel distance (cm/10min ± SE) 
6 month old 6 month old 
No DOX 3 month DOX 
Female Tat- 1904.68±334.36 2184.96±183.83 
Female Tat+ 2484.53±116.25 1682.55±190.38 
Male Tat- 2045.54±165.53 2027.74±128.80 
Male Tat+ 2152.74±199.09 1689.94±  94.54 
B.     
Light/Dark test 
% of Travel distance in dark side 
(cm/10min ± SE) 
6 month old 6 month old 
No DOX 3 month DOX 
Female Tat- 79.77 ± 12.03 80.28 ±  5.63 
Female Tat+ 77.49 ±   7.57 83.44 ±  6.48 
Male Tat- 71.71 ±   8.68 77.82 ±  3.01 
Male Tat+ 71.39 ±   4.06 81.26 ±  4.69 
                                                                         DOX, doxycycline. 
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Chapter 5  
Final Conclusions 
 
 The introduction of cART has dramatically improved survival rates in the 
HIV/AIDS population; however, neurocognitive impairments in these patients still remain 
in high prevalence. 60% of HIV-infected people are estimated to be affected by HIV 
related neurocognitive disorders (Ellis et al. 2007; Wojna et al. 2006) and the prevalence of 
HAND has shown no decline, even with cART treatment (Dore et al. 2003; Lawrence and 
Major 2002; Sacktor et al. 2001). Low blood brain barrier (BBB) permeability of many 
cART medicines might contribute to these phenomenon, so that higher viral loads still 
remained in the CNS compared to peripheral tissues where cART is quite effective in 
decreasing viral load (Gonzalez-Scarano and Martin-Garcia 2005; Sacktor et al. 2001). 
Approximately, 30% of HIV positive patients were infected through the use of 
contaminated needles during injection (UNAIDS 2009). HIV-positive, opiate abusers have 
high a risk for faster progression to acquired immune deficiency syndrome (AIDS), as well 
as higher incidence of subtle form of neurocognitive disorders compared to non-drug 
abusers, especially since misuse of drugs leads them to decrease their adherence to cART 
medications (Bell et al. 2006; Bell et al. 2002; Byrd et al. 2011). HIV-associated 
neuropathology in the CNS is considered as a combined and complex result generated from 
the direct toxicity of multiple viral proteins on neurons as well as by the indirect effects of 
pro-inflammatory factors or nitro-oxidative stress propagated by surrounding glial cells 
(Brack-Werner 1999; Gendelman et al. 1994; Hauser et al. 2007; Kaul et al. 2001; Kramer-
Hammerle et al. 2005b; Persidsky and Gendelman 2003). NPCs exist both in the pediatric 
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and adult brain, and the size of their population is relatively small compared to other CNS 
cell populations. NPCs are primitive, undifferentiated cells having the capacity of 
proliferation and the multi-potential ability to generate various neural lineages of mature 
brain cells including neurons, astrocytes, and oligodendrocytes. The size of the NPC 
population is substantially reduced with age, as is their distribution and recruitment. The 
effect of HIV-1 ± opiates on NPCs has been less well studied compared to other cells, 
partially because their small populations and transient characteristics make their study 
difficult. We have hypothesized that NPCs may be targets of HIV proteins ± opioid drugs 
of abuse and that exposure of HIV ± opiates may alter the balance of cells in the CNS that 
derive from NPCs.  
In Chapter 2, we have shown that HIV-1 Tat1-86 selectively increases the production 
of β-chemokines, CCL3/MIP-1α, CCL4/MIP-1β and CCL5/RANTES from striatal 
progenitors using a multi-plex cytokine/chemokine assay. Because of our interests in the 
effects of co-morbidity between opiate drugs of abuse and HIV exposure in the CNS, we 
chose to examine the striatum, an area which is both rich in opiate receptors and extremely 
vulnerable to HIV-induced neuropathology. The chemokines upregulated by Tat also 
induced a chemotactic migratory response of both primary microglial cells and the BV-2 
mouse cell line. Furthermore, we showed that these effects were mediated by CCR5 by 
using antibody blockade, as expected with β-chemokines. Even though 
immunohistochemistry on NPCs showed that they were immunopositive to MOR and 
CCR5/CXCR4, there was not any synergistic effect of opiate interaction or toxicity of 
gp120 alone in these experiments. In addition, the survival rate of NPCs was not affected 
by any treatments. These findings are significantly relevant to HIV related neuropathology, 
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as Tat mRNA and/or protein have been detected in CNS tissue samples from patients 
infected with HIV (Hudson et al. 2000; Wiley et al. 1996). Furthermore, some recent 
reports suggested that human neural progenitors may be infected by HIV (Lawrence et al. 
2004; Rothenaigner et al. 2007; Schwartz and Major 2006), although the extent of NPC 
infection in the brain is still controversial. The potential contribution of this infected 
population to the chemokine secretions and their effects require further studies. 
Importantly, our results show that Tat can affect the function of NPCs in the absence of 
infection. In this chapter, we examined two critical components of NPC function, their 
communication with other cells through secreted factors and their survival. We suggested 
that secretions of β-chemokines by NPCs might be useful in promoting microglial 
surveillance of newly formed NPCs and clearing toxic debris. Other potential effects might 
to provide trophic support or to regulate microglial proliferation and differentiation, 
although we have no evidence for these. Other critical NPC/GPC behaviors including 
proliferation and lineage decision are examined in other chapters.  
 In Chapter 3, to investigate the effect of HIV-1 on proliferation of NPCs in 
developing systems, we firstly examined the effect of Tat ± opiates on murine striatal 
progenitors in vitro. Individually, Tat and morphine did not affect the proliferation of either 
Sox2+ or Olig2+ cells in vitro at 12 h, although the combination of Tat and morphine 
interactively reduced the total population of Sox2+, and Sox2+ proliferation index. At the 
later time points, Tat alone reduced the proliferation and population of Olig2+ cells, 
although interactive effect of Tat + morphine was seen on its proliferating cells. By using 
doxycycline-inducible Tat transgenic mice, in vivo experiments were performed in 
perinatal model as a next step. Tat and morphine independently both reduced the 
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proliferation of Sox2+ and Olig2+ cells. An interactive effect was seen only on Sox2+ 
proliferation. The Sox2+ population was reduced by both morphine and Tat, while the 
Olig2+ population was reduced by only by Tat. We did not observed any interaction 
between Tat and morphine on the cell populations we hypothesis that these might be 
measured at later time points. Since HIV is a human specific virus, we also examined the 
effect of supernatant from HIV-1SF162-infected cells or Tat ± morphine on proliferating 
hNPCs. The proliferation of human Sox2+/nestin+ NPCs is similarly reduced by Tat, 
morphine, and infective HIV-1SF162 supernatant, and an additive effect between HIV-1SF162 
and morphine reduces proliferation further. The additive effect of HIV supernatant and 
morphine in reducing hNPC proliferation, which was not seen in Tat + morphine treatment, 
may reflect the interaction between multiple factors in HIV supernatant including other 
viral proteins such as gp120 (Lee et al. 2011) as well as numerous secreted or reactive 
factors present in the medium. Previously, we mentioned that NPCs may be a target of HIV 
infection. To examine this, we imaged the HIV-1SF162 supernatant treated NPCs with p24 
immunohistochemistry, and our finding supports the possibility of low level hNPC 
infection. Taken together, our results show that the effects of HIV-1 Tat or HIV-1SF162 
supernatant and morphine significantly reduce the proliferation of NPC/GRPs, and 
interactions among them can compromise both murine and human progenitor production 
even further. These findings suggest the possibility that HIV infected pediatric patients, 
who have developing brains with significant number if NPCs and immature glia, likely will 
develop neuropathological complications due to HIV infection alone, and the 
complications maybe worse if they are exposed to opiates. 
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In Chapter 4, we extend our interest into the effect of long-term Tat exposure on 
animal behavior, since chronic low levels of HIV replication in CNS may play a significant 
role in the development of neurocognitive disorders in HIV patients. We utilized several 
standard rodent tests to examine the effect of long-term Tat induction in animal model. 
Interestingly, male Tat+ mice showed overall greater deficits than all other groups. 
Doxycycline-induced male Tat+ mice had decreased rotarod performance and forelimb grip 
strength, and they also showed increased anxiety-like behavior as compared to 
doxycycline-induced female Tat+ mice and control groups. There was no sex related 
difference in open field locomotor activity. In parallel to these behavioral tests, we 
performed correlative experiments to assess Tat effects on certain cell populations. We 
determined that microglial activation was more enhanced in striatum of induced Tat+ males 
compared to that of induced Tat+ females, although their microglial number was increased 
to the same extent. NeuN levels in striatum were also more reduced in male Tat+ mice by 
Tat induction as compared to all other groups. Interestingly, we determined that the 
reduction in NeuN immunoreactivity was not consequent to loss or death of neurons in 
striatum, suggesting down-regulation of NeuN expression in living neurons. Since we were 
also interested in the effect of Tat on NPCs, we also examined the populations of NPCs and 
OLs by immunostaining for Sox2 and Olig2. The reduction in their populations was similar 
in doxycycline-induced Tat+ males and females. These data suggest that sex related 
behavioral changes may be modulated by enhanced microglial reactivity, which may also 
cause the depletion of NeuN level in neurons and the reductions in populations of NPCs 
and OLs in striata. However, a cause-and-effect relationship remains to be established in 
later studies. Overall, our data suggest that HIV patients may be vulnerable to developing 
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neurocognitive disorders in a sex dependent manner, making sex an important variable in 
human studies.  
In conclusion, one of most important findings in our studies is that NPCs are major 
targets of HIV-1 viral protein Tat and that certain effects of Tat are interactively affected 
by concurrent morphine exposure. Most of our studies are directly related to 
neonatal/perinatal systems, which is relevant to the neuropathogenesis in pediatric HIV 
population. The role of NPCs is well studied in stem cells, memory formation and repairing 
CNS after injury/insults, however, the importance of them has been understudied in HIV-
induced pathology in the CNS. Even though neurons in most CNS are formed prenatally, 
but production of gliogenesis continues into the postnatal and adolescence period (Chan et 
al. 2002; Lee et al. 2000; Skoff 1990; Skoff and Knapp 1991). Because of this reason, the 
CNS of younger HIV patients have and require relatively large populations of NPCs 
compared to adult HIV patients. Furthermore, these pediatric/adolescent patients have a 
great possibility that their CNS could be exposed to opiates. This might appear through the 
use of opiates as pain control medication through their lives, for examples, during surgery. 
It might also occur during experimentation with drug abuse. Our data strongly suggested 
that certain major functions of NPCs are sensitive to both HIV-1 and opiate exposure and 
are vulnerable to the interactive effect between HIV-1 and opiates. There are presently few 
options for non-opiate, pain-control medications in HIV pediatric patients does not existed 
yet, therefore, the development of the new non-opiate, pain-control medications might be 
of great clinical benefit to these pediatric patients, for example, toll-like receptor (TLR) 
antagonists. Some studies suggested that opiates can induce glial activation mediated by 
TLR to lead neuropathic pain, and this glial activation can be alleviate by TLR antagonists 
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to reduce the neuropathic pain (Hutchinson et al. 2007). Another important finding in our 
studies is that NPC populations existing in the adult CNS can be vulnerable to long-term 
HIV exposure. Our data from an in vivo animal model also indicate that behavioral 
outcomes might be affected by long-term HIV-1 exposure to CNS in sex-specific manner. 
HIV-1 Tat transgenic mouse model, that we have, females show less cognitive and motor 
deficits along with less severity in neuropathogenesis compared to males. Interestingly, 
changes in Sox2+ NPCs and Olig2+ oligodendrocytes do not correlate to sex-related 
behavioral changes, but increased microglia activation and depletion in NeuN level do 
show a correlation. Even though a cause-and-effect relationship has not been shown here, 
and is required to be established in the future, we cautiously hypothesize that these sex 
differences in the phenotype of sub-population of microglia cells may reflect an effect of 
sex hormones, such as estrogen, on microglial activation induced by HIV-1 or viral 
proteins. Some in vitro studies suggested that pretreatment with estrogen can attenuate 
microglial activation, mediated by mitogen activated protein kinase and NF kappa B 
pathways, to reduce superoxide/nitrite release, phagocytic activity, and TNF-α secretion 
from microglia (Bruce-Keller et al. 2001). Since there have been few studies in adult NPCs 
under the long-term condition of HIV infection, further studies are needed to show how 
HIV effects on NPCs relate to overall CNS pathology in HIV patients, as well as to the 
behavioral deficits/abnormality in HAND, and the influence of sex should also be 
considered in future studies. 
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